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Background, objectives and setting: Despite global activity over the past 15 years to improve patient
safety, the measurement of adverse events (AEs) remains challenging.
Objectives: We aimed to obtain definitive longitudinal data on harm across NHS Wales and to compare
the performance of the Global Trigger Tool (GTT) with the two-stage retrospective review process, using
our findings to consolidate an approach to the ongoing surveillance of harm in Wales.
Data sources: Eleven of the 13 major Welsh NHS hospitals.
Review methods: The two-stage retrospective review methodology was used to quantify harm across
NHS Wales. In total, 4536 inpatient episodes were screened for AEs by research nurses. Records that were
highly suggestive of AEs were further assessed by physicians. NHS-led teams undertook GTT reviews on
the same case notes.
Results: At least one AE was determined in 10.3% of episodes of care [95% confidence interval (CI) 9.4%
to 11.2%] and 51.5% were preventable (95% CI 46.9% to 56.1%). The percentage of patients identified
with AEs using the GTT methodology was lower, at 9.0% (95% CI 8.82% to 9.18%). Differences in
AEs were evident across study sites. Methods were developed to profile the risk of AEs in individual
organisations by producing signatures of harm for each NHS site. Analysis indicated that neither the GTT
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nor the two-stage process was a candidate tool for routine surveillance, and a hybrid one-stage tool
(Harm2), based on phase 1 findings, was developed for ongoing AE monitoring. Using the Harm2 tool,
AEs were identified in 371 out of 3352 randomly selected discharge reviews (11.3%, 95% CI 10.2% to
12.4%), and 59.6% (95% CI 55.3 to 63.9) of these were preventable. In a cohort of randomly selected
deceased patient reviews, at least one AE was determined in 315 out of 1018 admissions (30.1%, 95% CI
28.1% to 33.8%), and 61.7% (95% CI 57.5% to 65.9%) of these were preventable. Factors associated
with AEs in the randomly selected discharge reviews included having peripheral vascular disease [odds ratio
(OR) 2.52], hemiplegia (OR 2.27) or dementia (OR 2.27). No association with chronic disease was identified
in the deceased episodes of care.
Limitations: The dependence on our health service partners in identifying notes to be reviewed, along
with the small sample examined each month, limits the generalisability of these findings and rates were
not standardised for hospital and size and level of services provided. We cannot rule out the possibility that
the rates we report may be underestimated.
Conclusion: The extent of harm detected across NHS Wales using both the two-stage retrospective review
process and the new Harm2 tool conforms to the findings in the literature, but this is the first longitudinal
study using these methods. With training and using a structured review process, non-physician reviewers
can undertake case note review efficiently and effectively, and the rates of AEs and of the preventability
and the breakdown of problems in care conform to those reported in studies in which physicians
undertake these classifications. Whether the patient died or was discharged alive significantly influences
the rate and composition of AEs. The Harm2 tool performed with moderate reliability in the determination
of AEs.
Future work: Future large-scale studies should attempt to specify types of AEs, such as hospital-acquired
infections and surgical complications, to enable the surveillance of the specific types of harm as well as the
overall level of AEs. In the longer term, we need to automate harm surveillance and set measures of harm
alongside measures of the beneficial effects of health care.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Glossary
Adverse event An injury to a patient related to medical management, in contrast to complications of
disease. Medical management includes all aspects of care, including diagnosis and treatment, failure
to diagnose or treat, and the systems and equipment used to deliver care. Adverse events may be
preventable or non-preventable.
Health board A NHS body responsible for planning, securing and delivering health-care services in
its area.
Improvement science An emerging concept that focuses on exploring how to undertake quality
improvement well.
Inpatient episode A complete episode of care irrespective of changes in consultant management.
Inpatient management Care of patients through the secondary care health infrastructure.
Intentional rounding A structured approach whereby nurses conduct checks on patients at set times to
assess and manage their fundamental care needs. Concerns about poor standards of basic nursing care
have refocused attention on the need to ensure that fundamental aspects of care are delivered reliably.
Modified early warning score A systematic recording of vital signs with clear escalation criteria.
Problem in care The classification of adverse events in the Harvard method.
Quality improvement A systematic approach that uses specific techniques to improve quality within a
health-care setting.
Randomly selected deceased discharges A randomly selected sample of patients from the total pool of
patients who died in any given hospital in a given month.
Randomly selected discharges A randomly selected sample of patients from the total pool of all
discharges in any given hospital in a given month.
Risk-adjusted mortality index A death rate that takes patient risk factors into account.
Skin bundle Skin bundle requires documented nursing intervention at least every 2 hours in the following
areas to reduce the likelihood of damage: monitoring the patient’s Surface – ensuring the patient is on the
right mattress or cushion; Keep moving – encouraging self-movement and repositioning; Incontinence –
meeting the patient’s toileting or continence needs; and Nutrition – keeping the patient well hydrated and
meeting their nutritional needs.
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AE adverse event
AF atrial fibrillation
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DNAR do not attempt resuscitation
DVT deep-vein thrombosis
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HAP hospital-acquired pneumonia
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Improvement
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Plain English summary
S tudies conducted around the world report that 1 in 10 patients will have something happen to themduring their stay in hospital that will harm them. We have assessed longitudinally, over 4 years, the
percentage of Welsh patients who are injured or who have complications as a result of their treatment in
order to assess where improvements can be made to health care and health-care processes. We confirm
that 10% of patients experience this harm in Wales, a similar proportion to that reported in other countries,
and around half of these events could be prevented if hospitals addressed their causes through
improvement projects.
We compared different methods to measure the problems that commonly happen, such as infections,
surgical complications and mistakes prescribing and administering medications. The Global Trigger Tool in
this setting was inconsistent and overall under-reported these harm events, and the Harvard two-stage
process was too cumbersome for routine use. We have developed a new tool, taking the best of both
approaches, and a method by which individual hospitals can identify where patients are most at risk of
being injured during the course of hospital care. Recognising this risk to patients offers the opportunity for
hospitals to target problem areas to reduce the number of patients exposed to injuries or complications.
If an approach of monitoring was continued across NHS Wales, Wales could become an international
leader in patient safety. In the longer term, health-care safety measures that affect a small proportion of
patients need to be placed in the context of the enormous benefits of health care to whole populations.
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Scientific summary
Background and aims
Despite global activity over the past 15 years to improve patient safety, the measurement of adverse event
(AE) rates remains challenging. Although many approaches have been used, and are in use, the dual-stage
retrospective review of medical records has been the methodology of choice in large-scale studies. The first
stage involves the completion of criterion-referenced screening review form 1 (RF1), which is undertaken by
nurses or experienced clinical governance facilitators, and the second, undertaken by doctors, is completion
of the modular review form 2 (MRF2). The Global Trigger Tool (GTT), developed by the US Institute for
Healthcare Improvement, is another widely used retrospective review of medical records, which uses a
time-limited pragmatic approach. This tool requires the random selection and limited case note review of
20 inpatient records per month per organisation. At the commencement of this study in 2011, Welsh health
boards had experience in using this tool, but its implementation was not regulated and commitment to the
methodology and the outcomes generated was highly variable across the Welsh health boards.
Study aims and objectives
This study aimed to obtain definitive longitudinal data on harm in NHS Wales hospitals and to compare the
performance of the GTT with the two-stage retrospective review process using findings to improve an
approach to ongoing surveillance of harm in the Welsh NHS.
The specific aims over the course of the project were as follows:
1. to gain an in-depth understanding of the nature and number of AEs occurring in the Welsh population
admitted to hospital over a 4-year period (2011–15), comparing the use of the retrospective two-stage
process and GTT reviews
2. to compare the scale and scope of health-care-related harm identified by the retrospective two-stage
process and GTT reviews
3. to develop a robust ongoing measurement system for harm
4. to embed this harm surveillance in organisations and to determine the organisational response.
Methods
The study was undertaken in two discrete data generation phases separated by a transition period to
undertake interim analysis informing phase 1. The second phase was followed by a final process evaluation
examining the impact of the study and its output data on the NHS health board recipients. The study
sample comprised two acute hospital sites from each of the six Welsh health boards. A sample size of
5000 records was calculated based on the incidence of harm found in previous studies.
Phase 1
In phase 1, we undertook a two-stage retrospective review of 20 adult patients per month with an inpatient
stay of > 24 hours who had been identified using a random system generator and whose notes had
been pulled for routine GTT review by health board staff. The study team then undertook a two-stage
retrospective review process. We added a harm determination phase at the end of the nurse screening
process and asked the nurses to rate their confidence in their decision on a 1–5 scale. Positive notes from
phase 1 were sent for a second-stage review by research physicians, who used the MRF2 to judge the
occurrence, nature, preventability and consequences of the referred event.
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Analysis of phase 1 data using Stata version 14 (StataCorp LP, College Station, TX, USA) followed the
conventional GTT method in which the aggregated data are converted into a harm rate and then compared
with a baseline. We used the same methodology to compare aggregate rates in the two methodologies. An
unweighted kappa coefficient was used to assess inter-rater reliability with corresponding 95% confidence
interval (CI) and the percentage of records that were concordant or discordant.
Transition phase
During the transition phase, a number of factors influenced the planning and execution of phase 2, including:
l the decision of NHS Wales to cease use of the GTT
l a mandate in Wales that every inpatient death must be assessed by review of the inpatient episode of
care, currently using the seven questions of the Universal Mortality Review (UMR) tool
l the need of the NHS for an operationally manageable tool using a one-step process.
On the basis of phase 1 data, we identified the criteria that were the most sensitive and specific markers
of AEs in current use and, furthermore, refined others to identify acts of omission to improve both the
identification of a wide range of events and the face validity of the tool with a range of health-care
professionals. The new screening criteria were included in a new tool, the Harm2 tool, which was developed
for the routine surveillance of AEs in practice. The Harm2 tool is a hybrid of the one-stage GTT process and
a condensed RF1 and MRF2 screening and measurement structure. We then trained a team of research
nurses in using the Harm2 tool to undertake medical record assessment across study sites.
Phase 2
The monthly sample of reviewed notes included 20 random discharges and 10 admissions of patients who
died from each study site using explicit case note selection criteria. During the analysis we assessed both
intermethod (RF1/MRF2 vs. Harm2) and inter-rater reliability.
We determined the percentage of patients experiencing an AE and the severity and level of preventability
of the incident. Univariate logistic regression assessed the relationship between demographic and chronic
disease states and the subsequent development of AEs. Descriptive statistics were used to describe
and compare the nature and severity of AEs in the random and deceased patient cohorts. We tested the
Harm2 tool against the two-stage process (intermethod reliability), and an unweighted kappa coefficient
was used to assess inter-rater reliability.
Service evaluation and impact assessment
From a constructivist perspective and using semistructured interviews, we explored the review process with
the RF1 reviewers and, from the perspective of key NHS informants, the value and use of the data by
health boards. Interview data were anonymised and thematically analysed. When available, documentary
evidence was used to confirm the narrative.
Findings
Phase 1
In total, 4536 episodes of care from 11 of the 12 invited hospitals were reviewed, with the number of
samples from individual hospitals ranging from 174 to 560. The mean age of patients was 64.1 years
(95% CI 63.48 to 64.66 years). A total of 1430 (32.6%) inpatient episodes of care had at least one
identified positive screening criterion for potential AEs (with a range seen across individual organisations of
between 23% and 43%) and, of these, 821 inpatient episodes (18.1%) were referred for in-depth physician
review and 790 were completed across the study sites (96.2%). At least one AE was determined in 10.3%
of all episodes of care (95% CI 9.4% to 11.2%). In total, 73.1% of patients with AEs needed additional
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxviii
treatment and/or days in hospital, 16% were discharged with a significant impairment to their functional
status and in 9% of cases the AE may have been associated in some way with the patient dying during the
inpatient episode. Physician assessment of problems in care in the referred sample revealed that failure
in clinical monitoring and management was identified in one-third of all events. Failure to manage and
prevent infection (29%), problems with an operation or procedure (21%) and problems in the prescribing,
administration or monitoring of drugs and fluids (18.7%) were identified as common problems in care.
We also found the following.
l There was a statistically significant increase in positive criteria with increasing age up to 85 years.
l The percentage of harm identified by non-physicians was 10.4%, which was comparable with that
determined by physicians, of 10.3%.
l Although there is a high level of agreement on harm identified in the professional groups, differences
in the type of events identified are recognised.
l There was a statistically significant association between mean length of hospital stay and risk of
experiencing an AE (p < 0.0001).
l The mean rate of AEs using the GTT methodology, across NHS Wales, was lower than the rate
reported through the two-stage retrospective review process (mean 9.0%, 95% CI 8.82% to 9.18%).
l We could profile the risk of AEs in individual organisations by producing signatures of harm for each
NHS site.
As part of the process of quality assuring the data generated from the RF1 reviews, we began to see
distinct patterns of harm emerging from individual organisations. We tested these patterns with site leads
by ranking the top five frequently occurring criteria that were linked to AEs for each organisation and
presenting these as their ‘organisational signatures’ of harm. Assessment of signatures of harm along with
the AE rate allows for (1) examination of how big an individual issue is within a health-care system, (2) the
triangulation of harm data with other organisational data such as incident reports, (3) a mechanism for
awareness raising around specific organisational issues or interventions and (4) a potential mechanism for
quality improvement evaluation.
Phase 2
Twelve NHS organisations participated in this phase between May 2014 and September 2015, during
which time we reviewed 4396 records from randomly selected discharges (n = 3352) and randomly
selected deceased discharges (n = 1044) samples. In the randomly selected discharges sample, at least one
AE requiring intervention or subsequent readmission was determined in 11.3% of all episodes of care
(95% CI 10.22% to 12.40%) and 59.6% of AEs were deemed to be preventable (95% CI 55.29% to
63.91%). In the deceased sample, at least one AE was determined in 315 (30.1%) episodes of care
studied (95% CI 28.13% to 33.8%2) and 61.7% of AEs identified were deemed to be preventable
(95% CI 57.49% to 65.91%).
Patient factors associated with AEs in the randomly selected discharges sample included being aged over
85 years and having peripheral vascular disease (PVD), hemiplegia or dementia. No association with
chronic disease was identified in the deceased group, but AEs occurred twice as frequently in emergency
admissions and were associated with increased length of stay.
In the 10% of the Harm2 tool records that were double reviewed, there was agreement in 336 out of
380 cases (88.4%; κ = 0.50, 95% CI 0.38 to 0.65). In 422 Harm2 reviews, the RF1 was also completed
and physicians using the MRF2 reviewed 74 inpatient episodes. Agreement on the presence of AEs was
evident in 58 out of 74 reviews or 78.4% (κ = 0.45, 95% CI 0.07 to 0.62), indicating a moderate level
of agreement.
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Service evaluation phase
We interviewed a total of 27 individuals including 14 reviewers (of whom 12 were from nursing or
midwifery backgrounds) and 13 members of health boards (of whom seven were medical directors or
assistant medical directors).
The review process
After training, reviewers found the Harm2 criteria clear and the tool easy to use, and monthly conference
calls enhanced reliability.
Factors that facilitated reviewing included the following:
l collaborative or unified notes, which made it easier to ensure that concerns and prescribed actions
were addressed
l live data, including discharge letters entered on the Welsh Clinical Portal (NHS Wales Informatics
Service), that were legible and could be accessed remotely.
Factors that challenged the review process included:
l poor-quality notes, especially those of deceased patients
l notes that had been digitised, as poor scanning, lack of searchability and automatic timeouts all
contributed to difficulties
l partly electronic and partly paper records, with separate records held by therapists
l a focus on a single episode of acute care, which prevented comment on the holistic care of people
with long-term mental illnesses admitted to an acute facility.
The management and usefulness of the data in health boards
Independent review was thought to be useful because it was resourced and offered freedom from
acculturation. However, it divorced learning from clinical practice. Owing to the small numbers of notes
reviewed monthly at the health board level, the usefulness of the data was perceived as limited in the early
months, although this increased as the numbers built up. The single page of output data was thought to
be excellent but not easily digested, and was thus considered too complex for widespread dissemination.
The key value of the data lay in the ability to compare harm rates in the randomly selected discharges
sample and randomly selected deceased discharges samples, as there was a suspicion that the study’s
mortality review process, similar to the UMR, was picking up features of the dying process rather than
harm per se. The harm signature presented to health boards contained no surprises, but was useful in
validating existing findings from Datix® (Datix, London, UK) and existing clinical dashboards.
Conclusions
The rate of harm detected across NHS Wales, using both the two-stage retrospective review process and
the new Harm2 tool, conforms to that found by previous studies conducted in both the UK and Europe.
Chronic disease is not strongly associated with the risk of incurring AEs or complications and data do not
need to be collected routinely on the presence of all comorbid conditions for improvement purposes.
With training and using a structured review process, non-physician reviewers undertake case note review
efficiently and effectively, and rates of AEs, preventability and breakdown of problems in care conform to
studies in which physicians undertake these classifications. The determination of preventability is, however,
challenging for reviewers. In 78% of cases there is agreement between professional groups on the
determination of harm events. There are, however, differences in the events identified.
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The Harm2 tool performed with moderate reliability in the determination of AEs, although screening
criteria can be further refined. The rate and composition of AEs are influenced by both the balance of
cases selected from different specialties and whether the patient died or was discharged alive.
A pragmatic approach with a robust measurement structure offers the potential for routine screening of
AEs in NHS organisations. However, stability in case note review teams is highly valued to ensure reliability
and highlight local learning.
Although chronic disease is not strongly associated with the risk of incurring AEs or complications,
older patients with pre-existing diagnoses of dementia, PVD and hemiplegia appear to be at greater risk
of AEs, probably as a result of underlying functional and cognitive impairment. Our data suggest that
organisational quality improvement efforts to improve the safety of the ward environment may reduce the
levels of AEs in these groups.
The difficulties encountered by our reviewers in navigating and finding information, in both paper and
digitised case notes, suggest that similar difficulties may be encountered in clinical practice.
It would be relatively straightforward to devise a means of continuing the current approach by sampling
across the country on a regular basis and undertaking comparative work with incident reporting systems,
but in the longer term we need to set measures of harm alongside measures of the beneficial effects of
health care first at the level of populations and, then, more ambitiously, for individual patients.
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
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Chapter 1 The measurement of harm in inpatient
settings: an overview
Background
Since the publication of the first Institute of Medicine reports on quality and safety in health care,1,2
there has been growing awareness of the number of patients unintentionally harmed in the course of
health-care management. Global estimates of incidents using a common measurement strategy vary,
but rates are normally reported to be around 10% of all inpatient admissions, with a range of 8–12%.3
In the last decade considerable effort has been made to improve patient safety through programmes and
campaigns,4 but questions persist as to whether or not these efforts are well directed. Are patients any
safer as a result? For all the effort and resource devoted to patient safety, we still do not know how much
progress has been made. The lack of the surveillance of harm in the health-care system,5,6 along with the
difficulties encountered in using these kind of measures to demonstrate beneficial effects in the evaluation
of patient safety and quality improvement programmes, continues to pose significant challenges to the
quality improvement community internationally.7–10
Welsh context for the study
Wales is in a unique position in relation to harm measurement and mortality assessment, being supported
by strong health policy and strategic leads working collaboratively across government, NHS Wales and
academia. In 2010, at the start of the study, all NHS providers voluntarily signed up to a national harm
prevention campaign, undertaking Global Trigger Tool (GTT) reviews every month in order to monitor
progress over time. Data collection preceded the launch of the 1000 Lives Campaign11 and a methodology
was developed to quantify the number of episodes of harm averted on a quarterly basis. NHS Wales made
an explicit commitment to the continuation of harm measurement across Wales for a 5-year period from
April 2010. The study was therefore timely and designed to sit alongside the NHS work, providing evidence
of impact and contributing to the ongoing development of a health-care quality measurement strategy for
NHS Wales.
During the study period, Wales has developed an active Harm and Mortality Collaborative, in which senior
members of health boards, the Welsh Government (WG) and Public Health Wales meet to review strategy
and progress on organisational patient safety metrics every 6 months. Through this agenda, and development
work undertaken by individual health boards, NHS organisations in Wales stopped undertaking GTT reviews
in Wales in 2014, and a mortality review process was developed and, subsequently, mandated for every
death occurring within acute care. A screening process was developed to identify those individuals for whom
problems in care may have been in some way associated with the nature and cause of death for the purpose
of organisational learning. These episodes of care were then intended to progress to a second-stage review,
which was not prescribed and varied considerably in approach across organisations. This approach was
endorsed by the Palmer review12 along with a suite of audit and critical incident investigations to generate
holistic and triangulated assessment of quality of care through these methods.
The identified need for the study
Wales did not have a benchmarkable national rate of harm in health care and, although GTT reviews
were being undertaken and there was national guidance on the GTT process, there was variation in the
composition of teams and the way in which the reviews were being undertaken. Some health boards
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1
opted for a multidisciplinary approach in which physicians were involved in determining adverse events
(AEs), whereas others had an approach in which the reviews were undertaken by clinical governance staff.
We wanted to determine how effective the GTT was in identifying health-care-related harm by comparing
it with the two-stage retrospective case note review process and to use this learning to develop an
approach for ongoing harm measurement. We know that system failures and causes of harm cannot be
addressed efficiently until issues are identified. Furthermore, the quantification of the nature and extent of
the problem provides the basis from which solutions and intervention programmes can be developed and
subsequently monitored and evaluated. The starting point for this study was to quantify national rates of
harm longitudinally across NHS Wales and to develop methodologies for the reporting of trends of common
AEs, thereby providing organisations with the methodological know-how and data to complement current
incident reporting practice and support the adoption and embedding of innovative ways of working and
revised practices and processes.
The work fitted into a tripartite arrangement comprising the NHS, academic units and the WG (Figure 1).
The aim was to develop a comprehensive programme of work describing the epidemiology of harm in NHS
Wales hospitals, and to develop and evaluate methods for the systematic assessment of harm collected
from a wide range of sources, with the end point being a move towards the active surveillance of salient
events.13 At the national level, the priority was the accurate and holistic measurement of harm14,15 as part
of the development of national safety indicators. At the local level, the aim was to promote a culture of
learning both from critical incident investigation and the identification of systemic issues in order to inform
safety and quality improvement programmes.
NHS-led and -funded harm monitoring
• Development of GTT methodology 
• Monitoring of HSMR
Participation by all NHS organisations in 
Wales funded by the Welsh NHS
Academic-led measurement and validation 
funding through research bodies
• Definitive measurement of harm in the 
   Welsh NHS
• Development of pragmatic measurement 
   tools
Methodological capacity-building 
initiatives funded through 
the Welsh Government
• Funding of health-care quality and safety 
   academic network
• Small grants supporting RDGs in patient
   safety research
• Methodological seminars
• 1000 Lives11 improvement work
The epidemiology of 
harm in the Welsh NHS
FIGURE 1 Tripartite arrangement addressing the epidemiology of harm in NHS Wales. HSMR, hospital standardised
mortality ratio; RDG, research development group.
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The measurement of harm
In the UK, a review of case notes from single study sites suggest that 8–10% of patients experience an AE
during inpatient management.14,16 One systematic review of international studies, published in 2008,
attempted to gain an overview of data and quantification of what is widely recognised as a ‘serious
problem in health care’.3 The median overall prevalence of in-hospital events was 9.2%, with a median
percentage of preventability of 43.5%. More than half of these patients experienced no or minor disability,
and 7.4% were associated with, but not necessarily causally implicated in, the death of a patient.
Although the reporting of snapshot prevalence data has its uses, we know that the examination of AEs
in health care is complex. As seen in aggregate data from studies, summated AE rates are difficult to
interpret and conceal a range in severity from minor injuries caused by hospital equipment to catastrophic
wrong-site surgery. Work undertaken to date has provided little detail on how the measurement and
characterisation of AEs informs learning and the development of interventions, which then have the
potential to have a demonstrable impact on clinical processes and practices.
In recent years, as interest and awareness of patient safety issues in health care grows, different
methodologies have been used in widely different settings and contexts and for various purposes.17–21
Although progress on measurement and evaluation is being made within the emerging international
agenda of improvement science, challenges remain. Despite comprehensive work undertaken to develop
an international classification for patient safety,22 there is still evidence that key concepts and terms are not
consistent across research studies and improvement efforts. Fundamental questions still exist around the
prevalence and nature of AEs and, perhaps most importantly, opportunities for the effective targeting of
interventions and prevention programmes.23
Reporting systems, such as the National Reporting and Learning System in the UK, have been the principal
mechanism through which AEs are reported into a centralised repository that is organised at both local
and national levels. Vincent et al.13 describe how these systems invite voluntary reporting of unspecific
safety incidents with the aim of learning lessons and feeding the findings back into the system. Although
providing useful examples of cause and effect for the purposes of both professional and organisational
learning, the reporting systems are not representative of AEs in patient populations, and a number of
studies give rise to concern of significant under-reporting. In one UK study, reporting systems detected
only 6% of AEs found through the systematic review of inpatient records24 and similar findings have been
reported within the US health-care system.4 With heightened awareness of the number of patients being
harmed as a result of health care, there is consensus across health, academic and policy settings that,
although these systems are a valuable component of a safety system, they are primarily warning and
communication mechanisms within organisations and will never act as a measurement system for safety.13
In 2015, health-care organisations and strategists still continue to grapple with identifying reliable and
valid, yet pragmatic, tools to measure the quality and safety of care routinely provided.4
Methodology of adverse event measurement
Measurement describes events in terms that can be analysed statistically, and should be free from random
and systematic error.25 The measurement of errors and AEs in health care, however, is complex and AEs
need to be assessed and understood in the context in which they occur.26 James Reason’s27 ‘Swiss cheese
model’ has increased our understanding that errors and AEs in health care are commonly the result of
numerous latent errors in addition to an active error committed by a practitioner.26 Despite this growing
understanding and theoretical underpinning, the actual determination of an AE is still often a subjective
and complex task for even the most experienced clinician.
The literature reports numerous methodologies used to quantify harm and error in health care, with each
method being associated with strengths and limitations.26 They include the review of post mortems and
medico-legal claims, summative data outputs from reporting systems, clinical outcomes reported through
administrative data set analysis, structured review of medical records, ethnographic observation of practice
and the clinical surveillance of specific events. Methods differ in a number of ways. Although some
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methods are oriented towards detecting the number of AEs, others address their nature and contributory
factors. The scale also varies significantly: some focus on single cases or a small numbers of cases with
particular characteristics, such as claims, whereas others attempt to randomly sample a defined population.
Thomas and Petersen26 suggest that the methods can be placed along a continuum, with active clinical
surveillance of specific types of AE (e.g. surgical complications) being the ideal method for assessing
incidence, and methods such as case analysis and morbidity and mortality meetings being more oriented
towards causes. It is clear that there is no ideal way of estimating the incidence of AEs in health care and
all methods give a partial picture of the true extent of the problem.
Retrospective case note review
Retrospective review of medical records has been for 25 years the methodology of choice in large-scale
studies of harm in health-care systems. Originating from the Harvard Medical Practice Study,28,29 and
adopted for UK use by Woloshynowych et al.,30 the process aims to assess the nature, incidence and
economic impact of AEs and to provide some information on their causes. An AE is defined as an
unintended injury caused by medical management rather than the disease process that results in harm
to the patient or, at the very least, additional days in hospital. The review is undertaken in two stages.
In stage 1, and using the review form 1 (RF1), nurses or experienced clinical governance facilitators are
trained to identify case records that satisfy one or more of the 18 well-defined screening criteria shown
to be associated with an increased likelihood of an AE. These criteria include unexpected death, clinical
complications such as myocardial infarction (MI) and deep-vein thrombosis (DVT), unplanned transfer to
a higher level of care, and readmission to hospital within a specified time frame.31 In stage 2, using the
modular review form 2 (MRF2), doctors trained in the use of a standard set of questions analyse positively
screened records in detail to determine whether or not they contain evidence of an AE. The basic method
has been followed in all the major epidemiological studies,14,16,32–39 although there have been modifications
to the review form and data capture methods.30
Previous work in a UK setting,16,24 assessing the sensitivity of the two-stage review process, reported a
sensitivity of 92% and a specificity of 62%. There was high inter-rater reliability between trained nurse
reviewers in a subset of records (84%, κ = 0.68) and lower agreement by physicians on the presence
(86%, κ = 0.64) and preventability of AEs (83%, κ = 0.44). In the largest study to date, undertaken in
the Netherlands, the reliability of the assessment of screening criteria by nurses was reported to be good
[82%, κ = 0.62, 95% confidence interval (CI) 0.54 to 0.69], with lower reliability reported in (1) the
determination of AEs by physicians (76%, κ = 0.25, 95% CI 0.05 to 0.45) and (2) the determination of
the preventability of AEs (70%, κ = 0.40, 95% CI 0.07 to 0.73).39 An in-depth analysis of the methods
used to undertake case note review in a UK setting confirmed this trend; inter-rater reliability was higher
when objective criterion-based tools, such as screening tools, were used than when more holistic
assessment is required in order to make a clinical judgement on the quality of care provided (intraclass
correlation coefficient 0.61–0.88 vs. 0.46–0.52).
Professional determination of adverse events
The traditional methodology of AE determination involves nurse screeners examining records for criteria
that are suggestive of an AE [known as explicit (criterion)-based assessment]; this is followed by an implicit
(holistic) assessment, also referred to as a global assessment of care, which is undertaken by physicians.18
Relying on physician review of whole episodes of inpatient care is time-intensive and expensive, a factor
that is naturally prohibitive and has resulted in a trend in health-care organisations of using either nursing
staff or trained clinical governance staff to complete retrospective case note reviews. Nursing review may
well be the way that organisations can afford to invest in a longitudinal assessment of quality-of-care
issues. However, it is important to ensure that organisations understand what different clinical groups are
measuring and the attendant implications for the results reported through any such activity. Of interest,
work undertaken in the UK indicates poor consensus between physicians and nurses when assessing the
quality of overall care (intraclass correlation coefficient 0.24–0.43).18 Detailed analysis of the clinical
summaries of the episode provided by the reviewers has revealed that the professional groups provide
detail on different aspects of care. Non-clinical staff reported facts from the notes, nurses provided
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commentary around the process of care, along with implicit judgement on the quality of care, and
physicians focused on technical aspects of care, making explicit judgements on the quality of care.18
Weingart et al.40 also drew similar conclusions, reporting that nurse and physician reviewers often came to
substantially different conclusions while examining the same episode of care. Professional groups agreed
more often about complications of care than global quality-of-care assessment, but inter-rater agreement
varies substantially by the nature of the complication being assessed. They concluded that ‘reviewers
agreed more often about complications in surgical cases than medical cases (κ 0.59 vs. 0.36), but
agreement about quality was little better than chance’.40 Strategies have been proposed to improve the
inter-rater consensus between reviewers by including multiple implicit reviewers and excluding reviewers
with extreme ‘hawk and dove’ approaches to case note review, but these have little applicability to
service-led quality improvement that is oriented around professional and clinical learning and, furthermore,
have been found not to improve agreement in research studies.39
The Global Trigger Tool: a pragmatic approach to case note review
The GTT is another retrospective method used to review medical records, which was developed by the
Institute for Healthcare Improvement (IHI) and is used throughout the world by countries adopting the IHI
improvement methodology. It uses a time-limited pragmatic approach. The methodology centres on the
random selection and limited case note review of 20 inpatient records per month per organisation.
Qualified nurses and clinical governance facilitators commonly undertake reviews and the tool comprises
similar criteria to those included in stage I of the two-stage review described previously in Retrospective
case note review.
The largest reported study to date, which described temporal trends of AEs in 10 hospitals in North
Carolina, USA, reported 25.1 AEs per 100 admissions. This rate of harm is significantly higher than rates
reported using the two-stage retrospective review process, but statistically significant changes in rates over
a 5-year period were not observed despite concurrent improvement efforts in the study sites.19 Even higher
rates of detection of AEs using the GTT methodology have been confirmed in other studies, for which AE
rates in hospitalised patients are consistently reported to be > 30% of all inpatient admissions.4,21,41–43
Naessens et al.41 assessed the ability of nurse reviewers, using GTT methodology, to detect AEs in four US
hospitals and reported favourable levels of detection of both triggers (κ = 0.63, 95% CI 0.58 to 0.68) and
AEs (κ = 0.51, 95% CI 0.45 to 0.57). In a study evaluating the reliability of the GTT in tracking local and
national AE rates, agreement by nurse reviewers was reported to be within a range of κ = 0.40–0.60.
Significantly, internal teams were found to perform consistently better than external teams coming into
organisations to undertake reviews of care.
A comparative analysis of the Global Trigger Tool and the Harvard
method approaches
The GTT was conceived and developed to circumnavigate many of the challenges in implementing a
resource-intensive multidisciplinary two-stage review process in routine clinical practice. The origins, key
characteristics and measurement processes are described in Table 1, which is adapted from Unbeck et al.42
Although intending to measure the same construct, a few key differences emerge. First is the origin of
development. The GTT aims to provide information to support patient safety efforts and monitor trends of
harm events over time. In contrast, the Harvard tool, despite having origins in a medico-legal context, is
now commonly used to provide point prevalence estimates of harm in health care on a national scale. The
Harvard tool is labour-intensive; the GTT is time limited. Perhaps more significant differences emerge in the
type of harm identified and the subsequent assessment of that harm. The Harvard tool directs the reviewer
to potential harm events that include acts of both omission and commission, whereas the GTT detects only
acts of commission. A physician confirms the presence of a harm event in the Harvard methodology and a
physician who may have not read the record of the episode of care confirms the harm event in the GTT.
Preventability is not assessed in the GTT, but, along with management causation, is central to the
Harvard methodology.46
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The GTT and RF1 do, however, overlap in some of the methodological components and have criteria/
triggers in common where it would be expected that there would be minimal variation in the identification
of these in records. However, rates of AEs in the Harvard method are computed on the determination of
harm and preventability and, in this respect, there are significant differences between the approaches. In
the absence of a structured phase 2 process in the GTT, harm determination is viewed to be more prone
TABLE 1 Key characteristics of the Harvard and GTT methods
Characteristic of
interest
Method
Harvard GTT
Origin of tool The Harvard Medical Practice Study Quality improvement tool for clinical practice
developed by the IHI
Medico-legal and focus on negligence in
the first studies and, thereafter, quality
improvement and preventability perspective
Track A&E rate over time in a hospital or a clinic
Definition of harm An unintended injury or complication that
results in disability at discharge, death or
prolonged hospital stay and is caused by
health-care management rather than the
patient’s underlying disease
Unintended injury resulting from or contributed to
by medical care that requires additional monitoring,
treatment or hospitalisation, or that results in death
Nature of harm Includes both omission and commission Includes commission, excludes omission
Sample Random, big samples to measure the
incidence and to generalise the result
Random, small samples sufficient for the design of
safety work over time
Screening Generally undertaken by one nurse who
screens for 18 criteria in the medical record
First screening independent for one of 54 triggers
by trained nurses (can be other professionals),
focus on triggers, no comprehensive reading, reads
just relevant parts related to found triggers; second
reviewer provides consensus
Frame for
inclusion
An AE had to have occurred before or during,
and be detected during and/or after, index
admission
30-day inclusion period before and after index
admission
Criterion/trigger An indication that patient harm may have
occurred. Directs the medical reviewer to
relevant parts of the records by the notes
54 triggers, mostly narrow
18 criteria; some criteria/triggers are AEs by
definition, for example health-care-associated
infections and hospital-incurred injury
Review stage 1 Comprehensive reading: non-time-limited
identifies screening criteria indicating an AE
may be present in the notes
Time limited
Finds triggers, describes the potential AE and
categorises harm according to the NCC MERP’s
Categorizing Medication Errors Index44,45
Review stage 2 Assess the AE by using different scales
according to, for example, causation, severity,
preventability, timing, causes and types
One physician, who does not generally review the
record but does authenticate the consensus findings
of the reviewers and the severity rating, and
answers questions from reviewers in review stage 1
No assessment of preventability
Number of harm
events
Generally includes only one AE per patient,
that is, the most severe
All identified AEs are included
A&E, accident and emergency department; NCC MERP, National Coordinating Council for Medication Error Reporting
and Prevention.44,45
Source: adapted from Unbeck et al. 2013. © 2013 Unbeck et al.;42 licensee BioMed Central Ltd. This is an Open Access
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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to systematic bias.5,41,43 Further questions arise as to what the GTT methodology is actually measuring, as,
even when events caused by omission are not quantified, rates of reported harm are threefold higher than
when the Harvard method is used. It might well be that triggers are being misclassified as AEs and/or
multiple triggers relating to one AE are being classified as multiple AEs.
The assessment of internal validity of the GTT is challenging. In a European context, von Plessen et al.47
examined rates of harm using the GTT in five Danish hospitals and reported significant variation between
hospitals ranging between 18% and 33%. However, in another, more regulated, smaller study comparing
the identification of AEs in 350 orthopaedic admissions in Sweden, the Harvard method detected 155 AEs,
compared with 137 events detected by the GTT. AEs causing harm without disability accounted for most
of the observed difference, with the positive predictive value being 40.3% and 30.4%, respectively.42
Importantly, this suggests that, within a controlled study environment, the performance of the
methodologies can be reasonably similar.
Retrospective case note review in inpatient deaths
Using case note review as a way of examining the quality of care in patients who die has always been a
traditional part of modern surgical practice. Following the introduction of the hospital-wide mortality ratio
in the early 2000s, the scope of hospital death reviews widened as they became a mechanism for
understanding the underlying causes of variations in these measures and determining if ‘excess deaths’
identified represented deaths that were attributable to avoidable health-care-related harm. In 2010, the
Mid-Staffordshire Foundation Trust scandal focused attention on the issue of avoidable deaths in the NHS
and prompted the WG to mandate case note review of all deaths in health boards to provide reassurance
for patients and quality assurance within the Welsh NHS.48,49 The approach built on local mortality review
processes, which were variable in terms of the number and clinical background of reviewers, sampling,
review tools and organisation. In 2012, an element of standardisation was introduced with the adoption
of a single screening tool. The majority of hospitals in England have also been developing systems for
mortality review and, as in Wales, the approaches adopted have varied between sites.
Mortality review can provide a window on a hospital’s safety and quality. Patients who die as inpatients tend
to be older, have more comorbidity and require more complex interventions. Such patients test the system
and reveal weaknesses that, in turn, may generate harm. Evidence from retrospective case note record review
studies does indicate that the types of problems in care experienced by patients who die are different from
those who survive, with more diagnostic errors and problems related to clinical monitoring and relatively fewer
problems related to surgical or technical procedures.29,32,39 Mortality review is not just an efficient approach to
identifying avoidable health-care-related harm, but also provides a window on the quality of the clinical care
received by the patient, particularly during the dying process. With a growing elderly population, and the
recent withdrawal of the Liverpool Care Pathway following some high-profile abuses,50 this area of care has
been attracting increasing scrutiny in the UK. Moreover, clinicians are concerned about deaths and these
concerns act as a rallying cry to engagement in quality improvement initiatives.
There are obvious limits to the scope of feedback on quality and safety that can be provided by reviewing
deaths. Fewer than 1.5% of the 15 million admissions to the NHS in England and Wales each year end in
death, and some specialties, such as ophthalmology or dermatology, will experience such an event only very
rarely.51 Examining deaths at the hospital level may result in uncovering relatively few heterogeneous quality
and safety problems, making it challenging for staff to know where best to direct their improvement efforts.
Over half the population end their natural lives in hospital,52 and judgements on whether or not a death was
caused by health care and, therefore, avoidable are notoriously difficult in patients with only hours or a few
days of natural life remaining. For these reasons, any comprehensive hospital-based surveillance programme
requires identification of health-care-related harm across the full spectrum of patient admissions, both those
who die and those who are discharged alive. The approach taken to date in Wales includes assessment of
harm events across the whole inpatient population and an overview assessment of every patient death,
ensuring that there are no concerns identified in the care provided in the final inpatient episode.
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Summary
Over the last 25 years there has been concerted effort internationally to quantify the safety of health-care
delivery. The original Harvard method, which was developed primarily as a research tool, informed the
development of a more pragmatic method for routine surveillance and patient safety work. As the Harvard
tool is predominantly used in academic settings, Wales adopted the GTT as a routine surveillance and
patient safety tool across Welsh health boards and was gaining experience in its use. The GTT was used as
part of a measurement strategy in both the Health Foundation’s Safer Patients Initiative and the 1000 Lives
Campaign,11 and with some success. However, the experience of NHS Wales Hospitals using the IHI GTT
was similar to that reported in Danish hospitals,47 and there was significant variation in rates and
experience in its use across hospital sites. As Wales was committed to ongoing harm measurement and
monitoring, we set out to compare the methodological approaches in order to identify the optimal
approach to quantify the nature and extent of AEs occurring across NHS Wales’s acute hospitals over time
and ensure the robustness of our current approach. Furthermore, we aimed to explore the contribution
of harm measurement within a broader health-care quality metric framework and, most importantly,
to understand how harm data can be used to inform and evaluate improvement efforts.
Study aims and objectives
Research question
What is the nature and extent of AEs occurring in the Welsh population admitted to hospital over a
4-year period?
Study aims
This study aimed to obtain definitive data on harm in NHS Wales hospitals and to compare the
performance of the GTT with the two-stage retrospective review process, using findings to develop an
approach to ongoing surveillance of harm in the Welsh NHS.
The specific aims over the course of the project are as follows:
l to gain an in-depth understanding of the nature and extent of AEs occurring in the Welsh population
admitted to hospital over a 4-year period comparing the use of both the retrospective two-stage
process and GTT process
l to compare the scale and scope of health-care-related harm identified by the retrospective two-stage
process and GTT process
l to develop a robust measurement system for harm
l to embed this harm surveillance in organisations and determine the organisational response.
Study outcome definitions
Adverse event
We defined an ‘AE’ as an ‘unintended injury or complication causing temporary or permanent disability
and/or increased length of stay (LOS) and resulting from health-care management’.
Preventable adverse event
A six-point scale was used to assess the likelihood of a causal link between the care given and the injury
and the likelihood that the event was preventable. The assessment of preventability was restricted to the
research team and MRF2 reviewers, as the assessment of preventability is not a component of the GTT
methodology.46 A judgement was therefore made by research physicians on the likelihood that the harm
event may have been prevented (if care was delivered to the standard you could expect in that particular
situation). Preventability was reported in three major categories as outlined in Box 1.
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Severity of adverse events
The assessment of the severity of harm in the MRF2 second stage of the two-stage process is rated in both
physical impairment and emotional trauma terms, and ranges from no impairment or trauma to death and
severe trauma lasting more than 1 year. The scale is outlined in Table 2.
In the GTT, severity is rated using categories E to I of the National Coordinating Council for Medication
Error Reporting and Prevention (NCC MERP)’s Categorizing Medication Errors Index53 (Table 3).
Overview of study design
The overall aim of phase 1 was to compare outcomes and rates of harm from both the retrospective
Harvard and GTT methods. Using a common sample, NHS teams undertook harm assessment using the
GTT and the research team used the Harvard method. Aggregate levels of harm were compared in the
two methodologies using the same methodology. Secondary analysis involved linking generated data sets
by unique study number and examining the consensus between methods and professional groups on the
identification of AEs. Findings and experience from phase 1 were used to inform the national case note
review process in phase 2.
The study transition from phase 1 to phase 2
A transition phase from phase 1 to 2 was not originally built into the project plan. A no-cost extension was
sought, as we undertook analysis of the data and synthesis of the learning from the comparative data
generated from phase 1. This development period ensured that evidence, experiential learning and the
current NHS and policy environment informed the method and implementation of phase 2. Phase 2 aims
and methods were subsequently agreed with the National Institute for Health Research Health Services and
Delivery Research programme and operationalised 6 months after completion of phase 1 (Figure 2).
Considerations for the development of harm phase 2
There are a number of factors that influenced the way we planned and executed the second phase of the
study, and these are detailed as follows.
BOX 1 Likert scale of preventability of health-care harm
No preventability
1. Virtually no evidence for preventability.
Low preventability
2. Slight to modest evidence of preventability.
3. Possibly preventable, but not very likely (less than 50–50, but close call).
High preventability
4. Probably preventable (more than 50–50, but close call).
5. Strong evidence for preventability.
6. Virtually certain evidence of preventability.
Adapted with permission from BMJ Publishing Group Limited (Case record review of adverse events: a new
approach, Woloshynowych M, Neale G, Vincent C, vol. 12, pp. 411–15, 2003).30
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TABLE 2 Classification of physical and emotional harm from the Harvard methodology
Level of physical and emotional impairment Description of level of impairment
Physical impairment
0 No physical impairment or disability
1 Minimal impairment and/or recovery in 1 month
2 Moderate impairment, recovery in 1–6 months
3 Moderate impairment, recovery in 6 months to 1 year
4 Permanent impairment, disability 1–50%
5 Permanent impairment, disability > 50%
6 Permanent nursing
7 Institutional care
8 Death
8.1 Death unrelated to A&E
8.2 Minimal contribution from A&E
8.3 Moderate contribution from A&E
8.4 Death entirely due to A&E
9 Cannot reasonably judge
Emotional trauma
0 No emotional trauma
1 Minimal emotional trauma and/or recovery in 1 month
2 Moderate trauma, recovery in 1–6 months
3 Moderate trauma, recovery in 6 months to 1 year
4 Severe trauma, recovery lasting longer than 1 year
5 Cannot reasonably judge
A&E, accident and emergency department.
Adapted with permission from BMJ Publishing Group Limited (Case record review of adverse events: a new approach,
Woloshynowych M, Neale G, Vincent C, vol. 12, pp. 411–15, 2003).30
TABLE 3 The NCC MERP’s Categorizing Medication Errors Index of health-care error
Level of severity of harm event (category) Description of severity of harm event
E AE causing temporary harm and requiring intervention
F AE causing temporary harm and hospitalisation and/or
extended stay
G AE causing permanent harm
H AE requiring life-saving intervention
I AE contributing to or causing patient death
Adapted from NCC MERP Taxonomy of Medication Errors.53
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NHS Wales’ decision to stop using the Global Trigger Tool methodology
Prior to any recommendations from the study team, NHS organisations in Wales had already made the
decision to stop using the GTT, as it did not meet organisational requirements to understand harm
occurring within the system and provide accessible data to inform and evaluate remedial or improvement
activity. Most organisations, however, continued with the process, facilitating the completion of phase 1
aims. This NHS stance was confirmed in the interim descriptive analysis of our data, which demonstrated
the variability in the identification of AEs using this tool across study sites and the paucity of information
on whether or not the harm event was caused by health-care management or was preventable, thereby
limiting clinical learning and prioritisation. The last Welsh health board to stop using the GTT did so in
July 2014. At this point, the GTT ceased to be a viable option for NHS Wales and hence for the study
going forward into phase 2.
A UK-wide focus on inpatient deaths as a system-level measure of quality
Learning from the Mid-Staffordshire Inquiry, in 2013 Wales mandated that every death occurring within
the secondary care setting be assessed by a review of the inpatient episode of care.48,49 A screening
process was developed by the Harm and Mortality Collaborative (NHS led) to identify those individuals for
whom there were concerns about the nature and cause of death for the purpose of organisational
learning. These episodes of care were then to proceed to a second-stage review identifying contributory
factors and clinical and organisational learning. This development was aligned with the future expectations
GTT reviews undertaken
 and led by the NHS 
across Welsh health boards
Two-stage 
retrospective reviews 
undertaken on same case 
notes led by research team
Interim phase: January 2014–June 2014
Interim analysis of study findings from n = 4388 reviews of episodes 
of care
Synthesis of experiential learning to develop a new tool and 
methods for the implementation of phase 2
Pilot of Harm2 Tool
April 2010: end of 24-month patient 
safety 1000 Lives Campaign,11 using 
GTT as harm measurement tool
September 2010: launch of the 
Harm and Mortality Collaborative
April 2012: launch of 1000 Lives Plus 
programme54
May 2012: launch of Achieving Excellence: 
The Quality Delivery Plan for the 
NHS in Wales 2012–201655
January 2013: Providing Assurance, 
Driving Improvement: Learning From 
Mortality and Harm Reviews in 
NHS Wales54
July 2013: Delivering Safe Care, 
Compassionate Care48 – mortality 
reviews mandated for all acute 
care deaths
July 2014: cessation of GTT reviews 
across NHS Wales
July 2014: the Palmer Report:12 
review of the use of risk adjusted 
mortality data in NHS Wales 
October 2014: convening of 
All Wales Mortality Review 
Steering Group
 Phase 1: active data collection January 2011–December 2013
Phase 2: July 2014–October 2015
Active data generation measuring and assessing AEs across NHS 
Wales hospitals, using the Harm2 Tool
Evaluative phase: September 2015–December 2015
Evaluation of the operationalisation of Harm2 across NHS Wales 
and the NHS response to it
Final analysis of Harm2 and study write-up
FIGURE 2 Schematic diagram of the study process and corresponding national harm and mortality publications
or activity.
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of the medical examiner role, and a national steering group was set up to co-ordinate strategy, activity and
monitoring of implementation.
Although the Welsh mortality review process did not set out specifically to measure AEs and was focused
more on overall quality-of-care issues, a number of health boards were using GTT or RF1 screening criteria
to identify AEs during the mortality review. At the time of phase 2 development, there was no peer-reviewed
international literature examining AEs occurring in patients who die in the hospital setting. No study had
reported on whether or not AEs in inpatient deaths have the same profile and composition of AEs as those
occurring in the remaining 98% of the inpatient population. It is thus unclear if targeting deaths is an effective
mechanism for identifying problems in care and prioritising quality improvement at the organisational level.
Conversely, NHS leads for patient safety made the point that in respect of assessing quality across inpatient
populations, the measurement and monitoring of harm across the inpatient population may provide more
opportunities for learning. The identification of inpatient AEs gives a greater level of assurance of system-level
organisational safety and quality issues. A decision was made to include in our sample patients whose inpatient
episodes resulted in death in order to make a direct comparison in these groups and thereby rationalise and
provide an evidenced-based perspective on national-level priorities for patient safety monitoring.
NHS Wales’ reluctance to implement a two-stage review process for routine
harm monitoring
Every health board in Wales had committed resources to innovatively evaluate the quality of health care
through the review of every death occurring across the system. The resource issues associated with
adopting an additional two-stage review as part of routine harm assessment was something that would
not be sustainable at the end of the study period and the study team agreed with the NHS and policy
leads that this would not be an approach that we would pursue. This meant that neither the GTT nor the
Harvard method was a candidate tool for sustainable implementation in Wales, and further work was
needed to identify a method that had robust characteristics and was fit for purpose for ongoing routine
harm monitoring across NHS Wales.
Recognition that current tools may be effective in identifying adverse events caused by
commission but under-report and characterise events caused by omission
The GTT does not include AEs caused by acts of omission and nor are these acts explicit in the RF1 criteria.
As part of our interim and exploratory analysis, we undertook thematic analysis of selected clinical
summaries generated in phase 1 of the study. This analysis enabled a characterisation of AEs arising from
specific areas of clinical or managerial risk, such as readmission and unclassified risk, which did not fit into
any screening criteria. What emerged from this analysis were AEs that were caused by acts of omission,
which included delayed and missed diagnosis. Including these acts of omission in the screening criteria
offered the opportunity to expand the characterisation of the risk of AEs in secondary care settings and
became a key focus for phase 2 of the study.
As a result of the interim thematic analysis, the comparative data on the two most commonly used
methods to measure harm in a health-care system and our experience of using both methodologies over
a period of time, we were well placed to undertake an evidenced-based assessment of how NHS Wales
could continue to measure the safety of care delivered across health boards.
The review of phase 2 aims
In our original proposal, the focus of phase 2 was to robustly monitor AEs over time. As described, the
amount of learning from phase 1 superseded what became a blunt aim and we identified a number of
additional aims that were included in the revised protocol. These are detailed as follows.
To develop a robust measurement system for harm
One of the key points of learning emerging from phase 1 of the study was the need to rationalise the data
collected during the case note review process. The GTT provided a paucity of data and the Harvard
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methodology gave data sets that were unwieldy and labour-intensive both to collect and input. At this
point, these tools had been used repeatedly over studies and improvement initiatives with few structural
changes made to the original versions. Some countries, for example Sweden, were beginning to supplement
the GTT with components of the Harvard methodology, such as the assessment of preventability. We had as
our focus efficient data generation that could be used directly by NHS organisations but was still aligned in
measurement and definitional structure to robust AE determination.
Having data generated from > 4000 reviews using both methods, we set out to examine the components
of both tools, the data generated from each tool and how the tools fitted in with both national and
organisational priorities for safety and quality metrics. We also attempted to identify any changes that had
been made to the tools, as reported in quality improvement or research reports. In addition, as the review of
deaths was a key focus across UK countries, we also included a review of the PReventable Incidents Survival
and Mortality (PRISM) study tool for the assessment of avoidable mortality. This assessment led to the
subsequent development of the Harm2 tool, of which the main characteristics are pragmatic GTT structure and
a Harvard method AE measurement structure, with an assessment of preventability and contributory factors.
In addition to implementing this tool and assessing its performance against the Harvard method, phase 2
offered the opportunity to provide an evidenced-based perspective on AEs occurring in patients who die
during their period of hospitalisation. Not only was this intended to provide a comprehensive view of AEs
across the inpatient spectrum, but we believed that this could inform and clarify future priorities for
national system-level metrics for quality and safety based on empirical evidence and distanced from the
controversy surrounding the use of metrics, such as the hospital standardised mortality ratio. Although
aligned in terms of building the evidence base around safety in inpatient settings using structured case
note review, it differed from the work led by Hogan et al.20,56 (PRISM study), asking different questions
(what is the proportion of patients experiencing AEs? as opposed to what is the proportion of avoidable
deaths?), and being heterogeneous in terms of measurement end points (AEs vs. problems in care) and
sampling procedures (longitudinal monitoring vs. random snapshot).
A number of additional components were added to the tool, such as the assessment of comorbidity at the
time of inpatient management and the specific identification of issues (such as learning disability and
dementia) to increase our understanding across a national health-care system on the epidemiological
characteristics of AEs.
To embed this harm surveillance in organisations and determine the
organisational response
The Harm2 tool was operationalised in a similar way to phase 1. After training, research nurses screened a
random sample of inpatient records before making judgements on the presence of AEs and their severity
and preventability. A 10% sample of records was double reviewed using the Harvard method and research
physicians were used to confirm or refute the presence of AEs.
The tool was shorter and data fields designed to be entered easily into a spreadsheet. Improved timeliness in
terms of data entry enabled us to feedback periodically into organisations the summary findings and the
details of episodes of care for which AEs were identified. As this was a new tool with novel data and
information feedback, we undertook a service evaluation involving both the research team and NHS sites to
explore issues of logistics, feasibility, face validity and implications for quality improvement and assurance at
both the organisational and national level.
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Chapter 2 Measuring harm in Wales
Aim 1
To compare outcomes and the extent of harm in a random sample of NHS Wales admissions from both
the retrospective two-stage process and the GTT process.
Objectives
l To provide a baseline estimate of the number and percentage of Welsh service users who are harmed
during the course of their inpatient admission.
l To examine harm events and make a judgement on their preventability.
l To examine harm events and categorise them in terms of severity and the specialty and health-care
intervention resulting in the harm event.
l To examine episodes of harm in detail and characterise the service users most likely to experience a
harm event during their period of hospitalisation.
Methods
The retrospective two-stage process was undertaken alongside the current infrastructure of NHS-led GTT
reviews, in order to compare the rates and quality of information generated on inpatient harm at the
health board and national level.
The review tools
The two-stage retrospective review process methodology originally devised in the early 1970s for the
Californian Insurance Feasibility Study was refined for use in the Harvard study and subsequently used
internationally.14,16,32–39 The study groups all made sequential changes to the original form by adding or
subtracting questions, but maintaining the basic format. Charles Vincent and his group made revisions to the
review forms, providing a stronger focus on causation and a more tightly structured format after using the tool
in a UK setting; this iteration, known as the MRF2,30,31 is the one used in the study and found in Appendix 1.
Structurally, in terms of the screening criteria, the RF1 remained the same as used in previous studies. We
did, however, introduce to the RF1 a narrative of the inpatient episode to provide context to any positive
criteria or conversely any episode of care determined to be a negative screen. Furthermore, because we
were interested in examining the nursing cohort’s determination of AEs, we asked nurses to make their
own determination of AE occurrence at the end of the screening process and rated their confidence in
their decision on a 1–5 scale (1 being not at all confident and 5 being very confident). This nurse-led
process was structurally similar to the GTT process, in that a timely screening review was followed by AE
determination. A copy of the amended RF1 is found in Appendix 2.
The Global Trigger Tool process
No changes were made to the current practice and protocols for undertaking GTT reviews across NHS
Wales during the study period. The GTT reviews were undertaken using a structured Welsh GTT pro forma
derived from the IHI process,46 with teams being advised to spend no longer than 20 minutes reviewing
the discharge summary, medication charts, laboratory results for that admission, operative/theatre
documentation, and nursing and medical documentation. If a trigger was identified in the notes,
the reviewers made a decision on whether or not harm had occurred and rated its severity using the NCC
MERP’s Categorizing Medication Errors Index.44
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Study sample
The study sample comprised all the six health boards providing acute/general inpatient care within NHS
Wales. Two hospital sites were chosen from each health board to represent a 50–50 split of acute/
emergency care and less acute district general hospital-level care. Eligibility for study inclusion was being over
the age of 18 years at admission, having a LOS of > 24 hours and not being treated in a designated mental
health or obstetric facility. Two-stage retrospective case note review was conducted on the case records that
were sampled for the GTT process. Welsh NHS organisations randomly selected and retrospectively reviewed
20 sets of case notes each month, post discharge and after discharge summaries and coding had been
completed. Case notes for review were identified by NHS organisations by generating lists of all hospital
discharges fulfilling the inclusion criteria for the month in question and using a random number generator to
select 30 inpatient episodes for the period covered. Oversampling in this way was required to ensure that at
least 20 sets of notes had been through coding and had been returned to the filing library.
Sample size
The sample size for phase 1 was estimated on previous work undertaken in the USA, Australia and the UK.
A systematic review on AEs in health care reports a median percentage of AEs at 9.2%, with a range of
8–12%.3 The largest single UK-based retrospective review study, to date, on 1008 inpatient records reports
a percentage of records with at least one AE of 8.7%.16 If the percentage of AEs in Wales is around 10%,
we required a sample of 3457 records to detect a one-sided difference of 1%, with the reference value
with a power of 0.97 and an alpha from 0.05. If the incidence of AEs during hospital admission is lower at
8%, a sample of 4200 admissions is necessary to detect a one-sided difference, with the reference value
with a power of 0.80 and an alpha from 0.05.
The review process
In the first stage of the Harvard method, the case notes were screened for potential harm by a team of
clinical research nurses (n = 24) and research assistants (n = 2) from the National Institute for Social Care
and Health Research (NISCHR) Clinical Research Collaboration (CRC) infrastructure. The team was trained
in the use of the RF1 tool through face-to-face meetings with members of the research team, who then
supervised the first two case note review sessions in each site to troubleshoot any issues arising and to
ensure that the reviewers were confident in the use of the tool. The two non-clinically trained assistants
were partnered with experienced research nurses for review sessions. Three research nurse teams covered
the three geographic areas of Wales: north, south-east and south-west. If an episode of care screened
positive for any of the 18 criteria for an AE, the reviewers described how the criterion was met in a free-text
box. At the end of the review, a summary of the episode of care was written irrespective of whether or not
positive screens had been identified. There was no restriction set on the time the research nurse review
teams spent examining each set of notes.
Admissions that screened positive on at least one screening criterion were examined within the research
office before a decision was made on whether or not a full examination of the record needed to be
conducted by a senior research physician. This was undertaken to check for accuracy in the completion of
the forms, to identify if there was any potential for missed AEs and to ensure that screening criteria were
met in full, thereby rationalising the use of the intensive two-stage review when there was no indication
that a harm event had occurred. We therefore referred a small number of reviews for which screening
criteria did not identify any potential for harm but the clinical summary stated, for example, that a patient
was readmitted after a knee replacement with serous fluid oozing from the wound, or stated that no
obvious criteria were present but that this was a complex episode of care that would benefit from
physician review. Conversely, we did not refer cases for in-depth review when the narrative describing the
positive screen indicated that a fall had occurred but under the description of the criteria was documented,
‘no injury sustained’, when the descriptor for pressure ulcer read ‘buttocks red, cavalon applied’ or
‘moisture lesion present’ but tissue damage did not develop, when adverse drug reaction mentioned rash
or an isolated episode of diarrhoea but drugs were continued with no systemic ill effect, and when
readmission occurred in different clinical specialties with no connection. This was undertaken in the
research office and was independent of the nurse process and was part of a quality assurance process.
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Referred notes from phase 1 went on to a second-stage review, in which 12 research physicians, who
were experienced in record review through involvement with similar studies, used the MRF2 tool to judge
the occurrence, nature, preventability and consequences of the referred event on a per diem basis. The
research physician reviewed the admission in question and episodes of care either side of the admission
before making a determination on whether or not the patient experienced an AE before its subsequent
categorisation. The inter-rater reliability was assessed in a 10% sample of admissions, which were double
reviewed at both the nursing screening and physician confirmation stages and proportional to the
contribution made by each participating organisation.
Statistical analysis
The GTT is conventionally analysed using a three-step method. The aggregated data are converted from
episodes of harm into a harm rate and then compared with a baseline. We used the same methodology
to compare aggregate rates in the two methodologies. Secondary analysis involved linking GTT and RF1
(nurse-generated) and MRF2 (physician-generated) data by unique study number and examining the
consensus between methods and professional groups on the identification of AEs.
The two-stage review data were analysed to determine the percentage and corresponding CI of patients
who experienced an AE during the period of hospitalisation and the severity and level of preventability of the
incident both in individual hospital sites and nationally. Univariate logistic regression assessed the relationship
between patient variables and the presence of an AE in physician-determined AEs. An unweighted kappa
coefficient was used to assess inter-rater reliability with corresponding 95% CIs and the percentage of
records that were concordant and discordant, respectively. Missing data were assessed and, because of their
infrequency, (1) were presumed to be missing at random and (2) were analysed on the available data set.
Weighted means were calculated using simple techniques to calculate a weighted average of the percentage
of AEs in each study site, adding weights together and dividing by determined events.
Time series analysis was undertaken by plotting percentages of AEs by quarter and calculating the beta
of the coefficient with corresponding CIs. Statistical analysis was undertaken using Stata version 14
(StataCorp LP, College Station, TX, USA).
Data from different tools (RF1, MRF2 and GTT) were linked via the VLOOKUP function in Microsoft Excel®
(2016; Microsoft Corporation, Redmond, WA, USA). GTT cases were identified by their hospital number,
and the study data, including the MRF2 reviews, were identified through a unique study number. An
independent database, held separately from the study data, provided patient identification fields for the
match between hospital and study numbers. Cases of harm from the GTT and MRF2 review were
identified and matched together using this reference data and the VLOOKUP function in Microsoft Excel.
Ethics approval was granted from the Wales Ethics Committee 1 (integrated research application system
project identification 54861). Section 251 support was granted from the National Information Governance
Board [ECC-5-02(FT2)12011]. Research and development approval was granted from every participating
health board.
Findings: measuring harm in Wales
Aim 1
To compare outcomes and rates of harm from both the Harvard and GTT methods.
Findings
The findings are presented here in four parts. Part 1 describes the sample and extent of AEs determined
from the Harvard method. Part 2 outlines the nature and characteristics of the AEs and part 3 the
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efficiency of the RF1 screening criteria in converting to harm events and their use in characterising AEs in
secondary care settings. Finally, part 4 compares the percentage of patients experiencing AEs generated
from both the two methods.
Part 1: percentage of patients with determined adverse events identified
from the Harvard methodology
Sample size and quality of records
Twelve NHS hospitals across NHS Wales were invited to participate in the study, with 11 actively taking
part from the study commencement. Individual samples from study sites ranged from 174 to 560, but the
sample over time was significant, with one health board (sites 1 and 2) providing a larger sample than
provided in any other previous similar study in a UK setting (Table 4).
Record exclusions
Episodes of care were excluded from the final analysis on the basis of (1) errors in the patient record
retrieved for review, (2) incomplete documentation in the patient record preventing the completion of the
review and (3) not meeting age and inpatient LOS inclusion criteria. The percentage of reviews excluded
from analysis at the individual organisational level ranged from < 1% to 9.17%.
As part of the review process, an assessment was undertaken of the completeness of the inpatient record.
The percentage of records with insufficient information to undertake a robust appraisal of the episode of
care, that is, inadequate documentation, ranged from < 1% to > 6% (Figure 3).
Study sample characteristics Valid observations on key demographic characteristics were available for
4361 episodes of care (99.4%) and the mean age of the patient during the index admission under review
was 64.1 years (95% CI 64.48 to 64.66 years). The mean age of our study sample is older than the reported
breakdown of hospital admissions nationally, in which 43% of patients discharged from hospital nationally
are over the age of 65 years, compared with 56% in our study sample. It is likely that the non-inclusion of day
cases and paediatric admissions in our study sample accounts for most of this difference. All inpatient episodes
were stratified by age band and, as seen in Figure 4, the full age spectrum was represented in the study
sample. Representation increased sequentially until the over-85s age group, when there was a significant drop
in the number of reviews undertaken. Age-related data were unavailable in 27 episodes of care.
TABLE 4 Number of reviews undertaken across the 11 actively participating study sites
Site
Number of reviews
undertaken
Number of reviews included
in analysis
Second-stage review MRF2
undertaken (percentage of
total records reviewed)
1 560 553 98 (17.5)
2 537 530 65 (12.1)
3 441 432 99 (22.4)
4 394 375 53 (14.5)
5 338 309 73 (21.6)
6 174 172 49 (28.2)
7 317 290 57 (18.0)
8 341 330 55 (16.1)
9 413 393 64 (15.5)
10 494 484 111 (22.5)
11 527 520 97 (18.4)
Total 4536 4388 821
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The sample varied across participating organisations and one site (site 4) had a younger demographic
profile, which was explored by the research team at the interim analysis stage (Figure 5). We identified
potential problems with their sampling strategy, which was subsequently amended on request.
There was a 47% to 53% male to female gender split in the 4371 inpatient records examined, and in
17 cases (0.39%) age was not recorded.
The percentage of reviews with one or more postitive criterion of harm On completion of the RF1
screening process, 1430 (32.6%) inpatient episodes of care were identified that had at least one identified
positive screening criterion for potential AEs and, of these, 821 inpatient episodes (18.1%) were referred
after review by the research team for in-depth implicit physician review. At the time of the second-stage
reviews, a further 31 records were irretrievable for secondary review within hospital sites and a total of 790
MRF2 reviews were completed (96.2%). The percentage of cases with one or more positive criterion for
harm ranged between 23% and 43.8% (Table 5).
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FIGURE 4 Age distribution of the study sample across all participating sites.
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The percentage of patients with adverse events identified across NHS Wales After MRF2 review,
at least one AE was determined in 450 out of 4388 (10.3%) discrete episodes of care examined, with a
corresponding 95% CI of 9.4% to 11.2% [median 9%, standard deviation (SD) 2.44%]. Nearly 10% of
episodes had a further AE documented (n = 42). When the overall percentage of patients with AEs was
weighted for the proportional contribution of individual study sites to the study, the weighted AE rate
increased to 10.83% (95% CI 9.91% to 11.75%). Percentages of AEs by individual study sites ranged
from 7.9% to 16.1%, with 10 of the 11 participating organisations falling within the range reported in
previous two-stage retrospective review studies (Table 6).
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TABLE 5 The percentage of reviewed episodes of care with at least one positive criterion for harm
Site Number of reviews Number of valid reviews
Criteria present in data set (% of total
number of valid reviews) (n= 4388)
1 560 553 153 (27.7)
2 537 530 122 (23.0)
3 441 432 189 (43.8)
4 394 375 105 (28.0)
5 338 309 114 (36.9)
6 174 172 66 (38.4)
7 317 290 108 (37.2)
8 341 330 139 (42.1)
9 413 393 142 (36.1)
10 494 484 151 (31.2)
11 527 520 141 (27.1)
Total 4536 4388 1430 (32.6)
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For all episodes of care, we were able to categorise the primary AE into whether it was caused (1) by
health-care management, (2) by health-care management interacting with the disease process and
(3) solely by the disease process. The breakdown is shown by individual study site in Table 7.
Just over three-quarters of all determined AEs resulted from health-care management or health-care
management interacting with the disease process, with the remaining events being complications or
TABLE 6 The percentage of inpatient records in which AEs were identified using the Harvard methodology across
the 11 participating NHS Wales sites
Site
Total number
of RF1s
Number of
included RF1s
in analysis
Total number
of MRF2s
requested
Total number
of MRF2s
undertaken
Number of injuries or
complications identified
though review
Percentage
of AEs
identified
1 560 553 99 88 50 9.0
2 537 530 65 63 42 7.9
3 441 432 99 99 51 11.8
4 394 375 53 52 30 8.0
5 338 309 73 68 32 10.4
6 174 172 49 47 15 8.7
7 317 290 56 54 35 12.0
8 341 330 55 52 29 8.8
9 413 393 64 60 33 8.4
10 494 484 111 108 78 16.1
11 527 520 97 96 55 10.5
Incomplete information contained in review 3
Total 4536 4388 821 790 (96.2%a) 450 10.3
a Percentage of the total number of MRF2s.
TABLE 7 Breakdown of the causes of AEs across NHS Wales
Site
Causes of AEs
Health-care management
Health-care management interacting
with the disease process
Solely the disease
process
1 17 20 14
2 6 26 10
3 16 23 12
4 8 16 6
5 13 13 6
6 6 6 3
7 10 14 11
8 16 10 3
9 18 15 0
10 17 39 21
11 5 32 18
Total 132 (29.3%a) 214 (47.5%a) 104 (23.1a)
a Percentage of the total number of AEs.
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unavoidable events arising from an individual’s underlying health status. Figure 6 demonstrates that when
the cases that were deemed to arise solely from the disease process are removed from the AE rate, there is
a reduction in the variability of rates across NHS Wales sites.
Adverse events were also categorised according to the level of management causation on a scale of 1–6, for
which 1 is virtually no evidence for management causation/system failure and 6 is virtually certain evidence
for management causation. Of the 448 events classified, 195 (43%) events were graded 1 or 2 (i.e. no or
low evidence of management causation), 132 (29%) were graded as moderate in terms of evidence of
management causation and 121 (27%) were graded as highly likely to be caused by health-care management
(Table 8).
This judgement was made after consideration of all the clinical details of the patient’s management,
irrespective of preventability and is a measure of the level of confidence that the health-care management
caused the injury. In just under half of all cases (46.8%) there was sufficient confidence from the record of
care that there was a likelihood that health-care management was directly responsible for the AE. The cases
for which there was no evidence for management causation (23.7%) corresponds crudely to the 104 cases
(see Table 7) for which the physician judged that the AE was directly attributable solely to the patient’s
underlying disease status.
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FIGURE 6 Causes of AEs by study site across NHS Wales. SDP, solely the disease process; HCM, health-care
management; HCM and DP, health-care management interacting with the disease process.
TABLE 8 Assessment of management causation in AEs identified across all study sites
Level of confidence by physicians irrespective of preventability of
the management causation of the AE
Number of AEs
classified as
Percentage of the total
number of classified AEs
1. Virtually no evidence for management causation/system failure 107 23.7
2. Slight to modest evidence for management causation 88 19.6
3. Management causation not likely: < 50–50, but close call 42 9.3
4. Management causation more likely than not; > 50–50, but close call 90 20.0
5. Moderate/strong evidence for management causation 65 14.4
6. Virtually certain evidence for management causation 56 12.4
Not classified 2 0.5
Total 448
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The preventability of adverse events across NHS Wales Across all study sites, 51.5% of AEs were
identified as having at least some evidence of preventability when defined as events resulting from care
not being delivered to a standard considered to be good clinical practice, in normal circumstances (median
55%, SD 13.30%, 95% CI 46.88% to 56.12%) (Table 9).
When the percentage of preventable AEs was weighted by the individual organisation’s contribution to the
study sample, the mean percentage of preventability increased slightly to 53.13% (95% CI 48.52% to
57.74%). Preventability was also examined on a six-point Likert scale and in three main categories (Table 10).
TABLE 10 The level of preventability of the identified AEs across the 11 NHS Wales study sites
Site
Level of preventability
Percentage of AEs that
were preventable
Number of preventable AEs greater or equal
to a score of 2 (slight to modest evidence)
Number of AEs greater than a
score of 4 (probably preventable)
1 54 27 19
2 40 17 3
3 55 31 7
4 53 16 7
5 50 17 12
6 87 13 10
7 57 20 11
8 55 16 6
9 66 20 10
10 41 29 13
11 42 20 12
Total 51.5 226 (50.2%a) 110 (24.4%a)
a Percentage of the total number of preventable AEs.
TABLE 9 The preventability of AEs across study sites
Site Valid RF1s MRF2 undertaken
Number of injuries
or complications
Number of
preventable AEs
Percentage of
preventable AEs
1 553 88 50 27 54
2 530 63 42 17 40
3 432 99 51 28 55
4 375 52 30 16 53
5 309 68 32 18 56
6 172 47 15 13 87
7 290 54 35 20 57
8 330 52 29 16 55
9 393 60 33 22 67
10 484 108 78 32 41
11 520 96 55 23 42
Total 4388 790 (96.2%a)b 450 232 51.5
a Percentage of the total reviews.
b Incomplete information contained in review n= 3.
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The majority of all AEs (n= 226, 51%) was classified as having at least ‘slight to modest evidence for
preventability’, corresponding to scores of between 2 and 6 on the Likert scale (95% CI 46.88% to 56.12%).
In only 24% (n= 110) of cases, the level of preventability was determined to be ‘probably preventable; > 50–50
but close call’ corresponding to a score between 4 and 6 on the Likert scale (95% CI 20.43% to 28.37%).
The inter-rater reliability of the Harvard method in the determination of adverse events Ten per
cent of all records were double reviewed at both the RF1 and RF2 stages and the level of agreement
between reviewers was assessed, which is reported in Table 11.
The overall agreement on episodes of care having at least one positive criterion for harm after assessment
was moderate (the kappa falling between 0.41 and 0.60 on the Landis Koch Benchmark scale) (κ = 0.47,
95% CI 0.39 to 0.55) or 76.6% concordant and there was significant variation in the reliability
performance across the participating study sites.
Eighty-seven double reviews were undertaken for implicit MRF2 inter-rater reliability assessment.
Agreement between reviewers was achieved in 83% of cases (n = 72), with a kappa of 0.63 and a
corresponding 95% CI of 0.46 to 0.80.
Trends of adverse events across NHS Wales: October 2010 to March 2013 Our study sample was
longitudinal in nature and rates of AEs were plotted over the phase 1 period. Figure 7 reports crude rates
of AEs determined by research physicians after MRF2 review per quarter. Although a trend is suggested,
this was not statistically significant in linear regression. The beta of the coefficient was 1.58 (95% CI
–0.16 to 3.34; p = 0.070).
Part 2: the nature and severity of adverse events across NHS Wales
Physicians identified the principal problems in care that resulted in the occurrence of an AE. Table 12
shows the distribution of problems in care across the inpatient episodes examined and categorised when
management causation was established (n = 343). Failure in clinical monitoring and management was an
issue identified in one-third of all events (n = 115, 33.5%). Other significant problems arose from failure to
manage and prevent infection (n = 101, 29.4%), issues directly related to a problem with an operation or
procedure (n = 73; 21.2%) and problems in the prescribing, administration or monitoring of drugs and
fluids (n = 64; 18.7%). When assessed at the individual hospital site, variations in the relative importance
TABLE 11 Inter-rater reliability of nurse screening for the identification of positive criteria (RF1)
Site
Total number
of reviews
Number of pairs
Unweighted
kappa 95% CI Altman scale 199157Concordant Discordant
1 58 45 13 0.29 0 to 0.63 Fair
2 56 45 11 0.43 0.13 to 0.73 Moderate
3 49 33 16 0.32 0.05 to 0.60 Fair
4 48 36 12 0.37 0.06 to 0.68 Fair
5 32 23 9 0.43 0.13 to 0.75 Moderate
6 20 13 7 0.27 0.0 to 0.70 Fair
7 29 24 5 0.63 0.33 to 0.92 Good
8 41 32 9 0.56 0.30 to 0.81 Moderate
9 54 41 13 0.51 0.28 to 0.74 Moderate
10 53 43 10 0.59 0.48 to 0.82 Moderate
11 49 33 16 0.34 0.07 to 0.60 Fair
Total 492 377 121 0.47 0.39 to 0.55 Moderate
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of problems in care are observed, but it is evident that patients are at risk as a result of failures in clinical
monitoring, infection control-related procedures and drug and fluid administration across all sites.
If the occurrence of these common events identified through case note review is crudely extrapolated
across the total number of hospital discharges in Wales, per annum (760,418 events), they would equate
to around 19,900 events relating to failures in clinical monitoring, 17,500 AEs resulting from failures in
infection control, 12,650 events relating to problems with operations and procedures and 11,000 AEs
relating to the administration of drugs, fluids or blood. This reflects significant excess resource utilisation
and expenditure.
Adverse events have significant clinical impact but are also costly in terms of excess days in inpatient
settings with attendant excess treatment costs. Table 13 outlines the percentage of (1) patients with
physician-confirmed AEs across NHS Wales who were discharged with a level of disability not present at
admission; (2) patients who required an extended LOS and additional treatments and/or no extended stay
but additional treatment; and (3) patients whose AEs were associated with but not necessarily causally
related to, inpatient death. Nearly three-quarters (n = 329) of our cohort of patients with AEs needed
additional treatment and/or days in hospital, 71 (16%) were discharged with a significant impairment in
their functional status and in 40 patients (9%) the AE may have been associated with but not necessarily
causally related to, the patient dying during the inpatient episode.
TABLE 12 Percentage of AEs associated with specific problems in care categories
Problem in care category Frequency Percentage of total AEs
1. AE relating to diagnostic or assessment error 47 13.7
2. AE from failure to appreciate patient’s overall condition 18 5.2
3. AE arising from a failure in clinical monitoring management 115 33.5
4. AE in relation to failure to prevent/control/manage infection 101 29.4
5. AE directly related to a problem with an operation or procedure 73 21.2
6. AE relating to prescribing, administration or monitoring of drugs
or fluids including blood
64 18.7
7. AE relating to resuscitation 1 0.3
Note
More than one problem in care may have been attributed to a single AE.
y = 0.0043x – 163.18
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FIGURE 7 Trend of physician-confirmed AE determination, by quarter, across NHS Wales: October 2010–March 2013.
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The severity of the injury across NHS Wales
Physicians were asked to make an additional assessment of the severity of the event, in terms of both the
physical and emotional impact on the patient. This is reported in Table 14. An assessment of physical
disability was made in the 323 events reported (72%). Reviewers did not make an assessment of disability
in cases in which the AE was determined to have been caused solely as a result of the disease process.
Nearly 74% of the events assessed resulted in no or minimal physical impairment, with an expected
recovery within 1 month. At the other end of the spectrum, the physician determined in only 26 cases that
the event was associated with the patient’s death and in six cases that it was responsible for the death of
the patient.
The impact of the injury in terms of the likely emotional trauma experienced by the patient was less
comprehensively assessed, with categorisation available for 309 out of 450 AEs. The severity reported
follows a similar trend, with 61% of events categorised as no or minimal trauma and < 3% of events
classified as causing moderate to severe trauma, with recovery predicted to last over 6 months.
TABLE 13 Percentage of patients across NHS Wales with specific outcomes as a result of their AE
End point of AE Frequency
Percentage of patients with
AEs with a defined outcome 95% CI
Disability 72 16.0 12.6 to 19.4
Prolonged stay/subsequent treatment 328 72.9 68.8 to 77.0
Death 41 9.1 6.45 to 11.8
Note
More than one problem in care may have been attributed to a single AE.
TABLE 14 Physicians’ assessment of disability caused by the AE
Level of disability Number of AEs
Physical disability
Minimal impairment and recovery expected in 1 month 115
Moderate impairment, recovery in 1–6 months 41
Moderate impairment, recovery in 6 months to 1 year 6
Permanent impairment, disability 11
Death
Death with minimal contribution from the AE 5
Death with moderate contribution from the AE 13
Death entirely attributable to the AE 6
Death, but cannot judge association with the AE 2
Emotional trauma
Minimal emotional trauma and/or recovery in 1 month 78
Moderate trauma, recovery in 1–6 months 29
Moderate trauma, recovery in 6 months to 1 year 7
Severe trauma, recovery lasting longer than 1 year 3
MEASURING HARM IN WALES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
Adverse events and excess length of stays
For 45% of patients who experienced an AE, the research physician estimated the excess LOS at the hospital
resulting from the management of the injury. Of the 206 patients identified with confirmed AEs and estimated
excess LOS of > 24 hours in duration, one patient had a LOS of 564 days, which would have significantly
skewed the data and therefore was excluded from the analysis. Excluding this patient, the range was between
1 extra day as an inpatient to 43 extra days, with a median duration of 6 days. The distribution of excess LOS
by quartile is reported in Figure 8. One in four of the studied patients who experienced AEs had an additional
LOS of at least 10 days.
Readmissions to manage the clinical impact of the adverse events across NHS Wales
Adverse events are also commonly associated with a subsequent readmission necessary to deal with the
clinical sequelae of the event. In this cohort of patients experiencing an AE across NHS Wales, one-quarter of
all determined AEs resulted in a readmission to specifically manage attendant clinical complications (Table 15);
this equates to 2.7% of the total inpatient studied (120/4388). The readmission rate ranged from 9.38% to
40.0% of patients with confirmed AEs across participating hospitals. Common readmissions in the data set
include those required to drain and evacuate haematomas post-surgical procedures, to receive treatment for
hospital-acquired infections and to manage complications of drugs and other therapeutic treatments.
Overall assessment of the quality of inpatient care
At the end of the MRF2 process, physicians were asked the following question: considering all that you
know about this patient’s admission, how would you rate the overall quality of care? Among 450 episodes
of care for which AEs were identified, the physician cohort still deemed the overall quality of care to be
excellent or good in 71% of cases (Table 16). This assessment of quality is a subjective one. However, an
association exists between the rating of quality of care and the physician’s determination of a preventable
AE. The preventability of AEs by care quality rating is shown in Figure 9, with levels of preventability
increasing with poor quality-of-care rating. What this suggests is that physicians rate global quality-of-care
issues on whether or not care was delivered to accepted standards under normal circumstances, and this
therefore precludes, in many cases, deviation from common guidelines or adverse patient outcomes that
could have been potentially avoided. It is, however, also recognised that AEs might occur against a
backdrop of good overall quality of care.
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FIGURE 8 Distribution of excess length of hospital stay as a result of an AE by quartile.
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Factors independently associated with subsequent adverse event determination
The likelihood of having an AE during inpatient management was assessed with specific interest in the
patient’s age, sex and the duration of the inpatient episode (Table 17). Age is a significant factor in an
individual’s risk of experiencing an AE during inpatient care, with the risk increasing by 13% when
assessed by 10-year age bands [odds ratio (OR) 1.13, 95% CI 1.07 to 1.19]. An exception was observed in
the middle-aged groups (i.e. 45–54 years age group), in which the AE rate of 6.75 was lower than
expected. The AE rate peaks in the over-85 years age group, 14.4% of whom experienced an AE during
the inpatient episode (Figure 10).
TABLE 15 Percentage of AEs within NHS organisations that resulted in patient readmission
Site Number of AEs
Number of AEs resulting
in new admission Percentage of total number of AEs
1 50 18 36.0
2 42 7 16.7
3 51 16 31.37
4 30 12 40.00
5 32 3 9.38
6 15 5 33.33
7 35 8 22.86
8 29 10 34.48
9 33 11 35.48
10 78 17 21.52
11 55 13 23.64
Total 450 120 26.73
TABLE 16 Quality-of-care assessment in Welsh patients experiencing an AE
Site
Number of AEs where
estimated quality of care is
rated as excellent or very good Total number of AEs
Percentage of total number of AEs
where estimated quality of care is
rated as excellent or very good
1 35 50 70.0
2 36 42 85.7
3 38 51 74.5
4 24 30 80.0
5 15 32 47.3
6 5 15 33.3
7 28 35 80.0
8 15 29 51.7
9 17 33 51.5
10 67 78 85.9
11 40 55 72.7
Total 320 450 71.1
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The mean LOS across study sites for the 4388 valid episodes of care was 7.16 days (95% CI 7.06 to 7.42
days), with a median of 5 days. The average total length of hospital stay is 6.2 days across Welsh hospitals
and 5 days per finished consultant episode. A 37% increased risk of AE determination is evident when
assessed by incremental inpatient durations of 3 days (OR 1.37, 95% CI 1.29 to 1.46). The percentage of
patients experiencing an AE ranged from 5.9% of those with a LOS of 2–4 days to 19.8% of those whose
inpatient stay was > 2 weeks in duration (Table 18).
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FIGURE 9 Assessment of the quality-of-care rating by physician determination of the preventability of the AE.
Quality-of-care rating: 1, excellent; 2, good; 3, adequate; 4, poor; and 5, very poor.
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FIGURE 10 The percentage of patients, by age group, with physician-confirmed AEs.
TABLE 17 Summary of independent variables associated with the determination of physician-confirmed AEs
Variable OR 95% CI p-value
LOS (3-day groupings and > 14 days) 1.37 1.29 to 1.46 < 0.001*
Age band (18–24 years, 10-year age groupings and over-85 years) 1.12 1.07 to 1.19 < 0.001*
Sex (male) 0.99 0.82 to 1.20 0.949
Admission status (emergency admission) 0.83 0.65 to 1.06 0.128
*Statistically significant.
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The interaction between LOS and AE determination is difficult to interpret and may reflect either longer
length of exposure or longer inpatient duration to deal with the AE. The mean age of patients in each length
of hospital stay band was assessed to determine the influence of age on duration of inpatient admission
(Figure 11). Age does not appear to be a significant factor up to and including a length of hospital stay of
10 days. The mean age is significantly higher in patients whose inpatient stay was > 10 days.
Sex and admission status (i.e. elective or emergency) were not found to be statistically associated with AEs
across NHS Wales, although being an elective patient appears to predispose patients to around a 17%
increased risk of experiencing an AE (OR 0.83, 95% CI 0.65 to 1.06). This suggests an increased risk of
AEs in surgical/procedure episodes of care, but failed to reach statistical significance. The breakdown in
our elective/emergency case mix again differs from the case mix reported nationally, 41/59 cases compared
with our 23/77 split and, again, the exclusion of cases on the basis of being an inpatient for < 24 hours
significantly influences the sample from which our reviews were undertaken.
80
70
60
M
ea
n
 a
g
e 
(y
ea
rs
) 
in
 L
O
S 
g
ro
u
p
50
3 4
LOS band
1 2 5 6
FIGURE 11 Mean age and corresponding CIs of patients whose inpatient stay was > 10 days in duration.
TABLE 18 Presence of AEs determined by research physicians by hospital LOS
LOS Frequency Frequency of physician-confirmed AE Percentage of total frequency
< 48 hours 114 9 7.9
2–4 days 1752 104 5.9
5–7 days 1049 97 9.3
8–10 days 523 79 15.1
11–14 days 372 50 13.4
> 14 days 527a 104 19.8
Total 4337 443 10.21
a One patient had a LOS of > 500 days.
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Inpatient specialty as a risk factor for inpatient adverse events
The AE rate was also assessed crudely according to whether patients were managed within a medical or
surgical inpatient area. Of the 450 AEs identified, 263 (58%) were managed within surgical specialties
and the remaining 187 (42%) within medical areas. Given that only approximately one-third of our study
population received surgical care, the risk of AEs is substantially higher for this patient group.
As AEs are known to occur more frequently in surgical patients than medical patients and there were
significant differences in the percentage of AEs identified site by site, we examined the reviews undertaken
within each individual health board, assessing the composition of surgical and medical patients within the
individual samples (Table 19).
The percentage of the study sample that was derived from surgical patients ranged from 21% to 83%
across participating organisations. Excluding two sites (sites 4 and 9) where there were recognised issues
with the sampling or the number of reviews that were undertaken, AE rates are higher in organisations in
which the sample included a higher percentage of surgical patients.
Key characteristics of differences between AEs that were surgical in nature and those that were medical in
nature were explored and are reported in Table 20. The mean age was significantly different, being 73 years
on admission to medical wards and 64.3 years on admission to surgical wards (p < 0.001). Other differences
are noted, but failed to reach statistical significance, and these included higher rates of readmission in
surgical patients (29% vs. 23%); higher rates of disability at discharge in surgical patients (19% vs. 12%);
and a higher percentage of surgical patients requiring a prolonged inpatient stay (77% vs. 67%). The
association between AEs and death, although not representing any causality, was lower in surgical patients
than in medical patients (8% vs. 10%). We conclude that, across NHS Wales, events occurring in surgical
patients are more frequent and are associated with both a higher level of disability and greater inpatient
resource utilisation. Examples of typical AEs seen in these two settings are given in Table 21.
Part 3: conversion of harm criteria to determined adverse events in the Harvard method
Screening criteria for harm have been comprehensively assessed in a number of previous studies, including in
terms of their sensitivity, specificity, positive predictive values and negative predictive values, and these were
not fully assessed in this research. However, we monitored the rates of conversion from a nurse-identified
criterion for AEs to physician confirmation of AEs to gain insight into the relationships between the two in
order to assess the efficiency of the screening criteria in identifying AEs in the Welsh context (Table 22).
TABLE 19 Percentage of surgical patients by individual study site
Site AE rate in organisation
Percentage of surgical patients in
sample from surgical care
1 9.0 62.0
2 8 21.4
3 12 58.8
4 8.0 83.3
5 10 43.8
6 9 26.7
7 12 62.9
8 9 37.9
9 8 60.6
10 16 75.6
11 12 69.9
Total 10.3 58.4
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TABLE 21 Examples of typical AEs identified through two-stage retrospective case note review across NHS Wales
Example of
Surgical AE Medical AE
Infected swelling of umbilicus post hernia repair 1 month
previously. Rx surgical excision under LA and follow-up with
community wound team
Presented with 1-month history of epigastric pain, jaundice,
pale stool and dark urine. Underwent ERCP confirming bile
duct blockage and stent inserted. Became unwell and
transferred to HDU with pancreatitis and biliary sepsis
Elective admission for liver biopsy. Became haemodynamically
unstable 2 hours post biopsy. CT showed subcapsular
haematoma and collection in pelvis – subsequently developed
infection. Required ERCP, antibiotics and painkillers
Patient admitted 1-week post MI and angioplasty.
Commenced on ramipril. Admitted with hypotension,
swelling of lips and rash. Ramipril stopped
Admitted for total right hip replacement. Fell on ward
2 weeks post surgery and had a periprosthetic fracture
requiring revision with long stem
Admitted with left-sided pleuritic chest pain post
hysterectomy 2 weeks earlier. Diagnosed with PE secondary
to DVT. Patient admitted with PE. Treated with warfarin
but developed warfarin-induced skin necrosis on left hip.
Admitted with haematuria. History of PE and DVT and on
warfarin. INR of > 10 on admission and warfarin stopped
Laparoscopic cholecystectomy. Postoperative bleed requiring
return to theatre, drain and transfusion
Admitted with cellulitis. GP had assessed for DVT, but ruled
out in A&E. Given one dose of prophylactic Clexane®
(Sanofi-Aventis, Guildford, UK). Collapsed on ward as a
result of a PE
Neurosurgical patient with tumour complained of abdominal
and leg pain post operation, prior to discharge. Diagnosed as
trapped wind and constipation. Died 2 days later at home
with thromboembolic event
Acute admission following fall. Sustained wedge fracture of
thoracic spine and admitted for hyponatraemia. Fell on
ward, sustaining fracture of left ankle
Admitted for elective endovascular stenting of aortic
aneurysm. Severe back pain present 1 day post operation.
CT angiography 3 days later revealed non-perfused left
kidney and blocked renal artery. Eventual kidney infarct
Admitted after mechanical fall and laceration to leg
and arm – sutured by oral and maxillofacial surgery.
Subsequently had CVA on ward and grade 2–3 pressure
damage noted to sacral area
A&E, accident and emergency department; CT, computerised tomography; CVA, cerebrovascular accident; ERCP,
endoscopic retrograde cholangiopancreatography; GP, general practitioner; HDU, high-dependency unit; INR, international
normalised ratio; LA, local anaesthetic; PE, pulmonary embolus; rx, treatment.
TABLE 20 An exploration of differences in the nature, severity and impact of patients experiencing AEs in surgical
and medical settings across NHS Wales
Variable or characteristic of interest
Patients with AE managed in
Assessment of
differenceMedicine Surgery
Mean age (years) with AE (95% CI) 73 (70.71 to 75.5) 64.3 (62.0 to 66.7) t = 5.036; p< 0.001*
Median LOS (days) with AE (SD) 5 (7.70) 7 (7.65) NS
Median excess LOS (days) with AE (SD) 6 (6.10) 6 (2.2) NS
Readmission attributable to AE (%) (95% CI) 23.2 (17.7 to 29.9) 28.9 (23.7 to 34.7) χ2 = 1.958; p= 0.162
Injury caused solely by disease process (%)
(95% CI)
23.1 (17.6 to 29.8) 22.9 (18.2 to 28.4) χ2 = 0.0008; p= 0.977
Preventable AE, % (95% CI) 52.9 (45.8 to 60.1) 50.8 (44.7 to 56.8) χ2 = 0.2072; p= 0.649
Percentage with prolonged hospital stay
due to AE (95% CI)
67.4 (60.3 to 73.8) 76.8 (71.3 to 81.5) χ2 = 6.681; p= 0.083
Percentage whose AE was associated with
death (95% CI)
10.1 (7.0 to 16.1) 8.0 (5.2 to 12.0) χ2 = 4.268; p= 0.371
Percentage who had a degree of disability
at discharge (95% CI)
11.8 (7.8 to 17.3) 19.0% (14.7 to 24.2) χ2 = 6.681; p= 0.083
Time spent to review the episode of care
in minutes (95% CI)
26.3 (24.1 to 28.5) 26.2 (24.6 to 27.8) NS, t = 0.08; p= 0.468
*Statistically significant; NS, not statistically significant.
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Rates of conversion vary considerably across the tool, with 7 out of the 18 criteria resulting in a conversion
rate of around 25%, and 4 out of 18 criteria in a conversion rate of > 50%. Although not providing the
epidemiological insight offered by the full assessment of screening parameters, the conversion data are
important as (1) they were more intuitive to understand by those using the tools in routine practice and
(2) they confirmed findings reported by organisations that some criteria are better at identifying AEs and
have greater face validity than others. An assessment of these factors enhanced our understanding of the
origin of risk to patients and highlights areas in which screening criteria may be refined to represent
specific clinical AEs more closely.
Studying variation in the composition of harm events at the organisational
level to inform improvement priorities
The measurement of harm occurs in two settings: academic groups undertaking robust research, testing
and validating methods and measurement properties; and health-care organisations monitoring the nature
and extent of harm in their local context. Both have quality assurance and improvement as philosophical
end points, but to date it is difficult to see how the data generated are used by clinicians and managers
to realise safer care. Figure 12 highlights how harm measurement is the first of a five-step journey of
improvement leading to understanding, problem-solving, ongoing assessment and the implementation of
new processes or interventions. It is a cycle that is dependent on new information being generated to
assess progress and priorities for targeted intervention.
TABLE 22 The conversion from positive screening criteria to confirmed AEs
Criteria
Frequency in
Percentage
conversion
4388 admissions
in RF1
MRF2-confirmed
events
1 Admission pre index admission within 1-year period 376 93 24.7
2 Admission post index admission within 30 days 454 115 25.3
3 Hospital-incurred accident or injury 240 112 46.7
4 Drug error or reaction 169 76 45.0
5 Unplanned transfer to higher level of care, for example
ITU
47 20 42.5
6 Unplanned transfer to another hospital 23 5 21.7
7 Unplanned return to surgery 41 22 53.6
8 Procedure-related organ or internal injury 16 10 62.5
9 Complications including CVA, DVT, MI 75 35 46.7
10 Neurological deficit not present on admission 52 20 38.5
11 Unexpected death 39 14 35.9
12 Inappropriate discharge/planning 129 46 35.7
13 Cardiac or respiratory arrest 44 13 29.5
14 Injury or complications of labour/termination of pregnancy 4 1 25.0
15 Hospital-acquired infection 191 112 58.6
16 Patient/carer complaint 100 24 24.0
17 Litigation documented in the medical record 5 1 20.0
18 Other not included in the criteria above 220 75 34.1
CVA, cerebrovascular accident; ITU, intensive therapy unit.
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We have presented some of the epidemiological information generated from the Harvard methodology,
but the full data set is akin to a root-cause analysis and, although undoubtedly useful, both data collection
and extraction make it challenging within a service setting. The GTT, by contrast, is pragmatic with a
limited data set and, although advantageous in terms of the ability of the service to both collect and
analyse data, the outputs are restricted to rates on a small monthly sample (demonstrated in Figure 13)
and counts of the number of harm events associated with common triggers. Such data are presented to
executive boards periodically, but the reason for doing so is unclear and there is limited anecdotal evidence
of it being understood and acted on within the quality agenda in organisations.
As part of the process of quality assuring the data generated from the RF1 reviews, we began to see patterns
of harm emerging from individual organisations. For example, we recognised that some organisations
seemed to have very few pressure ulcers, whereas others had them regularly within their monthly quota of
notes. Other organisations, which were outside the main urban centres in Wales, had harm events linked to
delayed diagnosis, which we did not see often elsewhere, and others had harm events arising from the
untimely identification and management of sepsis. We tested these patterns with site leads by ranking the
top five frequently occurring criteria that were linked to AEs for each organisation and presenting these as
their ‘organisational signatures’ of harm.
The top five were chosen rather than the full spectrum of criteria, as the total number of events in any
organisational sample is small and the aim was to highlight a few key areas for each organisation for which
the AE risk is highest. This process provides a clear distinction between the managerial assurance generated
from the quantification of harm and the clinical learning generated from what happened, which can be
triangulated with local knowledge and data. In our experience, issues that could be addressed include those
of a structural, managerial, clinical, process, educational and resource nature. The following examples begin
to elucidate some of these issues.
Figure 14 outlines the phase 1 harm signature for site 1. A mixed pattern of harm is observed, with the
underlying AEs in this organisation being linked mainly to infections, readmissions, hospital-acquired
injuries, medication errors, thromboembolic events and the ‘other’ events criterion in the RF1 pro forma.
The percentages reported reflect the contribution of each individual criterion to the organisation’s overall
risk profile. This profile is fairly representative of the spectrum of AEs commonly seen in clinical practice.
1. Measuring harm
2. Understanding causes
3. Identifying solutions
5. Translating evidence into safer care
4. Evaluating impact
FIGURE 12 The role of harm measurement in the cycle of quality improvement (World Health Organization, date
unknown).58 © Copyright World Health Organization (WHO), 2017. All rights reserved.
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In site 3, the pattern of harm highlights issues with patient flow and discharge. Thirty-five per cent of this
organisation’s AEs were associated with patients requiring repeated admissions for related problems, with
the remaining arising from hospital-acquired infection, hospital-acquired injuries and medication errors and
reactions (Figure 15). The percentages reported reflect the contribution of each individual criterion to the
organisation’s overall risk profile.
This was not new knowledge to the organisation, which had already embarked on a significant
programme of investigating patient flow and innovative modelling of process and service redesign.
However, a relatively small number of reviews confirmed that this was a well-targeted priority for
improvement along with a focus on the management of sepsis.
In site 5, ward-based care issues were predominant, with harm being associated with hospital-acquired
accident and injury, hospital-acquired infection and problems arising from discharge planning processes
(Figure 16). The percentages reported reflect the contribution of each individual criterion to the
organisation’s overall risk profile. In this organisation attention has been drawn to these issues externally,
and efforts are under way to monitor care standards across the organisation. In all cases, the harm
signatures identified organisational issues that could be assessed and improved through concerted effort.
The representation of harm in this way offers a number of opportunities:
1. Knowing both the percentage of inpatients experiencing an AE and the proportional breakdown of
AEs allows for a crude extrapolation of the magnitude of an issue in a health-care system, thereby
facilitating assessment and prioritisation. In larger samples, attention may be focused on developing
harm signatures for subsets of data, such as those that are most likely to improve outcomes for patients
as a result of their level of preventability.
Hospital-acquired infection/sepsis, 19%
Unplanned admission prior, 14%
Hospital-incurred patient accident or 
injury, 13%
Any other desirable outcome, 11%
Other patient complications to include 
MI, DVT, PE and CVA, 10%
FIGURE 14 Harm signature for site 1. CVA, cerebrovascular accident; PE, pulmonary embolism.
Unplanned admission post, 19%
Unplanned admission prior, 16%
Hospital-acquired infection/sepsis, 14%
Adverse drug reaction/error, 10%
Hospital-incurred patient accident 
or injury, 9%
FIGURE 15 Harm signature for site 3.
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2. Areas of harm deemed to be important can be triangulated with other organisational data and an
appraisal instigated of current monitoring and intervention efforts. For example, if pressure areas are
described in the AE profile, efforts might be well directed at reviewing compliance with interventions
such as intentional rounding or skin bundles. Similarly, with infections, compliance with hand washing,
asepsis, antibiotic administration and timely response to deranged early warning scores may be
appropriate areas for assessment.
3. Areas for awareness raising or specific intervention can be identified at the corporate level, with
accountability for action distributed to relevant clinical teams.
4. It is conceivable that these profiles of harm will change over time and some types of AEs may
completely drop out of the signature and be replaced by another area for assessment. They therefore
also offer potential as an evaluative tool in quality improvement efforts.
5. Simple diagramatic representation of harm can be used to engage and influence practice at all levels of
an organisation from the chief executive officer to anxcillary staff, acknowledging every member of
staff’s role in promoting patient safety.
Part 4: comparison of the Global Trigger Tool and the two-stage retrospective review
process rates of harm across NHS Wales
The percentage of inpatient episodes determined to contain evidence of an AE using the GTT methodology
across NHS Wales was lower than that reported through the two-stage retrospective review process (mean
9.0%, 95% CI 8.82% to 9.18%, median 10.9%, SD 6.36%). However, there was significant variation in
the extent of harm observed at the individual organisational level (range 1.9–23%). This indicated that,
in routine use in some organisations, harm events were not being picked up and, in others, more events
were being identified than when the Harvard method was used on the same notes. When weighted for
percentage contribution to the study sample, the weighted mean increased to 11.63% and was higher than
the percentage reported using the two-stage retrospective review process (Table 23).
To undertake matched-pairs analysis of the two methodologies, we matched outcomes of the two
different methodologies using a unique study identifier. Despite having 4546 two-stage reviews and 4833
GTT reviews, we successfully matched only 77% of available records with a range of between 31% and
93% across study sites (Table 24). Reasons for the failed matches varied across the organisations
and included loss of paper records of GTT reviews before they could be entered on a database and
incompatible hospital numbers. Probability matching was not pursued, as the study was sufficiently
powered to detect a difference in 3504 matched reviews. There was so much variability in the reported
GTT rates, together with low frequencies of harm events occurring across the GTT triggers, that plans for a
sensitivity analysis of individual triggers and further analysis became redundant.
Hospital-incurred patient accident or 
injury, 18%
Hospital-acquired infection/sepsis, 14%
Unplanned admission post, 11%
Inadequate discharge plan, 9%
Any other desirable outcome, 9%
FIGURE 16 Harm signature for site 5.
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The reported difference in the occurrence of AEs using the two methodologies is 2.3% (95% CI 0.93% to
3.67%) (Table 25).
The Harvard method detected more AEs in 6 of the 11 study sites and, in four of these, the number of AEs
detected was at least double the number identified in the GTT (Figure 17).
In the five organisations in which the GTT detected more AEs, the increase was smaller, with only one
organisation reporting a rate that was substantially higher than the rate detected using the Harvard
method (site 7). The internal validity of the GTT in this context is questioned; we report that in Wales,
when used longitudinally over a period of time, the GTT did not perform as well as the two-stage Harvard
method and AEs were under-reported in most study sites. Further diagrammatic representation of the
overlap between the GTT and Harvard method AEs is found in Appendix 3.
TABLE 24 Outcomes of the matching process linking GTT and Harvard methodology reviews across participating
organisations
Site
Number of GTT
reviews
Number of RF1
reviews
Total number of cases with
complete RF1 and GTT data
Percentage match
per organisation
1 680 518 429 83
2 661 531 474 89
3 463 442 401 91
4 438 418 246 59
5 288 341 274 80
6 160 176 154 88
7 99 316 99 31
8 477 347 287 83
9 560 421 351 83
10 348 501 292 58
11 659 535 497 93
Total 4833 4546 3504 77
TABLE 23 Percentage of inpatients with AEs detected by the GTT across study sites
Site Number of GTT reviews undertaken Number of AEs determined Organisational GTT rate
1 680 33 4.9
2 661 21 3.2
3 463 19 4.1
4 438 53 12.1
5 288 17 5.9
6 160 3 1.9
7 99 23 23.2
8 477 65 13.6
9 560 61 10.9
10 348 47 13.5
11 659 88 13.4
Total 4833 430 9.0
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There are two key drivers for AE monitoring: assurance and improvement. Assurance is derived from
quantifying the extent of a problem and having a reference rate against which benchmarking is possible.
Both the GTT and Harvard method percentages reported fall within the range of AEs previously reported
and, therefore, fulfil this function. However, the clinical implications of the observed difference lie in the
second driver for undertaking harm monitoring, that is, clinical and organisation learning. Health-care
organisations need to understand the origins of their AEs and the opportunities for those AEs to be
reduced through programmes of quality improvement. Other outcome measures that we report, namely
severity and preventability, are arguably more important in any individual organisation’s quality
improvement activity.
TABLE 25 The percentage of AEs detected by the GTT and the Harvard methodology in 3504 matched records
across 11 NHS Wales hospital sites
Site
Percentage of cases with an AE
MRF2 GTT
1 9 4
2 8 3
3 12 4
4 8 13
5 10 6
6 9 2
7 12 23
8 9 13
9 8 10
10 16 13
11 12 13
Total 10.3 8
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FIGURE 17 Percentages of AEs detected in 3504 matched reviews using the GTT and Harvard methods.
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The impact of Global Trigger Tool-determined adverse events for patients
and organisations
The GTT data were further explored to elucidate clinically relevant information that could potentially inform
improvement priorities (Figures 18 and 19). A total of 158 out of 315 harm events identified by the GTT
method resulted in temporary harm requiring intervention (50%), and a further 115 (37%) events required
initial or prolonged hospitalisation. Nine per cent of all GTT reviews across the study sites were associated
with more significant clinical harm, including eight events that contributed to the patient’s death.
As no information is derived from the GTT method on issues such as management causation, the
preventability of the AE and additional treatment or identification of contributory factors, the spectrum of
triggers identified that were aligned with AEs were explored.
Figure 19 represents the most commonly occurring triggers in the GTT data set determined to be a harm
event. The most frequently occurring trigger was readmission within 30 days (G4) (n = 107), followed by
complications of treatment (G7) (n = 33) and falls (G2) (n = 30). These three triggers accounted for 55% of
all harm events reported through the GTT method.
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FIGURE 18 Percentage of GTT AEs falling into the NCC MERP’s Categorizing Medication Errors Index.44 E, contributed
to or resulted in temporary harm to patient requiring intervention; F, contributed to or resulted in temporary harm to
patient and required initial/prolonged hospitalisation; G, contributed to or resulted in permanent patient harm;
H, required intervention to sustain life; and I, contributed to the patient’s death.
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FIGURE 19 Frequently occurring triggers resulting in harm events across NHS Wales 2011–13.
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Furthermore, the conversion rate from triggers to established harm was very low for a high number of
frequently occurring criteria. For example, in the case of lack of early-warning score, which was triggered
on 424 occasions, the conversion rate to harm events was 4% (17/424). The number of events in other
categories was so low that comparison with the RF1 criteria was not undertaken. Details on all GTT
triggers can be found in Appendix 4.
Summary of key points arising from Chapter 2
l In total, 4388 inpatient episodes of care were screened in phase 1 of the study and 450 were identified
using the Harvard methodology (10.3%, 95% CI 9.4 to 11.2%). A total of 51.5% of AEs were
identified as having at least some evidence of preventability (95% CI 46.88% to 56.12%).
l Agreement between reviewers on the presence of AEs was achieved in 83% of cases (n = 72) with a
kappa value of 0.63 and a corresponding 95% CI of 0.46 to 0.80.
l Nearly three-quarters of patients with AEs needed additional treatment and/or days in hospital, 16%
were discharged with a significant impairment in their functional status and, in 9% of cases, the AE
may have been associated with, but not necessarily causally related to, the patient dying during the
inpatient episode. The median additional inpatient LOS was 6 days.
l In 450 episodes of care in which AEs were identified, the physician cohort still deemed the overall
quality of care to be excellent or good in 71%, with poor quality-of-care ratings being more common
in AEs that were deemed to be preventable.
l Older age and longer length of hospital stay were statistically associated with physician AE
determination [OR 1.12, 95% CI 1.07 to 1.20; and OR 1.37, 95% CI 1.12 to 1.20, respectively].
l Assessment of the conversion from positive criteria to confirmed AEs suggest areas for the assessment
and development of screening criteria for AEs.
l Signatures of organisational harm may provide (1) opportunities for the prioritisation of quality
improvement programmes, (2) triangulation of hypothesised harm with other organisational metrics
and information, (3) increased awareness of patient safety issues and (4) a monitoring and
evaluation tool.
l The percentage of inpatient episodes determined to contain evidence of an AE using the GTT
methodology across NHS Wales was lower than that reported through the two-stage retrospective
review process (mean 9.0%, 95% CI 8.82% to 9.18%). However, there was significant variation in the
extent of harm observed at the individual organisational level (range 1.9–23%).
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Chapter 3 Development of nurse-led
identifications of adverse events and the Harm2 tool
Methods
Aim 2
To use the findings of phase 1 to develop a robust measurement system for harm.
Objectives
l To respond to stakeholder feedback on the feasibility of the two-stage retrospective case note
review process.
l To review the contents of the Harvard method.
l To compare rates of nurse-determined and physician-determined AE rates.
l To measure the inter-rater reliability of nurse-determined AEs.
l To determine trends in nurse-determined AEs over time.
l To determine the degree of association between positive criteria and nurse-determined AEs.
l To evaluate RF1 screening criteria to determine if these criteria capture the full spectrum of harm,
especially harm attributable to omissions.
l To assess the implications of a time-limited approach in case note review methodology.
l To develop a new tool to identify AEs.
Background
At the end of phase 1, a decision needed to be made on the methodological approach required to meet
the aims of phase 2. As no transition period was built into the project plan, a no-cost extension was
agreed with the National Institute for Health Research to undertake interim analysis of phase 1 data and to
consult with our stakeholders on how to operationalise phase 2. Activity undertaken during this period
included the assessment of nurse determination of harm events, review of the GTT and Harvard method
outputs with key stakeholders, the assessment of the efficiency of harm screening criteria, and a review of
the structure and content of the common tools in practice. Towards the end of this period it became
apparent that a hybrid set of tools was required to provide robust information on harm, which hospitals
could use on an ongoing basis for harm surveillance and to drive quality improvement.
Stakeholder consultation and testing of phase 1 findings
We reviewed with medical, nursing and managerial colleagues the nature of data generated from both
the GTT process and the Harvard method in phase 1 of the study. Most organisations at this point had
already made the decision to stop undertaking GTT reviews and were articulate about the limitations of
this approach. The information generated from the Harvard method was viewed as providing a reliable
measure of harm in the system capable of generating information for organisational learning, which is
grounded in the ‘patient story’. Stakeholders also valued the potential for outcomes to be benchmarkable,
that is, whether or not they as organisations were outliers or, perhaps more significantly, have AE rates
greater than the 1 in 10 figure commonly stated. Harm signatures were viewed as having an exciting
potential to identify priorities for organisational intervention and a mechanism for wider engagement in
patient safety monitoring across organisations. Although the Harvard method delivered on what
organisations said they needed, it became apparent on the review of the tools that this was not going to a
sustainable approach in a NHS setting once the second phase of the study was complete.
This drove our methodological approach for phase 2 and our aims were to generate outcomes from the
data that (1) provided high-level metrics, which are benchmarkable with the international literature and
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other epidemiological studies of harm; (2) inform future strategies for case note review methodology in
terms of team composition; (3) improve the face validity of screening criteria by understanding the
association between positive screens and AEs; and (4) engage frontline clinical teams, as well as managers
and executive teams, in monitoring patient safety risk and outcomes.
This transition phase of the study therefore facilitated an early descriptive overview analysis of the RF1 and
MRF2 data and a review of the clinical summaries in order to prioritise areas for further exploration and
testing in the second phase of data collection. The areas of specific focus were the (1) assessment of
screening criteria and their association with AEs, (2) identification of acts of omission that are not explicitly
covered in current screening methodologies and (3) review of current tools in use and the subsequent
identification of key components of harm measurement for phase 2.
Nurse determination of harm events
In most harm measurement methods, non-physicians undertake the screening process with physicians
making a subsequent determination on the presence of an AE. We added nurse determination of AEs to
the screening process in phase 1 in order to assess the rates generated and the composition of AEs
identified. Having two professional groups review the same case notes provided an opportunity to study,
along with AE rates, the differences in the identification of events, therefore, providing a robust
assessment of the optimum and the most cost-effective approach to team composition in retrospective
case note review.
As the non-physicians were making an AE determination outside the logical and structured process
outlined in the MRF2, their confidence in making the decision was rated on a scale of 1 to 5. This was to
ensure that lack of confidence did not prevent the identification of any potential AEs. The confidence scale
ranged from 1, not at all confident, to 5, very confident, and the inter-rater reliability of their judgement
was assessed in a 10% sample of all records that were double reviewed for agreement.
We compared the nurse and physician rate of harm nationally and by individual hospital site, and
computed rates of harm in the non-physician cohort by the level of confidence that the reviewers had in
an AE being present. For both reviewer groups, rates of AEs were plotted longitudinally in order to assess
trends over time.
Review of stage 1 adverse event screening criteria including thematic analysis
In order to assess the relationship between the criteria that screened positive and the subsequent
determination of AEs, we quantified, for each of the 18 criteria in the screening component of the RF1,
the frequency of positive criteria and the subsequent rate at which they converted to confirmed AEs. This
rate of conversion was assessed for both the non-physician cohort when they made a decision on the
presence of AEs at the end of the screening process and after the research physicians had reviewed the
case notes and made a definitive assessment on the presence of AEs.
A further step was undertaken to explore in greater depth criteria in which actual patient risk was difficult to
elucidate in terms of subsequent AE determination. For example, in the case of a readmission either side of
the index episode being studied, readmission is an ambiguous criterion and could indicate a number of
clinical and pathway issues. We therefore aimed to explore these cases to establish what was happening to
these patients and why they were thought to have experienced an AE. Other criteria were also generic,
particularly ‘any other – not covered by the above’. The assessment of these specific criteria would not only
enhance our understanding of screening criteria, but also enable us to explore our hypothesis that acts of
omission accounted for many of the AEs in these categories. Thematic analysis was the methodological
approach chosen to examine the clinical summaries of all positive screens in criteria prioritised for exploration.
Review of the components of the stage 2 retrospective case note record review form
The two-stage retrospective review tools have now been in use for 25 years, during which time few
structural changes have been made to the original versions, and the GTT has been used for around a
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decade. The end point for the new tool was a process that could efficiently generate data that could be
used directly by NHS organisations in safety and quality work but was still aligned in measurement and
definitional structure to the validated tools in use.
As well as reviewing and developing screening criteria, other components of the proposed new Harm2
tool were informed and derived from the process of documentary analysis of other tools in current practice
and commonly reported measures and outcomes of validated tools in the international literature.
Outcomes included validated screening criteria, AE definitions, classifications of health-care management
causation, AE preventability, AE severity, contributory factors, along with other definitions including those
of ‘problems in care’, and avoidable mortality. Tools assessed included the Harvard method, various
versions of the GTT, the PRISM tool and the IHI mortality review process.
Statistical and thematic analysis
The RF1 data with nurse identification of AEs were analysed to determine the percentage and
corresponding CI of patients who experienced an AE during the period of hospitalisation, and the severity
and level of preventability of the incident both in individual hospital sites and nationally. An unweighted
kappa coefficient was used to assess inter-rater reliability with corresponding 95% CIs and the percentages
of records that were concordant and discordant. Records were assessed for missing data, and as the
number of missing data was low it was presumed that they were missing at random; thus, the analysis
was performed using the available data set. Statistical analysis was undertaken using Stata, version 14.
Data from different tools, RF1, MRF2 and GTT, were linked via the VLOOKUP function in Microsoft Excel.
GTT cases were identified by their hospital number, whereas the study data (including the MRF2 reviews)
were identified through a unique study number. An independent database, held separately from the study
data, provided patient identification fields for the match between hospital and study numbers. Cases of
harm from the GTT and MRF2 review were identified and matched together using this reference data and
the VLOOKUP function in Microsoft Excel.
The thematic analytical process incorporated the five stages of qualitative data analysis techniques:
familiarisation, identification of a framework, indexing, charting and interpretation. A literature review was
carried out to aid the establishment of an initial thematic framework and the RF1 clinical summaries were
then reviewed in Microsoft Excel 2010 in four distinct phases. First, the process involved reading through
all the patient records to assist with familiarisation. A second iteration identified and numerically coded key
concepts in the data. The third phase involved the formation of protothemes and subthemes under which
the coded data were placed. A final pass aimed to reaffirm categorisation and reduce any misclassification
of data. The classifications generated were presented in flow charts and tables, and rates of subsequent
conversion to determined AEs were presented in order to prioritise new criteria emerging, including acts
of omission that could be tested in the second phase tool. The in-depth analysis of criteria and the
identification of additional screening criteria provided the platform from which the other components of
the new tools could be identified or developed.
Findings: development of nurse-led identifications of adverse
events and the Harm2 tool
Overview
Aim 2
To use the findings of phase 1 to develop a robust measurement system for harm.
Findings are presented in two parts. Part 1 presents the findings of nurses’ determination of AEs in a
supplementary step within the RF1 in phase 1 of the study. Part 2 outlines the findings from the thematic
analysis and the development of the new screening criteria for AEs in phase 2 of the study.
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Part 1: the nature and extent of nurse-determined adverse events across NHS Wales
As we amended the RF1 process introducing narrative and AE determination, records were kept on the
time taken across organisations for the research nurse cohort to read and evaluate all documentation on
the episode of care and complete the study documentation. The mean length of time to undertake this
process per review was 20 minutes, but ranged from < 5 minutes to a maximum of 2 hours for complex
episodes of care (Figure 20).
The percentage of patients identified as experiencing AEs at the end of the RF1 process is higher than the
percentage determined by physicians. Across all NHS Wales sites, 811 (18.4%) inpatient episodes of care
reviewed were found to include an AE (95% CI 17.33% to 19.63%). When AEs were stratified by the nurse’s
level of confidence in his or her determination of the event, the percentage of patients identified with an AE
fell, and in the categories of ‘somewhat confident’ (4) and ‘very confident’ (5), the percentage of patients
affected was 10.4%, which is comparable to the physician-determined percentage of 10.3% (Table 26).
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FIGURE 20 Mean length of time taken to undertake the amended RF1 process across the study sites.
TABLE 26 The breakdown of nurse-determined AEs stratified by level of confidence
Site
Nurse-determined AEs
Percentage of AEs determined
at confidence level
Physician-confirmed
(MRF2) harmn/N % ≥ 3 ≥ 4
1 97/533 18.2 12.9 6.8 9.0
2 67/530 12.6 9.4 4.9 7.9
3 101/432 23.4 17.6 10.0 11.8
4 56/375 14.9 10.7 7.2 8.0
5 76/309 24.6 22.7 17.5 10.4
6 46/172 26.7 20.9 18.6 8.6
7 57/290 19.6 14.1 6.9 12.0
8 51/330 15.4 11.8 6.4 8.8
9 62/393 15.7 13.0 7.9 8.4
10 108/484 22.3 20.9 18.8 16.1
11 90/520 17.3 16.7 14.6 10.5
Total 811/4388 18.4 15.0 10.4 10.3
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Inter-rater reliability of nurse determination of adverse events
Agreement on the occurrence of an AE was higher among the nursing cohort (87%) (κ = 0.56, 95% CI
0.46 to 0.66) than when based on the presence of screening criteria (76.6%) (κ = 0.47, 95% CI 0.39 to
0.55), but was still moderate, with significant variation in the level of agreement across participating sites
(Table 27).
Conversion of screening criteria to nurse-determined adverse events
With the percentage of AEs identified by the nursing cohort almost double that determined by the
physicians, the conversion rate to determined AEs was higher. This is outlined for all screening criteria in
Table 28.
Further analysis of the difference in the identification of AEs comprising the physician-determined
percentage of 10.3% and the nurse-determined percentage of 10.4% when they are ‘confident’ or ‘very
confident’ in the presence of an AE is presented in Table 29.
In eight screening criteria, the difference in the rate of conversion from positive screening criteria to
determined AEs is observed to be < 5%. Moderate differences in the rate of conversion are seen in the
identification of AEs arising from criteria such as neurological deficit not present on admission (9.5%)
and hospital-acquired accident and injury (7.9%), both of which are higher in nurse-determined AEs.
Differences of greater significance are associated with two criteria, patient or carer complaint documented
in medical record (24%) and unexpected death (25.6%), both of which are higher in nurse-determined
AEs. Trends suggest a number of points:
1. Nurses may lack confidence, and in some cases knowledge, in some of the more clinically technical
elements of AE detection.
2. Physicians may not identify AEs if they are not documented in the medical progress notes and may not
capture the full spectrum of AEs.
3. The overall AE rate may be higher if there is a balance of disciplines represented in case note
review teams.
TABLE 27 Inter-rater reliability of nurse determination of AEs
Site
Total number of
reviews
Numbers of pairs
Unweighted
kappa 95% CI
Altman
scale 199157Concordant Discordant
1 58 57 1 0.85 0.55 to 1.0 Very good
2 56 51 5 0.61 0.29 to 0.94 Good
3 49 43 6 0.33 0.25 to 0.83 Fair
4 48 43 5 0.65 0.36 to 0.94 Good
5 32 26 6 0.54 0.20 to 0.87 Moderate
6 20 18 2 0.61 0.092 to 1 Good
7 29 29 0 1 1 to 1 Very good
8 41 33 8 0.56 0.45 to 0.66 Moderate
9 54 47 7 0.55 0.24 to 0.86 Moderate
10 53 40 13 0.31 0 to 0.64 Fair
11 49 40 9 0.52 0.23 to 0.80 Moderate
Duplicates 3 2 1
Total 492 429 63 0.56 0.46 to 0.66 Moderate
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Part 2: findings from the thematic analysis – developing screening criteria for
adverse events
Screening criteria can be viewed as data that, when present, prompt further investigations into whether or
not the patient received substandard care leading to less than optimal outcomes. Criteria or triggers broadly
reflect harm to patients in inpatient settings. Criteria vary considerably in terms of their characteristics and/or
constructs. Some criteria are, by their very definition, AEs, and these include hospital-incurred injury and
hospital-acquired infection. Others describe common scenarios such as readmission within 30 days of
discharge or unplanned transfer to a higher level of care, which in themselves do not fulfil AE criteria but
highlight a situation in which patients might be at increased risk. The closer screening criteria are aligned
with AEs, the more accurately risk can be described and the greater the face validity screening tools will
have with their users. Interim analysis of RF1 data in the final stages of phase 1 described the variability in
the conversion of positive criteria of harm in both nurse- and physician-confirmed AEs (Figure 21).
In 4388 valid episodes of care reviewed, a total of 2225 criteria of harm were identified. Two of the criteria,
(1) injury or complications related to termination or labour and delivery (including neonatal complications)
and (2) documentation or correspondence indicating litigation, either contemplated or actual, occurred
infrequently (four and five times, respectively). Others, such as admissions either side of the index admission
under review, occurred frequently (a total of 820 times in the data set). When the conversion of criteria to
harm events was examined, a number of key issues were identified. Some criteria by their very name and
nature are AEs, for example hospital-acquired infection/sepsis and hospital-incurred patient accident or
injury, and the conversion rate to actual confirmed harm was high. Other criteria occurred frequently, but
the ‘labelling’ of the criteria did not give any indication of either the risk to the patient or the way in which
the patient was harmed and, in these cases, the conversion rate to clinical harm was relatively low.
TABLE 28 Conversion from positive screening criteria to confirmed AEs in nurse-determined AEs
Criteria
Frequency of criteria in
Conversion of criteria
to AEs in
4388 admissions AEs Nurses Physicians
Admission within 1 year before index admission 376 175 46.3 24.7
Admission within 30 days of index admission 454 200 44.1 25.3
Hospital-incurred accident or injury 240 190 79.2 46.7
Drug error or reaction 169 127 73.7 45.0
Unplanned transfer to higher level of care, for example ITU 47 36 75.2 42.5
Unplanned transfer to another hospital 23 10 43.5 21.8
Unplanned returned to surgery 41 36 87.8 53.6
Procedure-related organ or internal injury 16 15 93.8 62.5
Complications including CVA, DVT, MI 75 62 82.7 46.7
Neurological deficit not present on admission 52 37 71.2 38.5
Unexpected death 39 36 92.3 35.9
Inappropriate discharge/planning 129 94 72.9 35.7
Cardiac or respiratory arrest 44 29 65.9 29.5
Injury or complications related to labour/termination of pregnancy 4 2 50.0 25.0
Hospital-acquired infection 191 168 88.0 58.6
Patient/carer complaint 100 60 60.0 24.0
Litigation documented in the medical record 5 3 60.0 20.0
Other not included in the criteria above 220 144 65.5 34.1
CVA, cerebrovascular accident; ITU, intensive therapy unit.
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TABLE 29 Comparison of rates in conversion from positive screening criteria to confirmed AEs in nurse-determined
AEs at confidence levels of 4 and 5 and the physician-determined AEs
Criteria
Frequency of AEs in
nurse assessment at
confidence levels 4
and 5
Percentage
conversion
confidence
levels 4 and 5
Percentage
conversion in
MRF2
Difference in
conversion
rates (%)
Admission within 1 year before index
admission
102 27.1 24.7 +2.4
Admission within 30 days of index
admission
100 22.0 25.3 –3.3
Hospital-incurred accident or injury 131 54.6 46.7 +7.9
Drug error or reaction 74 43.7 45.0 +1.3
Unplanned transfer to higher level of care,
for example ITU
24 51.1 42.5 +8.6
Unplanned transfer to another hospital 5 21.7 21.7 0
Unplanned returned to surgery 23 56.1 53.6 +2.5
Procedure-related organ or internal injury 10 62.5 62.5 0
Complications including CVA, DVT, MI 40 53.3 46.7 +6.6
Neurological deficit not present on
admission
24 48.0 38.5 +9.5
Unexpected death 24 61.5 35.9 +25.6
Inappropriate discharge/planning 49 38.0 35.7 +2.3
Cardiac or respiratory arrest 17 38.6 29.5 +9.1
Injury or complications related to labour/
termination of pregnancy
N/A N/A N/A N/A
Hospital-acquired infection 108 56.5 58.6 –2.1
Patient/carer complaint 44 44.0 24.0 +20
Litigation documented in the medical record 2 40.0 20.0 +20
Other not included in the criteria above 94 42.7 34.1 +8.6
CVA, cerebrovascular accident; ITU, intensive therapy unit; N/A, not applicable.
0
10
20
30
40
50
Pe
rc
en
ta
g
e
60
70
80
90
100
Ad
m
iss
io
n 
pr
e
Ad
m
iss
io
n 
po
st
Ho
sp
ita
l in
ju
ry
Dr
ug
 re
ac
tio
n
Un
pl
an
ne
d 
ITU
Un
pl
an
ne
d 
tra
ns
fe
r
Un
pl
an
ne
d 
su
rg
er
y
Pr
oc
ed
ur
e-
re
lat
ed
 o
rg
an
 in
ju
ry
Co
m
pl
ica
tio
ns
, D
VT
, M
I, e
tc
.
Ne
ur
ol
og
ica
l d
efi
cit
Un
ex
pe
cte
d 
de
at
h
In
ap
pr
op
ria
te
 d
isc
ha
rg
e
Ca
rd
iac
, r
es
pi
ra
to
ry
 ar
re
st
In
ju
ry
 co
m
pl
ica
tio
n 
of
 la
bo
ur
Ho
sp
ita
l in
fe
cti
on
Pa
tie
nt
/ca
re
r c
om
pl
ain
t
Lit
ig
at
io
n
Ot
he
r
Percentage conversion in 
physician-confirmed events
Percentage conversion in 
nurse-determined events
FIGURE 21 Conversion from positive criteria to confirmed AEs. ITU, intensive therapy unit.
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Three criteria were of specific interest because of their (1) high frequency in the data set, (2) relatively low
conversion rate and (3) ambiguity around potential or actual clinical harm. The three are as follows:
1. unplanned admission within the 12 months prior to the index admission, as a result of any
health-care management
2. unplanned admission to any hospital post this discharge
3. any other undesirable outcome.
In addition, although criterion 3 occurred frequently and had a high conversion rate and therefore featured
commonly in organisational signatures of harm, the term ‘hospital-acquired patient accident and injury’ is
nebulous, and we felt that this area warranted further exploration and characterisation of these events in
the data set. The frequency of these criteria in the data set is outlined in Table 30 and all four criteria
underwent thematic analysis to further categorise risk to patients.
Thematic analysis of criteria 1 and 2, to improve understanding of the association of
readmission to secondary care with adverse events
Criteria 1 and 2 were examined together as ‘hospital readmissions’ in order to elucidate points in the patient
pathway and the potential reasons that may have resulted in an AE being associated with readmission. A
framework was developed through a literature review and causes of harm in readmitted patients from our
data set were grouped into whether the event was attributable to system or health-care professional
factors. System factors were subdivided into structural factors (such as the configuration of hospitals and
type of health care provided), which may predispose to harm, and logistical factors (such as communication
between the interfaces of care). Health-care professional factors were subdivided into the constituent parts
of care provision including pre-assessment, diagnosis, investigations, treatment and discharge categories.
An initial examination and coding of data facilitated the development of the initial structure to categorise
the causes of readmissions. Readmissions were deemed to be either planned or unplanned. Planned
readmissions are generally not the result of iatrogenic harm, but a predictable part of routine care. Unplanned
readmissions were categorised either as ‘failures in care’ or as arising from the ‘nature of disease’ (Figure 22).
The former involves causes of AEs that are amenable to intervention, whereas the latter includes issues of
patient care that are difficult to circumnavigate as a result of natural disease states and progression.
A total of 54% of unplanned readmissions across both criteria were a result of AEs potentially amenable
to intervention, compared with 42% within the planned readmissions cohort. There was a statistically
significant (p < 0.005) difference between the percentage of patients in the ‘failure of care’ and ‘nature
of disease’ categories who were identified as having had an AE.
TABLE 30 Conversion of RF1 criteria 1, 2, 3 and 18 in the RF1
Criterion
number Criterion
Frequency in Conversion in
Data set
Physician-
confirmed
events
Nurse-
determined
events
Physician-
confirmed
events (%)
Nurse-
determined
events (%)
1 Admission pre-index
admission within a 1-year
period
376 93 170 24.7 45.3
2 Admission post-index
admission within 30 days
454 115 193 25.3 42.6
3 Hospital-incurred accident
or injury
240 112 184 46.7 77.6
18 Other 220 75 145 34.1 65.3
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Figures 23 and 24 illustrate the breakdown of these categories into their subcategories, as generated
through the thematic analysis. Figure 23 illustrates the 10 subcategories relating to ‘failure of care’ events,
each of which identifies potential areas in the patients’ management that could potentially be addressed
to prevent readmission. Figure 24 shows the six subcategories derived under the ‘nature of disease’
category. Frequency is reported by each category along with the attendant conversion rate to determined
harm events. Further explanation of this classifications can be found in Appendix 5.
Identifying acts of omission resulting in failures in care and hospital readmission
Many categories reported as ‘failure of care’ were described in the other parts of the RF1 and these AEs
were already ‘labelled’ in other clinical criteria such as hospital-acquired infection and patient complications.
The ‘premature discharge’ category, which emerged through the thematic analysis, is an example of an
organisational issue, which again is covered in criterion 12 of the RF1, defined as ‘inappropriately discharging
patients or inadequately planning their discharge’. However, our analysis of readmissions did uncover causes
of readmission attributable to ‘diagnostic issues’, ‘ineffective symptom management’ and ‘prolonged waiting
times’ which were not effectively covered in other parts of the form and together account for around 63%
of the ‘failure of care’ categorised readmissions. Incorporating these areas into the screening criteria we
believe covers important areas of acts of omission, which will further enhance the routine characterisation of
harm in NHS organisations.
Thematic analysis of criterion 3, unintended patient accident or injury, and criterion 18,
any other undesirable outcome
The same methodological process was employed earlier in phase 1 to explore criterion 3 (‘unintended
patient accident or injury’) and criterion 18 (‘other undesirable outcomes’). The analysis was undertaken
on 3043 inpatient episodes and, at this point of data collection, 171 episodes of care fell under criterion 3
and 133 under criterion 18. Cases were excluded if the research nurse had not determined the positive
screen to contain an AE, providing a pool for thematic analysis of 136 and 100 cases, respectively. Figure 25
shows the flow chart of included cases. Case reports were included within multiple themes if more than one
AE was recorded.
During thematic analysis, narratives that were classified into criteria 3 or 18 were determined as being
misclassified if they fitted into another of the 16 remaining criteria more appropriately. These records were
excluded from the development of the thematic framework, as they did not contribute knowledge to the
development of new themes or categorisation of harm events. We believe that this misclassification may
have arisen because of (1) limited space for narratives of clinical summaries to be written in the RF1 and
(2) these events were secondary and more minor events in patients who experienced more than one event
during the inpatient episode.
Planned
(Future) (Present)
Failure of care
(Retrospective)
Nature of disease
Readmissions
Unplanned
FIGURE 22 Flow diagram describing the categorisation of readmissions.
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Characterisation of adverse events in criteria 3 and 18
Figures 26 and 27 illustrate the breakdown of these categories into their subcategories, as generated
through the thematic analysis. Figure 26 illustrates themes that are classified into the main cause of AEs
within criterion 3. The categorisation is straightforward, with the majority of events falling into the
categories of falls, pressure damage including pressure sores and injuries caused by equipment.
Twenty-five records indicated a pressure sore that developed during the inpatient stay. Clear diagnostic
process meant that these cases were well defined, often with the direct keywords ‘pressure sore’. Falls in
hospital were more complex, and 57 clinical summaries described a fall event. This theme was further
subdivided into records that showed a history or predisposition to falls and those that did not. The majority
were in patients who were in the former group, who were predisposed to falls because of a past medical
history of falls, sedation or instability. Keywords included ‘fall’ and ‘slip’ or ‘found on floor’.
Cases documenting a
criterion 3 event,
n = 171
(a)
Cases considered AEs,
n = 136
Cases considered
non-AEs,
n = 35
Cases thematically 
classified,
n = 93
Cases misclassified,
n = 43
Cases documenting a
criterion 18 event,
n = 133
(b)
Cases considered AEs,
n = 100
Cases considered
non-AEs,
n = 33
Cases thematically 
classified,
n = 66
Cases misclassified,
n = 34
FIGURE 25 Flow chart of included cases in the analysis of criteria 3 and 18.
Criterion 3
‘injury’
Equipment,
n = 16
Invasive,
n = 10
Non-invasive,
n = 6
With history/
predisposition,
n = 34
Without history/
predisposition,
n = 23
Falls,
n = 57
Pressure
sores,
n = 24
Miscellaneous,
n = 7
Misclassified,
n = 43
FIGURE 26 Categorisation of criterion 3: hospital-incurred accident or injury.
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Sixteen patient records indicated injury attributable to equipment use. This theme is further divided into
injury caused by equipment that was either invasive or non-invasive. The majority of invasive harm was a
result of intravenous (i.v.) cannula (BD Venflon™, BD, Oxford, UK) use, and phlebitis and cellulitis were the
adverse outcomes. This subtheme also includes complications from procedures arising from traumatic
catheterisation and drain insertion. Non-invasive causes of harm includes those from dressings and masks.
In all cases, the causation for injury was understood and clearly stated. Seven cases were considered
miscellaneous in nature, as they did not conform to other coding because of content or frequency, which
reflects the kinds of injury that may occur during an inpatient episode.
Characterisation of adverse events in criterion 18: other undesirable outcomes
The framework developed through thematic analysis of clinical summaries relating to other undesirable
outcomes is shown in Figure 27. Irregularities and omissions in written communication leading to delayed
initiation of treatment made up the largest percentage of incidents leading to an AE. In total, 19 records
indicated that the patient experienced a delay in treatment during their stay. The staff-related subtheme was
subdivided further into AEs caused by staff shortages, and those caused by delays in the process of clerking,
including delay in medication prescribing and response by the on-call team. Resource constraints include
bed availability, drugs and procedures, which contributed to the experienced delays either directly or
because of cancellations. Communication was the largest theme in this group and themes were categorised
into failure in both verbal and written communication. Thirty-four records were considered more applicable
to alternative criteria in the RF1 and, again, this probably indicates that these were secondary events.
Criterion 18 contained more staff-/organisational-level issues than criterion 3. The documented events
were predominantly errors arising during the process of admission and inpatient stay that were caused
by staff and communication failures, rather than harm caused directly by health-care intervention and
management. Examples of these classifications can be found in Appendix 6.
Criterion 18
‘other’
Delayed
treatment,
n = 19
Decisions,
n = 16
Stigma,
n = 1
Treatment,
n = 15
Failure of
follow-up,
n = 3
Notes
Written
communication,
n = 25
Missing,
n = 3
Discrepancies,
n = 4
Inappropriate,
n = 1
Insufficient,
n = 14
Clerking,
n = 6
Shortages,
n = 3
Mis/late
diagnosis,
n = 8
Resource
constraints,
n = 10
Staff
Verbal
communication,
n = 3
Misclassified,
n = 34
FIGURE 27 Categorisation of criterion 18: any other undesirable outcome.
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Acts of omission featured dominantly, informing the addition of several additional screening criteria in
the proposed new tool to improve the balance of screening criteria between acts of omission and acts
of commission.
The assessment of a time-limited approach to case note review
The time taken to review inpatient episodes of care is an important feature of case note methodology,
particularly when it is used routinely in clinical practice. The Harvard method is non-time limited, whereas
the GTT review restricts the time taken to examine the record of care to 20 minutes. As data were
collected on time to review the inpatient record as part of the RF1 process, we calculated AE percentages
by time taken to comprehensively screen the inpatient record. Figure 28 demonstrates that the review time
is associated with the percentage of AEs identified increasing sequentially by 10-minute periods until
60 minutes, at which point the percentage of AEs drops. A total of 72% (3150 of 4388) of reviews were
completed within 20 minutes, and the percentage of AEs detected in these cases was lower than in the
total sample (6.3% vs. 10.3%). Reviews taking 20–30, 30–40, 40–50 and 50–60 minutes were associated
with percentages of 18%, 23%, 39% and 49%, respectively. In reviews that took in excess of 60 minutes,
the percentage of inpatient episodes with an AE dropped to 23.8%.
Age was explored as a potential explanatory variable in increasing the length of time taken to complete
the review because of increasing complex care (Figure 29). In the time periods up to 60 minutes, there
is no significant difference in mean age by length of time to review the episode of care. In the > 60 minutes
group, the age difference is significant. This group, albeit small (n = 21), had a mean age of 83 years, and
does probably reflect a group with comorbidity and complex episodes of care, thereby increasing the length
of time to undertake the review.
This has important implications for case note review methodology. The majority of reviews can be
completed within 20 minutes but relying on a time-limited approach may lead to not considering all
relevant information or to the inappropriate attribution of AEs to positive criteria or triggers and AEs may
also be missed, as cases with AEs can take significantly longer than 20 minutes to assess and make a
robust decision on presence.
The development of the Harm2 tool
The thematic analysis generated acts of omission for inclusion in the amended screening criteria and this,
along with the examination of different tools in practice, informed the development of the Harm2 tool,
which included the following key components.
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Patient information and documentation This initial section draws heavily on the current Harvard
method, documenting demographic and type and source of admission before undertaking a complete
assessment of the quality of documentation contained in the inpatient record. It is further supplemented
by categorising the specialty at time of initial ward admission and the identification of patients with a
mental health diagnosis or a learning disability, the last on request of mental health colleagues. We
introduced the Charlson Comorbidity Index as a measure of comorbidity in order to assess, in a large
cohort of patients, comorbid states, which might increase the likelihood of any one individual experiencing
an AE during an inpatient episode. All this background information was intended to be readily and easily
available, and extractable from the original clerking entry in the medical record.
Harm screening assessment Informed by the thematic analysis, the harm screening assessment in Harm2
incorporated important new categories of both acts of omission and commission. The new criteria or
subdivisions are described in Table 31.
Determination of harm events The ‘determination of harm events’ and ‘identification of problems in
care’ follows the screening process, with the severity of harm for the sake of simplicity being categorised
from the NCC MERP’s Categorizing Medication Errors Index44 (GTT) and problems in care derived from
section D of the MRF2.30,31 The form was simplified to allow multiple AEs to be entered separately,
facilitating straightforward identification of patients experiencing multiple events sequentially. In cases in
which harm was determined, a short narrative section asks reviewers to provide a brief summary of the
inpatient episode, placing clinical context to the harm event. In the event of no harm, the review is
complete at this stage.
Assessment of harm events Reviewers are given options in a tick-box grid to identify the point in the
patient’s pathway at which the harm event occurred before identifying, again by ticking, any contributory
factors leading to the poor outcome for the patient. Assessment of preventability is taken directly from
the MRF2 and is a six-point Likert scale, with an option to provide narrative to highlight any key issues,
messages or points of organisational learning relating to the event.
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FIGURE 29 Mean age and corresponding CIs by length of time taken to review the episode of care.
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Assessment of inpatient death As a decision had been made to include a large number of deceased
patients in our phase 2 sample, we added a small section that is completed only for patients whose
inpatient episode resulted in death. Statements were taken from the PRISM tool20,56 in order to assess
whether or not a simplified process could generate data that are benchmarkable with robust tools in
identifying (1) whether or not the patient’s death was caused by a problem or problems in care,
(2) whether or not problems in care contributed to the patient’s death and (3) whether or not there
was any evidence that the death was preventable.
TABLE 31 Amended screening criteria in the Harm2 tool
Criteria
number Criteria
1 Unplanned admission within 30 days before index admission, as a result of any health-care management
2 Unplanned admission to any hospital within 30 days of this discharge
3 Hospital-incurred accident or injury
Pressure ulcer
Fall
Equipment-related accident or injury
Other not covered above
4 Adverse drug reaction, side effect or drug error
5 Unplanned transfer from general care to intensive care/high-dependency unit
6 Unplanned transfer to another acute care hospital
7 Unplanned return to theatre in this admission
8 Unplanned removal, injury or repair of organ or structure during surgery, invasive procedure or vaginal delivery
9 Other patient complications to include MI, DVT, CVA
10 Development of neurological deficit not present on admission
11 Unexpected death or referral to coroner
12 Inappropriate discharge home, inadequate discharge plan
13 Cardiac or respiratory arrest
14 Hospital-acquired infection
Wound infection
HAP
Sepsis
Other
15 Patient/family dissatisfaction with care received documented in the medical record and or evidence of complaint
lodged
16 Delays in or cancellation of treatment
17 Evidence of inappropriate decision-making regarding the treatment or intervention the patient received
18 Problems relating to communication
19 Problems relating to documentation
20 Missed, delayed or incorrect diagnosis
21 Any other undesirable outcomes not covered by any other criteria
CVA, cerebrovascular accident; HAP, hospital-acquired pneumonia.
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Assessment of overall quality of care Reviewers were finally asked to consider all that they know
about this patient’s admission and rate the overall quality of care received by this patient from the
health-care provider.
The combination of a condensed gold standard measurement structure and a process in line with current
GTT methodology seemed an appropriate way to implement a harm monitoring process for organisations.
Harm2 was designed for routine use within a climate of organisational financial constraints but
organisational commitment to track and monitor trends of harm in their organisations through both rates
of AEs and signatures of harm (a copy of the Harm2 tool is found in Appendix 7).
Summary of key points arising from Chapter 3
l In total, 18.4% of records reviewed were found to have an AE present when determined by nurse
reviewers (95% CI 17.33% to 19.63%). When AEs were stratified by the nurse’s level of confidence in
his or her determination of the event, rates of harm fell, and in the categories of ‘somewhat confident’
(4) and ‘very confident’ (5), the AE rate was 10.4%; this was comparable to the physician-determined
rate of 10.3%.
l Agreement was higher in the nursing cohort for the determination of an AE (κ = 0.56, 95% CI 0.46 to
0.66): 87%.
l Interim analysis of RF1 data in the final stages of phase 1 described the variability in the conversion
of positive criteria of harm in both nurse- and physician-confirmed AEs and thematic analysis was
undertaken for the categories of readmission, hospital-incurred injuries and ‘other’ not meeting any
other criteria.
l Our analysis of readmissions uncovered causes of readmission attributable to ‘diagnostic issues’,
‘ineffective symptom management’ and ‘prolonged waiting times’, which were not effectively covered
in other parts of the form and together account for around 63% of the failure of care-categorised
readmissions.
l The injury and other events analysis indicated that events were predominantly errors arising during the
process of admission and inpatient stay. Errors were typically due to staff and communication failures
such as staffing levels and shortages and delays in the process of checking including tardiness in chart
authorisation and response by the on-call team rather than to health-care intervention and management
directly. Acts of omission featured dominantly, informing the addition of several additional screening
criteria in the proposed new method.
l Incorporating these areas into the screening criteria we believe covers important areas of acts of
omission, which will further enhance the routine characterisation of harm in NHS organisations.
l The overall AE rate may be higher if there is a balance of disciplines represented in case note
review teams.
l A time-limited approach may have significant implications for the identification of AEs as records that
take longer to review are more likely to contain them.
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Chapter 4 The implementation of a harm
surveillance system using the Harm2 tool
Aim 3
To test the Harm2 tool to monitor trends and improvement over time.
Objectives
l To train and supervise a team of research nurses to use the Harm2 tool to undertake medical record
assessment, screening for AEs and subsequent determination of AEs in the identified inpatient episode.
l To compare the occurrence of AEs in a random sample of discharged patients with a cohort of patients
in whom the inpatient episode ended in death.
l To compare the performance of Harm2 with the two-stage retrospective case note review process.
l To assess the intermethod reliability (parallel form reliability) of AE identification and AE outcomes (such
as severity and preventability of AEs) in a 10% sample of records that have been reviewed using the
gold standard two-stage retrospective review process and the Harm2 tool.
l To assess the inter-rater reliability (concordance among raters) of key outcomes using the Harm2 tool,
by double-reviewing 10% of all case notes reviewed.
l To determine the feasibility and acceptability of this approach among key stakeholders.
Methods
A one-stage harm screening and determination method was implemented across Welsh health boards in
order to quantify the nature and extent of AEs occurring at the individual organisational level and national
level across NHS Wales.
The review tool and training
The Harm2 tool, a hybrid of Harvard method AE determination and GTT one-stage process, was developed
alongside a 39-page guide on how to use the tool, the definitions of the criteria and a guide to identifying
an AE. An example of the instructions given to the reviewers to identify AEs can be found in Appendix 8.
Reviewers (n = 24), predominantly from a nursing background (n = 22), were commissioned from the
NISCHR CRC and had previous experience of screening medical records for criteria of harm. Training in the
use of the Harm2 tool was both instructive and experiential; didactic teaching in the components of the tool
and supervised review sessions were included. Reviewers were taught where to look for screening criteria
and the technique of case note review. The focus was on the discharge summary, nursing and medical
documentation, the medication/prescription chart, laboratory results for that admission, operative/theatre
documentation and any other documentation in the case notes. Initial training included outlining the basic
principles of AE determination and preventability. In determining judgement, reviewers were asked to
consider the patient’s overall health and whether or not the AE arose as a result of an error/system failure.
Face-to-face meetings or teleconferences were held on a regular basis to discuss challenging examples and
document outcomes to feed back to the wider team.
Harm and preventability determination
Harm/AEs were defined as an ‘unintended injury or complication causing temporary or permanent
disability and/or increased LOS resulting from health care’, and preventability was assessed on a six-point
Likert scale, as reported previously in phase 1.
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Injury severity was rated using categories E to I of the NCC MERP’s Categorizing Medication Errors Index,44
where E is temporary harm to the patient requiring intervention and I is patient death. The location,
principal problems in care and the identification of any contributory factors were recorded, along with
patient comorbidity, age, length of hospital stay, specialty treated within and admission status. Overall
quality of care was assessed on a 1–5 scale, with 1 being excellent and 5 being poor.
Study sample
The Harm2 tool sampling frame (n = 5000) included 20 random discharges and 10 randomly selected
admissions that ended in patient death from each study site using explicit case note selection criteria each
month. In order to locate 20 sets of case notes, organisations were advised to produce a list of 30 hospital
numbers randomly selected (from the list of all admissions in the specified month) using a random number
generator that was provided by the research team. The 10 deceased cases were randomly selected in the
same manner from the list of deceased patients in the month specified.
The study selection criteria for the 20 random admissions cases are as follows:
1. 20 randomly selected patients admitted in the specified month with a LOS of > 24 hours
2. patient aged > 1 year on the date of admission.
We did not exclude obstetric or paediatric cases as we estimated that the numbers would be small, but
future examination would highlight issues with using a generic tool across the whole acute sector, which
could be explored further in subsequent work.
In 9 of the 12 health boards involved in phase 1 of the study, hospitals agreed to ongoing involvement,
whereas in another two cases the health boards requested that other hospital sites participate in this
phase. One health board, which had only one hospital site involved in phase 1, increased its involvement
to two sites in phase 2. The 50–50 split between tertiary-level services and district general hospitals
remained.
The review process
Phase 2 commenced as a pilot in two organisations in April 2014, and across the 12 study sites in
July 2014, on inpatient discharges randomised from January 2014.
The process was condensed to a one-stage review process that was logistically simple. Arrangements were
negotiated with the health boards by the research office and a schedule of reviews was planned for the
duration of the study. Three research nurse teams covered the three geographic areas of Wales (north,
south-east and south-west) and individual review sessions were undertaken in teams of 2–4 reviewers.
In most cases, the schedule of 30 reviews would be undertaken in 1 day per hospital per month. Once
the notes were made available, the research team visited the NHS site and completed the review using the
Harm2 tool. A thorough assessment was made of the completeness of the medical record, and when
the nursing and medical documentation was not available the review was stopped. The review process
involved the review of the episode of care and any potentially relevant admissions either side of the index
admission and assessment for the presence of 21 criteria known to be sensitive to the occurrence of AEs.
If screening criteria were positive, the review continued to an assessment of the nature, severity and
impact of the event.
After completion of the reviews, a summary sheet was completed by the research nurse. This detailed the
number of reviews undertaken, any potential AEs identified and any requests for second opinions of the
inpatient episode within the organisation, ensuring that serious harm was flagged within individual
organisations. The use of the Harm2 tool was monitored both by inspection of completed forms when
returned to the research office and through regular liaison with researchers and regional leads.
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Intermethod and inter-rater reliability of the Harm2 tool
Ten per cent of all reviewed records were assessed using the one-step Harm2 tool and the two-stage gold
standard approach. Intermethod reliability assessed the degree to which key outcomes were consistent from
one review tool to the next. This involved the review teams also completing the RF1 screening tool from the
Harvard method after the Harm2 review had been completed. When positive criteria were identified in
the RF1, the record was referred to a research physician, who completed a MRF2 assessment, confirming the
presence of AEs and categorising the nature, severity, contributory factors and preventability of the event.
This formed the basis of the comparative analysis of the conversion rate from criterion of harm and the
determination of AEs from both the Harm2 tool and the Harvard method. The inter-rater reliability of the
Harm2 tool was assessed on 10% of inpatient episodes to assess the agreement or concordance of key
outcomes by different reviewers. Both forms of reliability studies were arranged on a random selection of
reviews on a quarterly basis.
Statistical analysis
The presence of harm in the episode of care was the primary study outcome. The Harm2 tool review data
were analysed to determine the percentage and corresponding CI of patients who experienced an AE
during the period of hospitalisation and the severity and level of preventability of the incident both in
individual hospital sites and nationally. Missing data were assessed and, because of their infrequency,
(1) they were presumed to be missing at random and (2) they were analysed on the available data set.
Weighted means were calculated using simple techniques to calculate a weighted average of the
percentage of AEs in each study site, adding weights together and dividing by number of sites.
Univariate analysis explored the association between demographic and chronic disease states and the
subsequent development of harm events. Descriptive statistics were used to describe and compare the
nature and severity of AEs in the random and deceased patient cohorts. An unweighted kappa coefficient
was used to assess inter-rater reliability with corresponding 95% CI and percentage of records, which were
concordant and discordant, respectively. When samples were independent, z-scores and corresponding
p-values were used to compare percentages. Statistical analysis was undertaken using Stata, version 14.
Findings: the implementation of a harm surveillance system using the
Harm2 tool
Aim 3
To test the Harm2 tool to monitor trends and improvement over time.
Findings are presented in four parts. Part 1 describes the study sample and the rate, preventability and
severity of AEs identified through the Harm2 tool. Part 2 re-examines the screening criteria in the Harm2
tool and their association with AE determination. Part 3 outlines factors independently associated with AE
determination in the Harm2 sample before part 4 outlines the nature and characteristics of AEs identified
by the Harm2 tool and differences in the random discharge and deceased patient reviews.
Part 1: the rate, preventability and severity of adverse events identified through
the Harm2 tool
Study sample and demographics
Twelve NHS organisations participated in phase 2 of the study, nine of which had previously contributed
data to phase 1 of the study. Two of the health boards requested that different hospital sites submit data
for this phase, and the health board that did not fully participate in phase 1 committed to this phase of
the study.
The active data collection was shorter in phase 2 of the study, running for a total of 16 months, between
May 2014 and September 2015. The number of episodes of care reviewed during this period was 4396.
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As we were less dependent on the study sites pulling notes specifically for the purpose of the GTT reviews,
there was less variation in the number of reviews submitted from each NHS site (Table 32). We did
encounter issues with capacity to undertake the full schedule of reviews in some regions, which in all but
one site (site 5) were circumnavigated. The identification of capacity issues within the NISCHR CRC
infrastructure meant that pragmatic decisions needed to be taken in terms of reducing the schedule of
reviews in deceased patients by 50% at the end of 2014. At the end of phase 2, 3352 and 1044 case
note reviews were undertaken in a random sample of discharge reviews and deceased patient reviews,
respectively.
As in phase 1, a number of reviews were excluded from the sample as the data were reviewed and quality
checked. Ninety-nine episodes of care were excluded from the final analysis on the basis of (1) errors in the
patient record retrieved for review, (2) incomplete documentation in the patient record preventing the
completion of the review and (3) the set of case notes not meeting phase 2 inclusion criteria.
Demographic profile of study population
Valid observations on key demographic characteristics were available for 4365 episodes of care (99.3%)
and the mean age of the patient during the index admission under review was 56.5 years in the randomly
selected discharge reviews cohort (95% CI 55.67 to 57.33 years) and was significantly higher, with a mean
of 78.8 years (95% CI 78.05 to 79.65 years), in the deceased patient cohort.
The random sample of inpatient episodes studied was more in line with the demographic distribution of
hospitalisations across NHS Wales, where 43% of the discharges occur in the over-65 years age group. In
this phase of the study, 46% of reviews in the randomly selected discharge reviews cohort and 88% of
the reviews in the deceased patient cohort were in patients over the age of 65 years during the inpatient
episode examined (Figure 30).
TABLE 32 Number of reviews undertaken across the 12 NHS Wales study sites
Site
Number of
Total number of
reviews included
in analysisDischarge reviews
Discharge reviews
included in analysis
Deceased patient
reviews
Deceased patient
reviews included
in analysis
1 289 287 96 92 379
2 293 285 82 82 367
3 298 292 103 101 393
4 273 254 106 100 354
5 237 236 86 86 322
6 255 249 75 72 321
7 290 290 89 88 378
8 290 282 57 57 339
9 264 252 79 77 329
10 266 259 97 91 350
11 297 296 88 87 383
12 300 297 86 85 382
Total 3352 3279 1044 1018 4297
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The gender breakdown in both cohorts is outlined in Table 33 and is more equal in the deceased patient
cohort than in the randomly sampled discharge reviews. Gender was not reported in 50 reviews
undertaken (1.2%).
Presence of positive criterion of harm in the randomly selected discharge reviews
data set
Across the 12 NHS study sites, 34.25% (95% CI 30.39% to 38.11%) of all episodes of care reviewed had
at least one positive criterion for harm, with a range seen across individual organisations of between
23.34% and 45.79% and a corresponding median percentage of 35.1% (SD 6.58%) (Table 34).
The percentage of adverse events in 3279 randomly selected discharge reviews and
1018 randomly selected deceased patient reviews across NHS Wales (2014–15) using the
Harm2 tool
The percentage of adverse events in 3279 randomly selected discharge reviews In the randomly
selected discharge review sample, at least one AE was determined in 11.3% of all episodes of care
(95% CI 10.22% to 12.40%), increasing to 11.68% (95% CI 10.58% to 12.78%) when weighted for
individual sites’ proportional contribution to the study sample. Multiple AEs during a single episode of care
were common. In these 371 episodes of care, a total of 497 AEs were identified, with one-quarter of patients
having at least one other AE identified. This was higher than the 10% with multiple AEs detected using the
Harvard method in phase 1 because we made it easier to record multiple events separately along with their
key characteristics in the Harm2 tool.
Table 35 reports on the percentage of AEs identified in all of the 12 participating NHS sites, with the range
of patients identified with AEs of between 8.7% and 14.86% and a median percentage of 10.72%
(SD 2.06%).
TABLE 33 Gender breakdown in the randomly selected discharge reviews and deceased patient reviews cohorts
Sex
Cohort
Discharge reviews Deceased patient reviews
Frequency Per cent Frequency Per cent
Male 1346 41.0 494 48.5
Female 1900 57.9 507 49.8
Unknown 33 1.0 17 1.7
Total 3279 1018
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FIGURE 30 Distribution of case note reviews across age groups.
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The percentage of adverse events in 1018 randomly selected deceased patient reviews In the
inpatient episodes examined that ended in patient death, at least one AE was determined in 30.1% of all
episodes of care (95% CI 28.13% to 33.82%). This is almost a threefold increase in the percentage of
patients experiencing an AE when compared with the randomly selected discharge reviews, indicating that
TABLE 34 Presence of positive criteria across the study sites
Site Number of reviews
Frequency of positive
criteria present
Per cent of reviews with
criteria present
1 287 67 23.34
2 285 82 28.77
3 292 117 40.06
4 254 103 40.55
5 236 86 36.44
6 249 84 33.73
7 290 86 29.66
8 282 110 39.01
9 252 71 28.17
10 259 69 26.64
11 296 112 37.84
12 297 136 45.79
Total 3279 1123 34.25
TABLE 35 The percentage of patients with identified inpatient AEs across participating NHS Wales sites
Site
Total number
of reviews
Cohort
Randomly selected discharge
reviews Deceased patient reviews
Frequency
of AEs
Per cent of
reviews with AEs
Number of
reviews
Frequency
of AEs
Per cent of
reviews with AEs
1 287 25 8.71 92 31 33.70
2 285 28 9.82 82 27 31.40
3 292 40 13.70 101 18 25.0
4 254 33 12.99 100 30 34.09
5 236 34 14.41 86 22 38.60
6 249 37 14.86 72 21 27.27
7 290 26 9.00 88 33 37.36
8 282 30 10.64 57 28 33.33
9 252 24 9.52 77 20 23.53
10 259 26 10.04 91 33 40.74
11 296 32 10.81 87 24 23.76
12 297 36 12.12 85 28 28.00
Total 3279 371 11.31 1018 315 30.97
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AEs occur, and are detected, more frequently in this group of patients. There was also considerable variation in
the percentage of patients with AEs, ranging from 23.76% in site 11 to 40.7% in site 10 (median percentage
32.37%, SD 5.63%). The reasons for such significant variation are likely to be multifactorial, reflecting issues
such as the percentage of the general population who access secondary health-care services for end-of-life
care and the complexity of services provided. As in the randomly selected discharge reviews, multiple AEs
during a single episode of care were common in the deceased patient cohort. In the 315 episodes of care in
which AEs are reported, a total of 512 AEs were identified, with 45% of patients having more than one AE.
The severity of adverse events in 3279 randomly selected discharge reviews and
1018 deceased patient reviews across NHS Wales (2014–15) using the Harm2 tool
The severity of all 497 AEs in the randomly selected discharge reviews was rated according to the NCC
MERP’s Categorising Medication Errors Index and the breakdown is shown in Table 36. Ninety-six per cent
of the events identified required intervention or subsequent readmission to manage the clinical sequelae of
the event and < 4% of all harm events were categorised as resulting in permanent patient harm or serious
clinical outcomes, including the death of the patient. Examples of the clinical context giving rise to the
Harm2-determined AEs falling into each NCC MERP index category can be found in Appendix 9.
The severity of AEs was also rated according to the NCC MERP’s Categorizing Medication Errors Index44 in
the deceased discharge cohort and the breakdown is shown in Table 37.
The reported levels of AE severity differed significantly between the randomly selected discharge reviews
and the deceased patient reviews (Figure 31). The proportion of all events falling into the lower levels of
severity, namely E (temporary harm) and F (temporary harm requiring further inpatient management), was
96.3% in the randomly selected discharge reviews, compared with just over half in the deceased patient
reviews (54.5%, z-score 15.4; p < 0.0001). Perhaps more significantly, although the AE was determined to
have contributed to the death of the patient in 1.4% of cases in the randomly selected discharge reviews,
this rose to 34.4% in the deceased patient reviews (z-score 13.6, p < 0.0001). On further exploration, it
became clear that the NCC MERP’s Categorizing Medication Errors Index is challenging to apply to many
AEs that are followed soon after by patient death. This is particularly evident in cases such as the
acquisition of hospital-acquired infection, and events categorised as level I would have been classified as
level F if the inpatient episode had not ended in the death of the patient. Furthermore, this may reflect the
process of dying even though AE criteria are met.
The clinical context giving rise to the Harm2-determined AEs in the deceased patient reviews cohort and
falling into each of the NCC MERP’s Categorizing Medication Errors Index categories can be found in
Appendix 10.
TABLE 36 The percentage of Harm2-identified AEs falling into the NCC MERP’s Categorizing Medication Errors
Index44 in the randomly selected discharge reviews (n= 3279)
Severity
AE (n)
Total number Per cent of total1 2 3 4
E 197 37 13 1 248 49.9
F 161 51 17 1 230 46.3
G 4 2 1 1 8 1.6
H 3 1 4 0.8
I 6 1 7 1.4
Total 371 92 31 3 497
E, contributed to or resulted in temporary harm to patient requiring intervention; F, contributed to or resulted in temporary
harm to patient and required initial/prolonged hospitalisation; G, contributed to or resulted in permanent patient harm;
H, required intervention to sustain life; I, contributed to the patient’s death.
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The preventability of adverse events in 3279 randomly selected discharge reviews and
1018 randomly selected deceased patient reviews across NHS Wales (2014–15) using the
Harm2 tool
In the randomly selected discharge reviews, 296 of the 497 (59.6%) AEs were deemed to have been
preventable if care had been delivered to a standard considered to be good clinical practice in normal
circumstances (95% CI 55.29% to 63.91%). The level of preventability for each AE was assessed on a scale
of 1–6 (Table 38), and the majority of all AEs (55.1%) were classified as having at least ‘slight to modest
evidence for preventability’, corresponding to scores of between 2 and 6 on the Likert scale (95% CI 50.73%
to 59.47%). In 32.7% of cases, the level of preventability was determined to be ‘preventability more likely
than not; more than 50–50 but close call’, corresponding to a score of between 4 and 6 on the Likert scale
(95% CI 28.58% to 36.82%).
TABLE 37 Percentage of Harm2-identified AEs in the randomly selected deceased cohort falling into the NCC
MERP’s Categorizing Medication Errors Index
Severity
AE (n)
Total number Per cent of total1 2 3 4
E 131 38 21 1 191 37.3
F 49 29 10 – 88 17.2
G 14 10 2 1 27 5.3
H 8 8 1 – 17 3.3
I 110 48 18 – 176 34.4
Unknown 3 8 2 – 13 2.5
Total 315 141 54 2 512
E, contributed to or resulted in temporary harm to patient requiring intervention; F, contributed to or resulted in temporary
harm to patient and required initial/prolonged hospitalisation; G, contributed to or resulted in permanent patient harm;
H, required intervention to sustain life; I, contributed to the patient’s death.
0
10
20
30
Pe
rc
en
ta
g
e
40
50
60
E F G H I
Severity rating
Random discharge
Deceased discharge
FIGURE 31 Comparative breakdown of the NCC MERP’s Categorizing Medication Errors Index44 in the randomly
selected discharge reviews and deceased patient reviews cohorts. E, contributed to or resulted in temporary harm
to patient requiring intervention; F, contributed to or resulted in temporary harm to patient and required initial/
prolonged hospitalisation; G, contributed to or resulted in permanent patient harm; H, require intervention to
sustain life; I, contributed to the patient’s death.
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Among the randomly selected deceased patient reviews, 316 of the 512 (61.7%) AEs were deemed to be
preventable (95% CI 57.49% to 65.91%), with the majority of all AEs being classified as having at least
‘slight to modest evidence for management causation’, corresponding to scores of between 2 and 6 on the
Likert scale (Table 39). This is not statistically different from the percentage determined preventable in the
randomly selected discharge reviews (z-score 0.7, p = 0.4948). Notably, in 78 cases in which preventability
was determined, no score was attributed to the level of preventability, reflecting the challenges faced by
reviewers in assessing AEs and the attendant preventability in this cohort.
General quality-of-care assessment in 3279 randomly selected discharge reviews and
1018 randomly selected deceased patient reviews across NHS Wales (2014–15) using the
Harm2 tool
At the end of the Harm2 process, the research nurses were asked the following question: considering all
that you know about this patient’s admission, how would you rate the overall quality of care?
TABLE 38 The preventability of AEs in the randomly selected discharge reviews
Preventable AE
AE (n)
Total number Per cent of total1 2 3 4
Frequency 219 57 17 3 296 59.6
Preventability score
1 18 3 1 – 22 7.4
2 28 5 5 – 38 12.8
3 50 16 2 1 69 23.3
4 54 13 3 – 70 23.6
5 32 7 4 1 44 14.9
6 37 9 2 1 49 16.6
Total 219 53 17 3 296
Unknown – 4 – – 4 1.4
TABLE 39 The preventability of AEs in the randomly selected deceased patient reviews
Preventable AE
AE (n)
Total number Per cent of total1 2 3 4
Frequency 195 87 34 – 316 61.7
Preventability score
1 8 6 1 – 15 6.3
2 30 10 1 – 41 17.2
3 64 18 12 – 94 39.5
4 21 14 4 – 39 16.4
5 15 5 9 – 29 12.2
6 13 7 – – 20 8.4
Total 151 60 27 238
Score not attributed 78 24.7
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Among 371 inpatient episodes in the randomly selected discharge reviews cohort in which AEs were
identified, the nurse reviewers deemed the overall quality of care to be excellent or good in 78.5% of
inpatient episodes examined (Table 40). The quality-of-care rating in the randomly selected deceased
patient reviews cohort was also very similar to that described for the randomly selected discharge reviews.
In 315 episodes of care in which AEs were identified, the overall quality of care was rated as excellent or
good in 72.7% of inpatient episodes examined. Across the total cohort, AEs that were deemed to be
preventable were again associated with lower overall quality-of-care ratings.
Comparison of the percentage of inpatients Identified with adverse events using the
Harvard method and Harm2 tool
In the nine organisations that contributed to both phases of the study, the percentage of patients
experiencing an AE in phase 2 was compared with that determined in phase 1 (Figure 32). In seven study
sites, the percentage of patients that experienced an AE showed little change. A more significant change
is observed in sites 4 and 5, with increased percentages in phase 2 reflecting a more robust sampling
strategy.
The CIs of the percentage of AEs occurring during phase 1 of the study determined using the Harvard
method (10.3%, 95% CI 9.4% to 11.2%) and the Harm2 tool (mean 11.3%, 95% CI 10.22% to
12.40%) overlap and, therefore, the rate of AEs determined by the two different methods is not
statistically different (z-score 1.4, p = 0.162).
TABLE 40 Quality-of-care assessment in Welsh patients experiencing an AE using the Harm2 tool
Overall quality assessment of episode of care
Cohort
Randomly selected discharge
reviews
Randomly selected deceased
patient reviews
Frequency
Per cent of
reviews rated Frequency
Per cent of
reviews rated
Excellent 86 23.2 63 20.0
Good 205 55.3 166 52.7
Adequate 45 12.1 57 18.1
Poor 4 1 6 1.9
Very poor – – 1 0.3
Not recorded 31 8.4 22 7.0
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FIGURE 32 Adverse event determination in nine NHS organisations in phase 1 using the Harvard method and in
phase 2 of the study using the Harm2 tool.
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The inter-rater and intermethod reliability of the Harm2 processes
Ten per cent of all Harm2 records were double reviewed to determine the extent to which different
reviewers agreed on the presence of an AE (Table 41). Among 380 episodes of care in the randomly
selected discharge reviews that were doubled reviewed, there was agreement in 336 cases (88.4%,
κ = 0.50, 95% CI 0.38 to 0.65).
In total, 132 episodes of care in the deceased patient reviews were double reviewed, and there was
agreement on the presence of AEs in 105 (79.5%) cases (κ = 0.54, 95% CI 0.39 to 0.70) (Table 42).
Intermethod reliability was also undertaken to assess the degree to which key outcomes are consistent
from one review tool to the next. In 422 Harm2 reviews, the RF1 was also completed and 77 inpatient
episodes were referred for physician MRF2 review. In total, 74 reviews were completed, and agreement on
the presence of AEs between the Harm2 and two-stage retrospective review process was evident in 58 or
78.4% (κ = 0.45, 95% CI 0.07 to 0.62), indicating a moderate level of agreement.
Part 2: assessment of screening criteria in the Harm2 tool
Conversion of individual criterion to harm events using the Harm2 tool
At the end of phase 2, we reassessed the conversion rate between any individual patient who screened
positive for any individual screening criterion and the subsequent determination of AEs in both the
randomly selected discharge reviews and the randomly selected deceased patient reviews (Table 43).
As harm determination was assessed in relation to each individual criterion in the Harm2 tool, rather than
by applying multiple criteria to predominantly single events as in the Harvard method, this allowed for
greater precision in the assessment of conversion. Although the difference in the rate of conversion was
< 10% across 15 criteria, a number of significant differences were seen. The Harm2 reviewers assessed
TABLE 41 Inter-rater reliability for presence of AEs using the Harm2 tool in the randomly selected
discharge reviews
Site
Total number of
reviews
Number of pairs
Unweighted
kappa 95% CI
Altman
scale 199157Concordant Discordant
1 31 27 4 0.52 0.043 to 0.99 Moderate
2 32 32 0 1 – Very good
3 31 30 1 0.78 0.36 to 1.00 Good
4 29 26 3 0.52 0.015 to 0.08 Moderate
5 28 23 5 0.58 0.24 to 0.91 Moderate
6 30 26 4 0.42 0.27 to 0.95 Moderate
7 28 25 3 0.34 0.00 to 1.00 Fair
8 30 24 6 NC NC Less than
chance
9 23 22 1 0.83 0.51 to 1.00 Very good
10 38 30 8 0.42 0.06 to 0.78 Moderate
11 29 23 6 0.13 0.00 to 0.75 Poor
12 51 47 4 0.67 0.36 to 0.98 Good
Not
known
1 Excluded from analysis
Total 380 335 45 0.50 0.38 to 0.65 Moderate
NC, not calculated.
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TABLE 42 Inter-rater reliability for presence of AEs using the Harm2 tool in the randomly selected deceased
patient reviews
Site Total number of reviews
Number of pairs
Unweighted kappa 95% CI
Altman
scale 199157Concordant Discordant
1 5 5 0 1 – Very good
2 9 8 1 0.77 0.34 to 1 Good
3 9 9 0 1 – Very good
4 10 8 2 0.52 0 to 1 Moderate
5 11 6 5 NC NC Less than
chance
6 20 14 6 0.38 0.21 to 0.80 Fair
7 14 13 1 0.81 0.45 to 1 Very good
8 11 10 1 0.81 0.47 to 1 Very good
9 9 6 3 0.30 0 to 0.95 Fair
10 10 7 3 0.40 0 to 0.97 Moderate
11 13 9 4 0.36 0 to 0.84 Fair
12 11 10 1 0.79 0.40 to 1 Good
Total 132 105 27 0.54 0.39 to 0.70 Moderate
NC, not calculated.
TABLE 43 Conversion from positive individual criterion and the determination of AEs using the Harm2 tool in 3297
randomly selected discharge reviews and 1018 randomly selected deceased patient reviews
Criterion
number Descriptor of criterion
Cohort
Difference in
conversion
(%)
Criteria
present/AE
present random
sample Rate (%)
Criteria
present/AE
present
deceased cohort Rate (%)
1 Unplanned admission within
30 days prior to index
admission as a result of any
health-care management
59/204 28.9 27/128 21.1 +7.8
2 Unplanned admission to any
hospital within 30 days post
this discharge
63/252 25.0 N/A
3 Hospital-incurred accident or
injury
15/57 26.3 14/44 31.8 –5.5
Pressure ulcer 21/45 46.6 50/78 64.1 –17.5
Fall 33/90 36.6 34/82 41.5 –4.9
Equipment-related accident or
injury
6/13 46.2 5/8 62.5 –16.3
Other not covered above 16/23 69.6 14/22 63.6 –6.0
4 Adverse drug reaction, side
effect or drug error
57/140 40.7 35/75 46.7 –6.0
5 Unplanned transfer from
general care to intensive care/
high-dependency unit
4/30 13.3 8/58 13.8 –0.5
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TABLE 43 Conversion from positive individual criterion and the determination of AEs using the Harm2 tool in 3297
randomly selected discharge reviews and 1018 randomly selected deceased patient reviews (continued )
Criterion
number Descriptor of criterion
Cohort
Difference in
conversion
(%)
Criteria
present/AE
present random
sample Rate (%)
Criteria
present/AE
present
deceased cohort Rate (%)
6 Unplanned transfer to another
acute care hospital
3/23 13.0 3/15 20.0 –7.0
7 Unplanned return to theatre in
this admission
13/33 39.4 5/11 45.5 –6.1
8 Unplanned removal, injury or
repair of organ or structure
during surgery, invasive
procedure or vaginal delivery
14/39 35.9 4/7 57.1 –21.2
9 Other patient complications to
include MI, DVT, CVA
15/30 50.0 16/55 29.1 +20.9
10 Development of neurological
deficit not present on
admission
5/14 35.7 13/53 24.5 +11.2
11 Unexpected death or referral to
coroner
5/18 27.8 43/149 28.9 –1.1
12 Inappropriate discharge home,
inadequate discharge plan
39/83 47.0 8/12 66.7 –19.7
13 Cardiac or respiratory arrest 1/13 7.7 18/96 18.8 –11.1
14 Hospital-acquired infection 19/52 36.5 21/73 28.7 +7.8
Wound infection 29/35 82.6 12/23 52.2 +30.4
HAP 29/43 67.4 104/159 65.4 +2.0
Sepsis 18/29 62.1 65/113 57.5 +4.6
Other 27/61 44.3 22/49 44.9 –0.6
15 Patient/family dissatisfaction
with care received documented
in the medical record and or
evidence of complaint lodged
12/106 11.3 14/70 20.0 –8.7
16 Delays in or cancellation of
treatment
35/132 26.5 32/65 49.2 –22.7
17 Evidence of inappropriate
decision-making regarding the
treatment or intervention the
patient received
30/41 73.2 24/67 35.8 +37.4
18 Problems relating to
communication
25/56 44.6 19/42 45.2 –0.6
19 Problems relating to
documentation
22/149 14.8 20/96 20.8 –6.0
20 Missed, delayed or incorrect
diagnosis
28/42 66.7 20/28 71.4 –4.7
21 Any other undesirable
outcomes not covered by any
other criteria
25/74 33.8 19/32 59.4 –25.6
CVA, cerebrovascular accident; HAP, hospital-acquired pneumonia; N/A, not applicable.
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more hospital-incurred injuries to be harm events in the cohort of patients who died in hospital. For
example, in the case of pressure ulcers, the rate of conversion was 46.6% in the randomly selected
discharge reviews cohort and 64.1% in the deceased patient reviews cohort. On examination of these
events, there appears to differences in the grading of tissue damage in the deceased patient reviews
cohort, with more of these graded 2 and above.
Other significant differences arise in other criteria. Although the number of surgical events was lower in
the deceased patient reviews cohort, the reviewers considered almost half of surgical wound infections in
this cohort not to be AEs, whereas the rate of conversion was 82.6% in the randomly selected discharge
reviews. In the case of clinical decision-making and evidence of inappropriate treatment and interventions
received by the patient, the conversion rate to AEs in the randomly selected discharge reviews cohort was
almost double that in the deceased patient reviews cohort (73.2% and 35.8%, respectively).
This analysis points to a number of factors: (1) the context of the individual patient is important in any
assessment of AEs; (2) the types of harm events seen in the randomly selected discharge reviews and the
deceased patient reviews appear to be different; and (3) some of the newly introduced acts of omission
had high rates of conversion to determined AEs.
Part 3: factors independently associated with subsequent adverse event determination
in the Harm2 sample
Assessment of inpatient risk of adverse events in the randomly selected
discharge reviews
The likelihood of having a Harm2-determined AE was assessed in this NHS Wales cohort of patients, with
specific interest in the patient’s age, sex, underlying comorbidity and the duration of the inpatient episode.
Increasing age, longer length of hospital stay, being an emergency admission and higher Charlson
Comorbidity Index scores were all independently associated with AE determination in univariate analysis.
Hospital site and the presence of a mental health diagnosis were not found to be statistically associated
with AEs in this cohort of patients (Table 44).
The role of age and underlying chronic disease status in the likelihood of being exposed to a harm event in
secondary care was explored further by examining the percentage of AE rates within each age band, and
in the major classifications of chronic disease constituting the Charlson Comorbidity Index.
Age is a significant factor in an individual’s risk of experiencing an AE during inpatient care, with the risk
increasing with age (Table 45). The likelihood of experiencing an AE peaks in the over-85 years age group,
16.09% of whom experienced an AE during the inpatient episode (Figure 33).
TABLE 44 Independent variables associated with the determination of Harm2-confirmed AEs in the randomly
selected discharge reviews
Variable Univariate OR 95% CI p-value
Hospital site 0.997 0.97 to 1.03 0.841
LOS band (3-day durations until 14 days, > 14 days) 1.47 1.37 to 1.58 < 0.001*
Age band (< 18 years, 18–25 years, 10-year age groups until over 85 years) 1.12 1.07 to 1.74 < 0.001*
Admission status (elective) 0.75 0.57 to 0.98 0.035*
Charlson Comorbidity Index score (cumulative scoring) 1.10 1.03 to 1.17 0.004*
Mental health diagnosis present on admission 1.14 0.79 to 1.64 0.495
*Statistically significant.
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In assessing chronic disease, only three of the chronic disease variables explored were statistically
significantly associated with AE determination (Table 46). These were peripheral vascular disease (PVD)
(with an associated 2.5-fold increased risk) and hemiplegia and dementia (with a 2.27-fold increased risk)
and corresponding p-values of 0.043 and < 0.001, respectively. Therefore, although physiological status,
such as immunosuppression, seemed to have no association with the increased risk of experiencing an AE
as an outpatient, having a chronic disease that affected levels of physical and cognitive function did appear
to predispose patients to increased risk.
This analysis was rerun to include only individuals over the age of 55 years at the time of their
hospitalisation. Having a confirmed diagnosis of dementia and PVD remained significant, but hemiplegia,
although associated with similar risk, failed to reach statistical significance, probably as a result of its lower
level of occurrence in the cohort (Table 47).
Furthermore, at the age of 55 years, the effect of age band and Charlson Comorbidity Index score attenuated,
and failed to remain significant for, risk factors for experiencing an AE during an inpatient episode, but
increased LOS and being an elective admission remained associated with increased risk (Table 48).
TABLE 45 Age stratification of the percentage of patients experiencing an AE by age band: randomly selected
discharge reviews
Age band (years) Number of valid reviews Frequency of AE Percentage of valid reviews
< 18 225 14 6.22
18–24 190 15 7.89
25–34 325 28 8.62
35–44 290 28 9.66
45–54 348 32 9.20
55–64 407 54 13.27
65–74 552 70 12.68
75–84 539 66 12.24
≥ 85 379 61 16.09
Unknown 24 3 –
Total 3279 371
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FIGURE 33 Percentage of AEs by age band using the Harm2 tool.
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TABLE 46 Underlying chronic disease associated with the determination of Harm2-confirmed AEs in the randomly
selected discharge reviews
Chronic disease Frequency Per cent of total OR 95% CI p-value
MI 219 6.68 1.21 0.81 to 1.82 0.352
Chronic heart failure 170 5.18 1.51 0.99 to 2.32 0.055
PVD 93 2.84 2.52 1.54 to 4.11 < 0.001*
Coronary vascular disease 259 7.90 1.34 0.93 to 1.93 0.117
Dementia 177 5.40 2.27 1.56 to 3.31 < 0.001*
Hemiplegia 36 1.10 2.27 1.03 to 5.01 0.043*
Chronic lung disease 373 11.38 1.14 0.82 to 1.59 0.405
Connective tissue disease 79 2.41 1.28 0.69 to 2.44 0.460
Diabetes 361 11.01 1.10 0.79 to 1.54 0.579
Gastric ulcer 27 0.82 1.79 0.67 to 4.76 0.242
Chronic liver disease 13 0.40 0.65 0.08 to 5.03 0.681
Moderate/severe liver disease 39 1.19 0.89 0.32 to 2.53 0.834
Moderate/severe chronic kidney disease 124 3.78 1.35 0.81 to 2.25 0.253
Lymphoma 10 0.30 1 – –
Leukaemia 8 0.24 0.97 0.14 to 9.12 0.916
Non-metastatic carcinoma 100 3.05 1.12 0.81 to 1.46 0.589
Metastatic tumour 62 1.24 0.997 0.45 to 2.21 0.995
*Statistically significant.
TABLE 47 Selected chronic disease and their association with the determination of Harm2-confirmed AEs in
randomly selected discharge reviews
Chronic disease Univariate OR 95% CI p-value
PVD 2.03 1.19 to 3.46 0.0091*
Dementia 1.95 1.32 to 2.88 0.001*
Hemiplegia 2.11 0.94 to 4.73 0.070
*Statistically significant.
TABLE 48 Independent variables associated with the determination of Harm2-confirmed AEs in the over-55-years
age group in the random discharges sample
Variable Univariate OR 95% CI p-value
LOS band (3-day durations until 14 days, > 14 days) 1.42 1.30 to 1.55 < 0.001*
Age band (< 18 years, 18–25 years, 10-year age groups until over 85 years) 1.07 0.94 to 1.2 0.330
Admission status (emergency) 0.70 0.50 to 0.99 < 0.001*
Charlson Comorbidity Index score (cumulative scoring) 1.04 0.97 to 1.1 0.211
Mental health diagnosis present on admission 1.18 0.72 to 1.94 0.509
*Statistically significant.
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Factors independently associated with subsequent adverse event determination in the
randomly selected deceased patient reviews
In the cohort of patients in whom death was the end point of the period of hospitalisation, increased
length of hospital stay was also significant, with an attendant 33% (95% CI 1.22% to 1.44%) increased
risk by inpatient duration, and being an emergency rather than an elective admission was associated with
a twofold increased risk of AEs (OR 2.10, 95% CI 100 to 4.41). Rather than reflecting actual risk or harm
associated with AEs, this probably reflects the nature and reason for admission, with a significantly lower
percentage of this group being admitted for elective surgery and a significantly higher percentage being
admitted for emergency clinical management and end-of-life care. Table 49 reports that neither increasing
Charlson Comorbidity Index score nor increasing age was associated with an increased risk of AEs in
this cohort.
Figure 34 shows the AE rate by age band and shows very little variation in the age-specific occurrence of
AEs. Table 50 shows that in univariate analysis none of the chronic disease variables explored was
statistically associated with AE determination.
TABLE 49 Independent variables associated with the determination of Harm2-confirmed AEs in the randomly
selected discharge reviews cohort
Variable Univariate OR 95% CI p-value
LOS band (3-day durations until 14 days, > 14 days) 1.33 1.22 to 1.44 < 0.001*
Age band (< 18 years, 18–25 years, 10-year age groups until over 85 years) 1.06 0.95 to 1.18 0.297
Admission status (emergency) 2.10 1.00 to 4.41 0.049*
Charlson Comorbidity Index score (cumulative scoring) 1.01 0.96 to 1.06 0.810
*Statistically significant.
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FIGURE 34 Age-specific percentage of patients with AEs determined in a random sample of inpatient
deaths (n= 1018).
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Part 4: the nature and characteristics of adverse events identified by the Harm2
tool and differences in the randomly selected discharge reviews and randomly
selected deceased patient reviews
We decided on a purposive sample that facilitated the direct comparison of patients who died during the
inpatient episode and a random sample of patients from across the inpatient spectrum. The aim was to
elucidate key areas of difference within these groups. Part 1 demonstrates that extent and associated
severity were significantly higher in the deceased patient cohort. Part 2 indicates that positive screening
criteria in the deceased patient cohort did not convert to AEs as frequently as they did in the randomly
selected discharge reviews. Part 3 confirms theoretically driven concepts, such as the fact that this is an
older group, who are less likely to undergo surgical management and more likely to receive end-of-life
care. In part 4, the differences in the nature and characteristics of the AEs are explored.
Origin of adverse events
As part of the AE assessment, the origin was determined for each event identified and is graphically
displayed in Figure 35.
The origin and timing of the AEs vary considerably between groups. Figure 35 shows that, in the randomly
selected discharge reviews, more AEs arise in the period before inpatient management. For example, in
general practice AEs arise as a result of failures in drug monitoring, whereas early in admission they are
more usually a result of assessment and diagnosis problems, and during surgery and procedures they are a
result of complications such as bleeding and infection. In the deceased patient reviews cohort, slightly more
events arose in the intensive therapy unit (ITU) and general ward environment. It was more of a challenge to
classify the origin and timing of the AE in the deceased patient reviews cohort, and in one in five cases it
could not be determined. Examples of AEs arising in these different settings are outlined in Appendix 11.
TABLE 50 Underlying chronic disease associated with the determination of Harm2-confirmed AEs in the randomly
selected deceased patient reviews
Chronic disease Frequency Per cent of total
Univariate OR
(p-value) 95% CI p-value
MI 144 14.16 1.22 0.84 to 1.78 0.292
Chronic heart failure 186 18.29 1.02 0.72 to 1.44 0.906
PVD 58 5.70 1.04 0.59 to 1.84 0.898
Coronary vascular disease 173 17.01 1.02 0.72 to 1.46 0.912
Dementia 175 17.26 0.82 0.57 to 1.18 0.280
Hemiplegia 30 2.95 0.91 0.61 to 1.38 0.662
Chronic lung disease 233 22.91 0.89 0.64 to 1.2 0.459
Connective tissue disease 24 2.36 0.89 0.49 to 2.73 0.742
Diabetes 179 17.60 1.19 0.85 to 1.69 0.300
Gastric ulcer 18 1.77 0.88 0.31 to 2.50 0.815
Chronic liver disease 7 0.69 1.73 0.39 to 7.79 0.473
Moderate/severe liver disease 45 4.42 1.42 0.77 to 2.64 0.265
Moderate/severe chronic kidney disease 127 12.49 1.07 0.71 to 1.59 0.751
Lymphoma 14 1.38 1.74 0.60 to 5.06 0.309
Leukaemia 17 1.67 0.70 0.23 to 2.18 0.543
Non-metastatic carcinoma 54 5.31 1.50 0.85 to 2.64 0.160
Metastatic tumour 139 13.67 0.85 0.57 to 1.26 0.416
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Breakdown and analysis of problems in care in the randomly selected discharge reviews
and randomly selected deceased patient reviews cohorts
A comprehensive breakdown of problems in care was undertaken for both cohorts, and the overview
breakdown is shown in Figure 36. Significant differences in the composition of AEs in the groups are
apparent. Of particular note is the number of hospital-acquired infections identified in the samples.
Overall, infection control issues were associated with 35% of AEs in the deceased patient reviews and
with 18.4% of AEs in the randomly selected discharge reviews. One surgical wound and 108 cases of
hospital-acquired pneumonia (HAP) were identified in the deceased patient sample, compared with
34 wound infections and 34 hospital-acquired respiratory tract infections in the randomly selected
discharge reviews, again reflecting the different reasons for and type of admission between the groups.
Other differences are evident in diagnostic and assessment errors and AEs relating to the prescribing,
administration or monitoring of drugs/fluids or blood (Table 51). Categories in which significant
differences were not detected include failure to appreciate the patient’s overall condition and failure
in clinical monitoring – areas more aligned to general ward care in which differences between the
two groups would not be expected.
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FIGURE 35 The assessment of the origin of AEs in the randomly selected discharge reviews and the deceased
patient reviews cohorts. HDU, high-dependency unit.
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FIGURE 36 Composition of AEs by problem in care categories in the randomly selected discharge reviews and
randomly selected deceased patient reviews cohort. A, problem in assessment investigation or diagnosis (including
assessment of pressure, ulcer risk, VTE risk and history of falls); B, problem with medication/i.v./fluids/electrolytes/
oxygen (other than anaesthetic); C, problem related to treatment and management plan (including prevention
of pressure ulcers, falls and VTE); D, problem with infection control; E, problem related to operation/invasive
procedure (other than infection control); F, problem in clinical monitoring (including failure to plan, to undertake
or to recognise and respond to changes); G, problem in resuscitation following a cardiac or respiratory arrest
(including CPR); I, any other problem not fitting categories above. CPR, cardiopulmonary resuscitation;
VTE, venous thromboembolism.
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Summary of findings in Chapter 5
l Using the Harm2 tool, at least one AE was determined in 11.3% (95% CI 10.22% to 12.40%) of all
episodes of care in the randomly selected discharge reviews and 59.6% (95% CI 55.29% to 63.91%)
of AEs were deemed to be preventable if care were to have been delivered to a standard considered to
be good clinical practice in normal circumstances.
l At least one AE was determined in 30.1% (95% CI 28.13% to 33.82%) of all inpatient episodes of
care that resulted in death, of which 61.7% (95% CI 57.49% to 65.91%) were deemed to be
preventable, with the majority of all AEs being classified as having at least ‘slight to modest evidence
for management causation,’ corresponding to scores between 2 and 6 on the Likert scale.
l The AE rate in phase 2 was compared with the rate determined in phase 1 in the nine organisations
that contributed to both phases of the study, and in seven of these organisations there was little
difference between the AE rate reported using the Harvard method and that obtained using the
Harm2 method.
l At the end of the Harm2 process, the nursing cohort deemed the overall quality of care to be excellent
or good in 78.5% of inpatient episodes examined in the randomly selected discharge reviews and in
72.7% of inpatient episodes examined in the deceased patient reviews cohort.
l The inter-rater reliability for the Harm2 tool results in agreement in 336 out of 380 cases (88.4%)
(κ = 0.50; 95% CI 0.38 to 0.65) in the random sample and in 105 of 132 cases (79.5%) (κ = 0.54;
95% CI 0.39 to 0.70) in the deceased patient reviews.
l Assessment of intermethod reliability was undertaken and agreement on the presence of AEs between
the Harm2 and two-stage retrospective review process was evident in 58 out 74 reviews, or 78.4%
(κ = 0.45, 95% CI 0.07 to 0.62), indicating a moderate level of agreement.
TABLE 51 Comparison of the percentage of problem in care categories in the randomly selected discharge reviews
and deceased patient reviews cohorts
Problem in care categories
Cohort
z-score p-value
Deceased patient
reviews
Discharge
reviews
n % n %
1. AE relating to diagnostic or assessment error
Total 43 8.2 57 12.2 –2.097 0.036*
2. AE from failure to appreciate patient’s overall condition
Total 26 5.0 14 3.0 +1.562 0.1183
3. AE arising from a failure in clinical monitoring
Total 135 25.7 130 27.8 –0.754 0.4508
4. AE in relation to failure to prevent/control/manage infection
Total 184 35.0 86 18.4 +5.875 < 0.0002*
5. AE directly related to a problem with an operation or other invasive procedure
Total 11 2.09 48 10.3 –5.439 < 0.0002*
6. AE relating to prescribing, administration or monitoring of drugs/fluid/blood
Total 57 10.6 80 17.1 –2.859 0.0042*
7. AE relating to resuscitation
Total 16 3.0 1 0.2 –
8. Any other problem not fitting categories above 53 10.1 51 10.9 –0.424 0.6716
Total 525 467
*p< 0.05.
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l Of the 21 screening criteria, only three were found not to be associated with AE determination in the
randomly selected discharge reviews and nine of the overall 21 criteria did not reach a statistically
significant level of association in the deceased patient reviews cohort.
l Age is a significant factor in an individual’s risk of experiencing an AE during inpatient care across the
general inpatient population, with risk increasing with age. The AE rate peaks in the over-85 years age
group, in which 16.09% of all patients experienced an AE during the inpatient episode.
l Three of the chronic disease variables explored were statistically associated with AE determination in
the randomly selected discharge reviews. These were PVD (with an associated 2.5-fold increased risk)
and hemiplegia and dementia (both with a 2.27-fold increased risk) and corresponding p-values of
0.043 and < 0.001, respectively. Hemiplegia was also associated with significant risk, but failed to
reach statistical significance in the over-55 years age group, probably as a result of its low frequency
within the data set.
l Adverse events occurring in the deceased patient cohort are different from those in the general
inpatient population and are less likely to arise from diagnostic, assessment and medication errors and
surgical procedures and are more likely to arise from hospital-acquired infections.
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Chapter 5 Evaluation of the operational elements
of the Harm2 process and impact of the harm study
across NHS Wales
Aim
To embed the Harm2 tool in organisations and determine the organisational response.
Objectives
l To implement a retrospective case note review study across the 12 study sites, reviewing a random sample
of 20 discharges per organisation per month for a period of 16 months (July 2014–October 2015).
l To develop mechanisms in study sites to flag the identification of AEs in a timely manner for the
purposes of increased organisational ownership of AE data and information.
l To develop and test data management and analysis tools for routine use in study sites to monitor the
rate and organisational profile of AEs.
l To map and document the case note review process across the NHS sites and the flow and use of data
through a service evaluation and impact assessment.
Background
The review infrastructure was developed from phase 1 of the study, but the research team invited one senior
member of the governance or leadership team from each health board to sit on the study management group.
This ensured that organisations had the opportunity to keep updated on study progress and any operational
issues associated with the study. Any problems with, for example, capacity or note pulling were flagged to
organisations early so that the research team could liaise with NISCHR CRC or the health boards to resolve any
issues. It was in this forum that data feedback tools and mechanisms were discussed and introduced.
Development of data and feedback tools
Phase 2 streamlined data entry and feedback mechanisms in order for organisations to have access to the
data as soon as possible after the reviews had been completed. We explored options for electronic data
capture, but access to reliable Wi-Fi and information technology equipment was variable, particularly in
the case of external reviewers coming into organisations to undertake reviews. The team also worked
collaboratively with the Welsh National Harm and Mortality Collaborative, with time protected within that
agenda to explore accumulating data and innovative methods for presentation of feedback data using
tools, such as the signatures of harm.
We developed feedback for organisations in the format of an organisational report. This was sent out as
data were accumulating and outlined the number of reviews undertaken nationally, the number undertaken
within that particular study site and the AE rates nationally and locally. In addition to rates, organisations
were provided with a graph representing all the criteria that were found to be present and the subsequent
conversion to AEs, facilitating identification of risk and data from which signatures of harm could be
generated. A list of all study numbers was provided with details on which criteria were present in the harm
identified and the attendant level of severity. Reports and explanatory materials were sent into organisations
via the organisational leads who sat on the study management group in most cases, along with the identifiers
so that they could re-pull the notes and review the episode of care within their own governance structures if
they felt that this was warranted. An example of an organisational report is shown in Appendix 12.
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We also, during phase 2, implemented an additional feedback process that was not included as part of the
formal research process but arose from organisational request. We asked the review teams to leave a copy
of the summary of the review session, with identifiers of the numbers of the notes where criteria were
present and AEs detailed, with the clinical governance teams at the end of the review session. This was
undertaken to highlight any serious concerns so that prompt follow-up could be actioned. In a small
number of cases the research office called senior members of the medical team in individual organisations
to raise specific concerns about specific cases.
The close working relationships developed between the research team and organisations during the study
period were invaluable in informing our approach and, as a final step in this work, we wanted to formalise
some of this learning and insight and we undertook a service evaluation and impact assessment. The
evaluative process aimed to examine and learn from the operational elements of the study, the perceptions
of our key stakeholders and the implications for the health boards that participated in the study. This
element was conducted by AJL, an experienced evaluative nurse researcher with a background in
researching health-care safety, who had been involved in the original proposal but had not been involved
in the collection or analysis of the quantitative harm data. The reporting follows the Consolidated Criteria
for Reporting Qualitative Studies (COREQ) guidance.59
Evaluation questions
l What have been the challenges experienced by those undertaking the routine note and
mortality audits?
l What are the implications of the electronic record for future audit studies?
l How are harm data being used and disseminated within the organisations?
l What is the added value of the harm data?
l What, if any, changes have been effected as a result of the study?
Methods
There were two main groups of participants: a sample of the RF1 reviewers who had undertaken the notes
audit and key contacts from the health boards. The names of these key contacts had been provided by the
health boards at the commencement of the study and were normally a medical director and a named
leader of the quality assurance team. As the study progressed, some members of this group changed and
the list was expanded in cases in which the medical directors delegated the role to an assistant. We also
interviewed an adviser to the WG.
The entire population of reviewers was approached by AJL, to whom they had been introduced during the
last year of the study. Members of the health boards were initially approached by e-mail by one of the
core research team (EB), who introduced AJL. Two of those approached immediately declined to
participate, one citing a change of role in the organisation. In some cases, invitees asked relevant others
(e.g. audit managers) to participate in the interviews and dates and times were duly arranged. Reminder
e-mails were sent out in the days before the interview, again attaching the participant information and
consent form. Two interviews were conducted remotely by Skype™ (Microsoft Corporation, Redmond,
WA, USA) and telephone, respectively; the remainder were conducted face to face in a place chosen by
the interviewee(s). Two were set up by the health board as group interviews: one with three people and
one with two. In one case a respondent had to pull out shortly before the interview and another dialled
into a videoconferencing facility call to a meeting room in their own board room. One respondent who
had not seen the data at the time of interview (they had not been forwarded by the medical director)
kindly agreed to a follow-up telephone interview. A copy of the output sheets was sent and a follow-up
interview was conducted by telephone.
Table 52 shows the total number of interviewees by health board, although it should be noted that some
RF1 reviewers carried out their work in as many as three organisations. Because of the small number of
health boards involved, we have deliberately anonymised both role titles and the precise names of
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committees, and quotations from respondents are attributed only by number, and are preceded by
reviewer, health board or WG. For the same reason, we have adopted the use of the grammatically
inaccurate but gender-neutral pronoun ‘they’ rather than ‘he’, ‘she’ or the clumsier ‘s/he’.
The semistructured interviews, conducted by AJL between September and November 2015, were based on
a guide, although we were ever alert to tangential issues raised by interviewees. The reviewers’ interview
guide was piloted with EB, who had undertaken some reviews personally. The interview guide for the health
boards was reviewed after the first interview and the order of questions was slightly altered. Interviews were
arranged to last for 45 minutes, but the actual time available was confirmed at its commencement and the
questions tailored to fit accordingly. In practice, interview duration ranged from 25 to 80 minutes. These
were subsequently digitally recorded, transcribed and anonymised by the interviewer.
Analysis
This was approved as and intended to be an evaluation of the Welsh Harm Study, rather than qualitative
research, but the approach used was a constructivist one, with themes expected to emerge from the
data rather than imposed a priori. The first stage of data analysis involved familiarisation with the data,
aided in this case by the fact that all interviews were conducted and transcribed by AJL personally. Once
a conceptual framework emerged, all transcripts were analysed thematically using a Microsoft Excel
spreadsheet, using one row per respondent, and adding columns for themes and subthemes as necessary.
Validity was enhanced by sharing the transcripts with SM, who independently analysed a small sample,
and discussing the single inconsistency. Synthesis was carried out by considering all of the responses within
a thematic column, noting areas of agreement and of exception and selecting exemplar quotations.
Emerging findings were also discussed with EB to determine whether or not they were consistent with the
experience of her close working with reviewers and health boards during the life of the study. The
qualitative element and its aims and objectives were outlined to research and development departments
within participating health boards and deemed to be service evaluation.
Findings: evaluation of the operational elements of the Harm2
process and impact of the harm study across NHS Wales
Aim
To determine the organisational response.
The reviewers’ perspective
The 14 respondents who were the source of these data were all CRC research infrastructure staff
(hereinafter referred to as the reviewers), 12 of whom came from a nursing or midwifery background and
TABLE 52 Respondents
Role of respondents
Health board
WGA B C D E F
Medical director – 1 – – – 1 –
Assistant medical director 1 – 1 1 1 1 –
Quality/governance/improvement/audit manager – 1 – – 1 2 –
Senior nurse manager – – 1 – – – –
Policy adviser – – – – – – 1
Reviewers 1 6 3 4 6 4 –
Note
Reviewers may have worked in more than one health board.
DOI: 10.3310/hsdr05090 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mayor et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
two of whom came from related health-care backgrounds. Their time with CRC varied from 1 to 12 years,
with a mean of 4.5 years. Only three had not been involved in the project since the beginning of phase 1.
Taken together, the respondents had undertaken data collection in all 12 hospitals in six health boards.
The data collection process
It was reported that the appropriate files had almost always been identified before their arrival in the
health boards, which was a result of close working between the review teams and the audit departments.
In only one health board was there a problem, represented by the quotation from reviewer 7. Occasionally,
the patients whose notes had been identified did not meet the criterion of having had a stay longer than
24 hours, as a result of the coding system in this site. By liaising with the records department, this coding
issue was quickly resolved by changing the criterion to a 36-hour minimum at this specific site. There were
some concerns about the the degree to which the notes were in fact randomly selected, and a comment
by health board audit staff recorded in the quotation below indicates some degree of occasional selection
bias, again reported and addressed. One group of reviewers noticed a surprisingly consistent selection of
cases across the hospital such that they could predict in advance how many patients from each specialty
they would receive, while others were sometimes surprised at the number of patients who had been
admitted for the same procedure. There were no mental health notes per se in the sample as these are
held in the mental health hospitals, rather than on the index acute hospital sites, although people with
long psychiatric histories did feature in the general sample when admitted to acute wards:
The validity behind the randomisation of some of those has not always been felt to be uniform across
the health boards sometimes. Sometimes the person pulling the notes has said ‘don’t worry – we
haven’t picked the thick ones for you . . .’ We recognised that internally and challenged it and fed it
back to the study team so that was tackled.
Reviewer 5
Medical records at [name] hospital in particular went through a very bad phase and had to actually
because of shortage of staff stop issuing notes for anything other than clinics and admissions or
anyone who wanted any records had to go and pull their own so you can imagine what chaos that
caused . . . as we’ve gone on that problem has been resolved but that was a reflection of where the
organisation was and the department was staffing-wise. I suppose that when they’re in the position of
not even being able to send notes to clinics then research is not their priority.
Reviewer 7
Whenever possible, the reviewers undertook the reviews in groups or in pairs. Notes were reviewed under
variable conditions, but all health boards tried to find suitable accommodation within space constraints.
Quality of the case notes
With the exception of one health board, the condition of the case notes was said to be poor, with those
of deceased patients being significantly worse than those of the randomly selected admissions. In many
cases, unsecured packs of loose papers, which might on occasion relate to several admissions, were placed
into the flap of the case note cover. In such cases it was difficult to identify the sequence of the paperwork
(which might moreover be undated) and this made it difficult for reviewers to state with confidence that a
risk assessment or a do not attempt resuscitation (DNAR) form had not been completed, as it was entirely
possible that the relevant paperwork had fallen out of the notes:
In the notes for deceased patients all the papers inside would be loose. There would be no order
necessarily and in some of the health boards we felt the papers had just been thrown in. They were
not filed. We saw that in quite a few deceased notes and we all spoke about it because we didn’t
think it was particularly great. We wouldn’t know if anything was missing . . . we could be saying
there was no DNAR form or no Waterlow score but it could’ve been there and could’ve slipped out.
Reviewer 2
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Pieces of paper misfiled or missing or the dates not on them or just crumpled up. I don’t know if that’s
just storage or because people have been in hospital for a long time so a lot of people are handling
them. I think there’s a lot of cases where they tried to save money so they stopped putting dividers in
and that makes things particularly difficult because people are in a hurry and they just shove it in the
first place they can and if you’re looking at a couple of inches of notes you’re just going to put it in
the front.
Reviewer 12
On occasion, papers such as prescription sheets lacked patient identifiers, and sometimes material relating
to other patients was found in the file being reviewed. In some cases, file covers were ripped and held
together with perished elastic bands that broke as reviewers removed them. On occasion it was simply not
possible to identify the relevant admission from a thick volume, or indeed several thick volumes, of case
notes and these had to be abandoned after 30 minutes of searching, although this was said to be rare.
There was variation in how the information in the case notes was presented. In one health board and in
specific areas of others, a unified or collaborative notes system was adopted, with doctors, nurses and
other health professionals writing in the same case notes. Collaborative notes allowed reviewers to follow
a patient’s pathway and identify both problems and their resolution. When medical and nursing notes were
held independently, tracing the journey of a patient, and checking whether or not a medical prescription
had translated into nursing or other action, required much flicking backwards and forwards from section to
section. Moreover, detailed records written by such people as physiotherapists might be held in their own
department and did not find their way into the case notes, the only record being ‘seen by physiotherapist/
nutritionist, etc.’ A quotation by reviewer 8 offers a picture of the difficulties presented by reviewing
independently held medical and nursing notes, while a quotation by reviewer 12 illustrates the
improvement brought about by unified or collaborative notes:
It’s all in sections and although you would start to look at the nursing records and tick off that you’ve
seen those maybe when you then get to the clinical notes something might make you think I need to
go back and look at that in the nursing notes and then you’re going backwards and forwards.
Reviewer 8
It was much easier when you could follow how the care was progressing and what the care package
was and how they were thinking and the communication between the teams. It’s much more effective
that way than having the nursing notes and the doctors’ notes and they don’t always marry and you’re
trying to follow the care process and I think it must be quite difficult for clinicians as well because
they’re time starved and they’re trying to find out what’s been done and what hasn’t been done.
Reviewer 12
The use of abbreviations was a challenge to all, including experienced nurses who had worked in many
specialties. One group of reviewers created a list of abbreviations to which they added as they worked,
but this was not exhaustive. One experienced nurse reviewer commented:
I think some people were just making them up.
Reviewer 4
Nursing notes were often found to be verbose and uninformative, with each entry, in the experience of
one team, on each shift on each day beginning with ‘I introduced myself to the patient’. It was said that
the quality of nursing notes tended to improve and become more business-like when collaborative notes
were in use.
Not all data, however, were available in the paper notes. Discharge letters and laboratory results might be
found on the clinical system accessed via the Welsh Clinical Portal, although two research teams were
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given no access to health board computer systems and were reliant on printed copies being inserted into
the notes. Reviewers explained how they knew where to find which data:
We just worked it out as we went along. Because we work in all the health boards anyway we’ve got
access to the clinical systems so if I was looking for some notes and it didn’t quite seem to add up or
there was an admission missing or there was something – I might log on and see if there was any
documentation uploaded that wasn’t in the notes.
Reviewer 1
The room we were using to review the notes we didn’t have access to the electronic system so we
only ever used the written case notes.
Reviewer 8
Digitised notes
It was clear that, in discussing digitisation, there were two quite different strands. The first related to live
electronic data (mainly operation notes, discharge letters, radiology data, laboratory results and, in some
health boards, entire stays in intensive care) recorded onto the Welsh Clinical Portal; the second related to
paper notes that had been scanned page by page, a process that resulted in a file consisting of images of
written notes. The former could be tabulated and graphed, whereas the latter could be neither searched
nor manipulated.
The one advantage of both electronic entry and digitisation was that, provided the reviewers were given
access to the electronic system, there was the option of undertaking the notes review in the research
offices, although, if being carried out in the hospital, access to a computer was necessary. Once accessed,
the live data were easily found and were always clear, being typed rather than handwritten. However, the
scanned material was more difficult to handle. In some cases, there was a ‘back scan’, a scan of all notes
up to a given date, so reviewers had to work out where to find the data they were looking for. In some
cases, the scanned notes were organised by date of admission and contained separate folders for the
medical and nursing notes. In other cases, however, images of handwritten nursing and medical notes and
prescription sheets were entered without any clear rationale as to what went where, and reviewers were
often faced with 200–300 pages of scanned material including pages scanned in upside down, with no
option to rotate the image. The problem was exacerbated by the system automatically logging reviewers
out after 20 minutes, leaving them to log back in and start again. There was no ability to carry out a word
search in scanned material:
Digitisation can be viewed as a predominantly positive thing . . . but the way it has happened is that
the notes have been scanned in as an image which you can’t search within. If you wanted to have a
look at certain documentation they are not always ordered within the right subheading so you can’t
go to nursing notes and see all the nursing notes – you are looking at all sorts of information and
140 pages . . . Sometimes there seemed to be no rhyme nor reason to the way it was scanned in . . .
it used to time out after 20 minutes and you’d literally have to sign in again – it was not user friendly.
Reviewer 5
The time taken to do a review varied from 15 minutes to 90 minutes depending on the LOS, the
complexity of the case and the state of the notes. In the case of digitised records, the estimate was that
they took 50% longer. One health board had invited the reviewers to give advice on their planned
approach to digitisation and they were happy to do this.
The Harm2 criteria
All who had been involved in phase 1 of the study found the Harm2 tool to be a great improvement, finding
the revised harm criteria clear, especially in conjunction with the accompanying guide, and reviewers grew in
confidence as the study proceeded. The research teams valued the opportunity to discuss cases among
themselves (which is why they carried out the reviews in groups) as well as the telephone meetings with
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research staff, which allowed them to air issues about which they were unsure. Sometimes, however,
the patients and their situations were less clear, so that a judgement of harm was difficult:
They were clear. They were well explained and everywhere I went I took my Harm tool with me and
we encouraged everyone to do the same.
Reviewer 6
It was really helpful and I think critical that we did our reviews in twos or threes sometimes so very
often there would be a lot of discussion between us although the person doing the review would
make the final decision. It was useful to bounce things around the team.
Reviewer 8
During the training of the nurses and in the monthly calls with the research team that took place throughout
the life of the project, the criterion ‘unexpected death’ caused a great deal of discussion. The patient might
not have been admitted explicitly for end-of-life care, but might have had serious conditions and comorbidities
and it might have become clear during the course of their hospital stay that they were unlikely to recover:
There was quite a lot of discussion about that one because it says unexpected death, i.e. not an
expected outcome of the disease during hospitalisation so I suppose that clarifies it a bit but people
did struggle with that one.
Reviewer 7
Clinical reviewers from a non-nursing background struggled more than the nurses, being unused to the
usual care pathways and the common medications. The following quotation is from a clinical research
officer and for reasons of anonymity is unattributed. However, even experienced nurses struggled when
confronted by a complex specialty, of which they had no experience and with whose pathways they
were unfamiliar:
Some criteria like errors in medication unless someone had written there was an error in medication,
I was not in a position to comment. I know some of the nurses used to debate whether certain
prescriptions were part of a normal clinical pathways but this would just highlight my own feelings of
inadequacy being on the study because I could never comment on something like that.
In response to the question ‘Has there ever been an occasion on which you were unable to record an
event which you felt was relevant?’, the answer was overwhelmingly ‘no’ because of the existence of the
‘other’ category. Within the context of the interview, it was difficult for people to recall how they had used
this category, although one thought that they had cited evidence of lack of communication.
The review process was inevitably more difficult and took longer in respect of deceased patients. The
admissions tended to be lengthier, their conditions were more complex and in most cases the outcome
seemed fairly inevitable. There also seemed to be more harm criteria evident among the deceased patients.
The more complex the case, the greater the temptation for the reviewers to qualify their findings and give
more explanation:
We knew when we were coming to a set of notes that we could potentially find harm more so in the
deceased notes . . . I think often they were more complex. I generally identified more issues with
communication and documentation. I used to find that’s where the biggest gaps in care were.
The documentation was quite poor at times. I suppose they had more going on.
Reviewer 2
A huge number of the cases at (name of hospital) were hospital-acquired pneumonias (HAPs) or
community-acquired pneumonias which then came into hospital and got a second infection so I found
that difficult to get my head round because I was thinking well that patient is immunocompromised
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anyway and it’s not really a harm, but eventually I started recording everything that was an HAI
[hospital-acquired infection] then wrote a little note that said I don’t really think this was a harm event.
Reviewer 1
Several respondents spoke of the difficulty of reaching judgements on occasions when long-term mental
health patients were admitted to a general hospital, in one case having taken poisons. This patient was
said to have had a history of such admissions and, although there was no identifiable harm in the care
received during the index admission itself, reviewers felt that discharge home on the following day was
inappropriate. They did not know whether community mental health teams had been notified, but
assumed that they would ‘learn the information from somewhere’:
Basically someone who’d taken overdoses and kept presenting at the poisons unit and being
discharged and eventually a week later or so they successfully overdosed and died.
Reviewer 1
Respondents were then asked about the converse situation: whether or not there had ever been an
occasion when they recorded a harm event that they felt was unjustified. Although some respondents
replied in the negative, a few pointed out that in contrast to the clarity of the criteria, the patients and
situations could be more ‘messy’:
Somebody falling in hospital. There had been a falls assessment and it was on record that they needed
observation to do everything yet the patient continued to do something that they shouldn’t have and
fell and broke something.
Reviewer 5
Sometimes it’s difficult because you’d say that’s harm because the drug hadn’t been given for an hour
but then from nurses’ documentation you’d see they were very short staffed. So you’d say is it actually
harm that the patient hadn’t had the drug for 2 hours but they had it and you can understand it –
maybe a cardiac arrest or something.
Reviewer 9
One respondent told the story of a woman who had had a severe reaction to an antibiotic to which she was
allergic. Her skin sloughed off and she did go on to die. However, the patient was in the intensive care unit,
other strategies had failed to resolve the infection and there was a documented discussion with the patient
detailing the risks before the drug was given so it was a calculated risk accepted by the patient, although
in the end the patient was undeniably harmed. On another occasion, a patient had a routine tonsillectomy
and was warned on admission that bleeding might occur during the following 48 hours and was given
advice on what to do if it did. When the bleeding did occur, the patient followed the advice given, and was
readmitted and dealt with successfully. Reviewers queried whether or not this qualified as harm in view of
the surgical consent, the advice and the successful resolution. A third criterion that was questioned related
to perineal tears and whether or not these qualify as harm. This was taken to a meeting and it was decided
that grade 1 and 2 tears were acceptable, but grades 3 and 4 were not. When unsure, respondents
reported that they tended to record everything and then put mitigating factors in the clinical summary.
We asked whether or not reviewers had any concerns about the loss of contextualisation when using the
criteria and most felt that they did not because they were able to include the contextualisation in the
free-text box of the RF1 and the clinical summary box of the harm tool. However, the small size of the box
meant that they could not always say all that they wanted to say in defence of the care given:
Sometimes you’d want to write more so I’d end up writing in the box if I couldn’t find exactly what
I was looking for . . . I’d usually say it was harm or potential harm and then write and explain myself
in more detail.
Reviewer 9
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With all my reviews I tried to give a back story – perhaps more information that was required so I was
on the other end of the spectrum, really . . . It’s all a balancing act.
Reviewer 5
When asked if any other changes should be made to the criteria, one respondent queried whether anyone
on antidepressants fell into the ‘mental illness’ category on the cover page or whether this should refer to
people with severe and enduring mental health problems. The tool was said to be easier to use than the
original RF1, although two people felt that there was room for streamlining it to make it clearer:
It had quite an ambiguous front cover criterion that various staff viewed differently. You had like
learning difficulties, dementia or mental health diagnosis and if someone came in on antidepressants
some people would query whether that counted . . . I thought overall the phase 2 tool was a vast
improvement on phase 1. It always gave us room to explain ourselves so my clinical summaries were
quite detailed.
Reviewer 5
The list of criteria was very much black or white and a lot of the situations were grey. And it probably
would be better if instead of having antibiotics wrong/delayed/omitted, anticoagulants wrong/delayed/
omitted it just said medications wrong/delayed and we added more to that. I remember having one
drug (and I can’t remember what it was) but it didn’t fit into any of these criteria.
Reviewer 4
Grading preventability was deemed to be difficult. If a patient fell, reviewers pointed out, it is sometimes
because they decided against advice not to walk alone. Despite actively looking for harm in the notes,
reviewers did frequently mention the fact that overall they found the quality of care to be reassuringly
good. Palliative care was mentioned as a particular exemplar in two health boards:
We did review some palliative care notes as well and the level of care there seems to be a step above
the care on general medical wards. A lot more now medical teams are having discussions with families
about patient care and especially about patients who are dying and being quite honest and up-front
and discussing patient care with families. That was something that came across to me as a positive
thing. Looking at the palliative care notes I think we have a lot to learn. They look at the individual as
a whole . . . pain, nausea and emotionally how they were feeling.
Reviewer 11
Three reviewers reported coming across nurses attributing, for example, late medications or failure to
contact relatives as early as they might have to shortage of staff. Staffing apart, reviewers were unable
to record other hospital/trust factors. One expressed the view that issues such as ‘inadequate senior
leadership’ was unlikely to find its way into the notes of individual patients.
A final word about the process related to the intense concentration needed to undertake such reviews
and the emotional toll of undertaking mortality reviews, which has to be taken into consideration when
planning a study such as this. Most were happy to have been involved in this study for only 1 or 2 days a
month. At one point, one respondent had been asked to undertake these reviews as a full-time job. They
declined. Another was eager to be assured that the study would not be repeated. A third went into detail:
Deceased patients on the whole have a longer length of stay and are more complex and also if you’re
sitting there doing 10 of them it is quite emotionally draining . . . certainly . . . where they had a bigger
team they put a sort of supervision session on for them. Because you sit there reading about death
after death and of course you know at the beginning of the journey how it’s going to end and it can
be quite harrowing.
Reviewer 7
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Key learning for health boards
We invited reviewers to state what, on the basis of their reviews, would be their key messages to the
health boards in which they had worked. Several reviewers were of the opinion that, although the level of
care was generally good and the best interests of the patient were obviously central, the poor condition
of the notes would raise concern should the family or a coroner ask to see them. In addition to the
unsatisfactory management of the hard copies set out above, respondents cited poor handwriting,
undated entries and prescription sheets without identifiers. It was pointed out that the condition of the
notes constitutes a legal threat and also mitigates against good reviews:
I appreciate we are in stringent budgets of time, money resources but I am sure there is published
work out there that accessing legible notes aids the clinical outcomes and treatment at all levels from
all members of staff involved in patient care and that somehow ring fencing sums to employ a team of
medical records staff . . . so there is time to refile dodgy notes.
Reviewer 5
There is an issue that comes up with the deceased patients which is this patient is deceased we can just
shove everything in the notes – they’re not going to be looked at it again and really these are the ones
that need to be in the best shape if the notes were going to be needed for any kind of legal case.
Reviewer 6
The members of one team of reviewers in particular were strong advocates for unified notes and wished to
encourage more departments to adopt them. From the point of view of following a patient journey the
unified record makes it easy for mortality reviewers, coroners (and, in the future, medical examiners) to
check that nurses’ concerns are picked up by doctors and that medical prescriptions are enacted by nurses.
Whatever the system in place, it was pointed out that recording care takes time and notes suffer when
staffing is poor:
I would definitely say that collaborative notes would help a lot and you’d have to look at the
conditions under which people were working as well. Do they have time to write in the notes and
document their concerns? Do they have time to call social services? There were instances where
people had done something but it wasn’t recorded in the notes but it was written later saying I
‘as requested I did this but was unable to document’.
Reviewer 12
Reviewers were of the view that the number of risk assessments (e.g. falls, thromboprophylaxis, pressure
damage, nutrition) that were supposed to be carried out on admission was unrealistic:
My feeling is there are so many risk assessments they are never all going to be completed. We are
talking 10, 20 different ones.
Reviewer 1
As indicated above, concern was expressed by several reviewers about the care received by people with
mental illness on admission to general wards. It should be stressed that no reviewer was given the notes of
people in mental health facilities but only records of their admission(s) to acute hospitals:
It seemed that these people were just being pushed around. The care that they had in the community
was fine, there was no problem with that, but you could see them coming in previously with the same
problems and had been discharged with the same problems and nobody seemed to know where to
go. It was difficult because the actual care that the patient had seemed okay – the problem was that
care around it. No one seemed to be taking responsibility for it.
Reviewer 4
EVALUATION OF THE HARM2 PROCESS AND IMPACT ACROSS NHS WALES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
92
The perspective of government and health board recipients of the
data outputs
Thirteen interviews with health board and WG personnel were carried out in total: two with medical
directors, five with assistant medical directors, one with a senior nurse manager, four with quality/
improvement/governance/clinical effectiveness managers and one with a policy adviser to the WG. When
asked about their reasons for agreeing to participate in the Welsh Harm study at its outset, respondents
pointed to the fact that they had been engaged in the assessment of harm for many years. All health
boards in Wales had participated in the 1000 Lives Campaign,11 one feature of which was the use of the
GTT to assess triggers for harm. In addition, health boards have participated in a mandatory review of all
in-hospital deaths since 2010.
Respondents reported that one of the motivators for participating in the Harm study was that they had
wished for a more meaningful tool than the GTT. Their experience of this instrument had ultimately given
rise to frustration, the results having formed a flat-line graph that had reflected neither deterioration nor
improvement and that had ultimately failed to trigger change. There was an expectation of learning from
the review process itself and a hope that the Harm2 tool would ultimately be a more sensitive and
meaningful tool that health boards might use:
We were getting really frustrated with it because we weren’t finding anything new from the GTT and
from [audit manager] point of view it was taking much more time to get everything sorted. We were
getting difficulty getting people to participate. They were dropping off. Their interest was waning so
we were looking to kind of invigorate that or have something in its place.
Health board 8
I would have imagined that there would be research publications teaching or helping us to understand
the best ways to measure harm within the organisation. The second thing is we were learning from
participation – i.e. looking at the data collection sheets and stuff and discussing the applicability live.
Health board 7
In addition to the wish to continue to learn about harm in their own organisation, respondents were
motivated to join the study by their conviction that the Welsh NHS was a worthwhile research population
that lent itself to a systematic study of harm. They also saw the study as having a good provenance and
recognised the potential for well-trained staff, with externally funded time, to undertake careful reviews, to
yield robust data that would offer added value to the organisation. The promise of harm signatures and a
comparison with all-Wales data was attractive in pointing to issues that needed to be addressed:
I think Wales as a community has an excellent opportunity to provide within a reasonable cohort –
i.e. a population of 3 million – information that we can make sense of in terms of trying to get some
understanding of what harm is occurring to patients in a systematic way.
Health board 3
When [SM] came to me and said we are doing this with Cardiff University I thought well we have the
experience of doing this and I think it would be a really valuable thing to do because we really do
need to get some mechanisms around measuring harm in a meaningful way and then the next thing
for us I suppose is how do we convert that knowledge into the changing our behaviour and we can
see an effect on that measurement.
Health board 2
Because of the aforementioned universal experience with the GTT, no health board reported encountering
any problem in drawing a random sample for the study. The actual tracing of the notes did, however,
present more difficulties, especially in the case of the deceased. Typically, notes are sent for coding at the
close of a patient episode and are then entered into the mortality review processes before being sent to
the file library. As, however, the study involved a sample drawn from patients admitted several months
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before, the notes might be anywhere on this journey. To allow for those that could not be traced, the
randomisation process had to identify a larger than needed sample:
Particularly the notes of dead people are not properly filed back because by and large we are the only
people who call on them and [name and name] who do all the notes collecting for us walked a very
long way to retrieve some of these notes which were hidden in nooks and crannies across the
organisation. So for patients who are deceased – their notes also go to coding but they get stuck in
the same nooks and crannies and when they get back to the file library they are often just put in a
massive big box and [name and name] have to sort through boxes of notes looking for names or
numbers as opposed to having a numerical order on a shelf and knowing exactly where to go.
Health board 5
There are always challenges in finding notes but the advice received was you obviously target a larger
sample to accommodate the required sample and that’s what we’ve done.
Health board 9
As noted in the preceding section, some of the data were not to be found in the paper notes at all, but
formed part of the electronic health record. While medical respondents, in particular, were enthusiastic
about the ability to manipulate the live data during the mortality review process, the digitisation of paper
notes, by contrast, detracted from it for reasons spelled out in detail by the RF1 reviewers. The quotation
from a senior source at health board 4 confirms their experience:
(With) the Welsh portal you can graph and tabulate the whole thing through the entire admission so
you can see what the sodium trend was and you can see when it started to go off and how does
that correlate with the [modified early warning] score and did anyone escalate it . . . The beauty of
digitisation is you can start to slice it in different directions so you can say I want to know the broad
chronology or I wonder what the [electrocardiograms] are like. I want to cross tabulate the rise in
troponin with some other biological or haematological variant.
Health board 1
Ours are not electronic records – they are scanned digital images and the audit team finds them an
absolute nightmare because you can pick up a set of physical case notes and are guided by the colour
coding but with digital records you have nothing. You cannot search for words – you have to go
through the photographs one page at a time . . . digitisation is not going to make life easier for
researchers and clinical audit staff.
Health board 4
Such is the difficulty of working with scanned notes that in another health board deceased patients whose
notes had been digitised were said to be de facto ‘at the back of the queue’ for review. The explanation
for this was that, given a backlog, the paper notes formed a more compelling and visible workload and
were significantly easier to review.
Mortality data
After it was revealed early in the first interview that neither of the interviewees had received any of the
outputs (the third, a designated recipient, had had to pull out of the interview at short notice), each
subsequent interview was begun by confirming that the interviewees had seen the outputs. All had seen
at least one set of data, but only five remembered seeing copies of the most recent outputs containing
figures for 12 months. The discussion on the mortality data elicited an unusually consistent view, which
was unsurprising given that it was a topic on which there had been much discussion across Wales. It
proved impossible to separate out respondents’ views on the Harm2 data from views around mortality
reviewing more generally. The requirement to review each death, it was explained by a WG adviser, was to
determine the standard of care by seeking to assess whether or not death was expected and inevitable,
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and to reassure relatives that everything that could have been done was done. If this was not the case,
opportunities for learning should be maximised:
When we started looking at mortality we want to get a better view around, not just was the death
avoidable but also was it a good death or a bad death because a lot of the things that come across my
desk when we get a lot of correspondence from aggrieved relatives and things is not necessarily that
the patient died but actually the care until their deaths left many questions unanswered for relatives –
lack of communication, poor care, etc. So what is it we need to learn about making end-of-life care
better as well and could we have done something that might have changed the outcome or at least
been such a hasty outcome so it’s more trying to make sure that we have a process that reassures
the families, gave us assurance around the quality of care but also was a mechanism for driving
improvement . . . So the whole thing is what are we trying to do better in terms of our care for those
at the end of life.
WG
The mortality review process, it was hoped, would stimulate conversations with families about whether or
not they had any questions or concerns about the death of their relative.
Although the detail varied from one organisation to another, all health boards followed the recommended
two-stage process, albeit not always on all deaths. In three health boards, the first review, using the
seven core questions of the Universal Mortality Review (UMR; which some had amplified), was carried out
by the junior doctor signing the death certificate, but in others the review was carried out by senior
medical personnel. If a cause for concern was identified (and health boards quoted the conversion rate
from first- to second-stage review as having a range of 10–40%), the notes were then passed to an
independent consultant reviewer (when junior staff had carried out the first review) or, in the case of a
senior first-stage review, were reviewed in greater depth. In either case, concerns identified in the stage 2
review were communicated to the consultant in whose care the patient had died. No health board had
any statistical data arising from stage 2 [other than incidents entered into Datix® (Datix, London, UK)]
but the concerns identified by these senior doctors were gathered in thematic form. As all respondents
expressed the view that the reviews should in an ideal world be multidisciplinary, given the numbers
involved (almost 300 a month in some large health boards), the logistical and workload implications were
seen to be too great. Thus, medical review was the norm in all but one health board and, unless unified or
collaborative notes were in use, harm linked to suboptimal nursing care would be unlikely to be picked up:
Nursing harms I think will be very poorly picked up in the case notes and the only times they get
written down by doctors are if the outcome is something that involves a doctor doing something or,
if I was being cynical, to make it quite clear where the responsibility for something lay. ‘Patient didn’t
get their 10 o’clock medication.’ It isn’t normally put in there in a kind of supportive and engaging
way it’s a don’t blame me for the fact that patient didn’t get their antibiotic.
Health board 6
There was a strong body of opinion that if detecting and eradicating harm was the key objective, then
mortality review, whether or not carried out by the RF1 reviewers or by the health boards themselves, was
not the most appropriate process. The reasons for this view, that the deceased are not an appropriate
group in which to study harm, lie, first, in the admission to acute hospitals of patients whose deaths were
either expected at the point of admission, or which at some point became inevitable, and, second, in the
manifestations of the dying process itself. In relation to the first point, respondents reported that many
admissions to acute hospitals were inappropriate inasmuch as it was clear that the person was terminally ill
and would not benefit from medical intervention. These admissions were often the consequence of a
dearth of alternative provision in the community and might come from residential homes, as emergency or
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general practitioner (GP)-mediated admissions, from nursing homes and even from the health boards’ own
community hospitals:
You could argue that that patient shouldn’t have been in hospital full stop . . . they should be at home
having a near normal quality of life with good palliative care.
Health board 3
We were finding patients in the community hospital were being blue-lighted into the acute hospital in
the middle of the night and were dying within 3 hours of admission so it would have been better if
they have just stayed where they were so that led to feedback to the doctors there about anticipatory
care plans.
Health board 4
As to the nature of the dying process itself, it was argued by almost all respondents that some of the harm
criteria are in fact a natural consequence of underlying pathological processes and the associated increase
in frailty and immobility. Two triggers were frequently cited in this argument. One related to falls, which
were often temporally, rather than causally, associated with impending death; the other was pneumonia,
which might even, in complex cases, be a fall-back diagnosis unsupported by microbiological assay. The
quotation from health board 10 comes from two respondents involved in one group interview:
I think if you look at falls and you compare fall rates between those who are in retrospect clearly dying
during their last admission and those who are not, I think that regardless of your falls strategy your
falls rate will be higher in that population because falls I suspect are as often as not the marker of
impending mortality. The same will also be true of the other harm events particularly what people call
hospital-acquired pneumonia, which I think is a dreadful term but the acquisition of pneumonia is
often an agonal event. It is a terminal mode of dying.
Health board 1
An awful lot of the infections in the mortality group of patients are part of the natural process of
dying . . . hospital-acquired pneumonia. It’s called the old man’s friend. People die of something don’t
they? If they’ve been in hospital a long time that tends to be what goes down on the death certificate
whether it’s true or not.
Health board 10
They are not confirmed by the lab.
Health board 8
It’s a catch-all diagnosis.
Health board 10
Overall, the hugely time-consuming mortality review process was picking up little besides the fact that very
frail and elderly people, with complex patterns of morbidity, were dying, arguably inappropriately,
in hospital:
I think if you’re going to detect harm and then make changes to prevent things happening I don’t
think you should pick the deceased as your group. I think you should review all of your deaths but for
a slightly different reason. I’m not saying that you shouldn’t do something when you detect harm in
that review but I don’t think they are the right group as a sample to be saying you are going to do a
harm study on. We need to be looking at admissions for the living to get our harm signature.
Health board 1
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I’m involved in the mortality review thing in Wales and it seems fairly considered that it’s a pointless
thing to do . . . because we’re dealing with a large number of expected deaths in a subselected group
that doesn’t reflect the population that you’re concerned about. For example if you’re taking frail
elderly deaths – I was involved in the RAMI [risk-adjusted mortality index] stuff personally and all we
saw was it’s a proportion of people who die in which location but the total number of people dying
aren’t changing. Crude mortality in England and Wales – if you add in hospitals and nursing homes
it’s exactly the same crude mortality it’s just there are more nursing homes in England per head
of population.
Health board 7
Harm2 data
As was the case with the mortality reviews, health boards also had their own data on harm. At the
national level, the Datix incidents are aggregated onto the National Reporting and Learning System and, in
addition, serious incidents and the results of their root cause analyses are reported directly into the WG.
Most respondents pointed out that the incidents recorded on Datix suffered from the disadvantage of
requiring staff to decide, and have the time, to make the report.
In addition, respondents made reference to complaints and to patient satisfaction surveys as sources of
harm data. However, a number of respondents either thought, or knew, because they checked patient
numbers against their own systems, that the Harm2 instrument had picked up issues in patients
unidentified by health board systems:
It is picking out harms where defects in care had been determined to have contributed to a death.
I cannot say with confidence that other mechanisms would so dispassionately come to such a
conclusion. Without looking at it my prejudice is that the patients you have identified in this probably
have not been identified through other mechanisms. That has been new information for us.
Health board 2
One respondent, however, while acknowledging this, also stated that there were some cases in which
harm identified by the health board using UMR had been missed in the Harm2 study. When asked if there
were missing criteria in the Harm2 tool, the respondent stated:
No, I think it is a reflection of manually reviewing case notes. Case notes are disorganised,
unstructured collections of information and people will see things in them that other people don’t.
Things like legibility to the way things are filed to the way people interpret what people have written
and it is the nature of the paper case note, I think.
Health board 6
We invited respondents to give their views on the added value of the output data derived from both
mortality and harm reviews. For the vast majority of respondents, the key value of the outputs lay in their
ability to validate or triangulate existing internal processes. If the harm signature peaked in places already
known to present problems, such as infections and communication, then health boards could be assured
that their own processes were picking up the appropriate issues. The same was true at government level:
We learnt that handover was difficult – we certainly learned that sepsis was an issue . . . We do have
the outputs from the stage 1 reviews and those are showing very similar patterns to what are being
described in the information that you are coming up with. We are learning that sepsis in terms of
chest infections, hospital-acquired pneumonia is being found here to be the major source in those
patients that die as a major contributing factor to possible avoidable death.
Health board 3
It’s given us that reassurance around the 1 in 10 or whatever we’re not an outlier compared to other
international studies.
WG
DOI: 10.3310/hsdr05090 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mayor et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
97
Such reassurance, at both the country and health board level, was not a small matter. As indicated,
mortality reviewing in Wales was being carried out differently by the various health boards and there had
been much lively discussion of the pros and cons of the processes adopted. One respondent stated:
As you know we’ve had various iterations of mortality review going on in Wales . . . One of the
challenges has been because the mortality reviews have been adopted very differently across Wales,
although there is now an endeavour to standardise it, we have very good rates of stage 1 UMR rates,
pretty close to 100% (it took a while) and we do that by getting the junior doctors to do the stage 1.
There is a proposal floating about and in some health boards they’ve adopted a system where they
have a very senior doctor doing the stage 1 review but their rates of completion are quite low . . .
What I find helpful is that these reports have triangulated quite well with what we’re learning from
our own process and its given the board some assurance that the process we’re using for identifying
potential harm is reasonably robust.
Health board 6
The above quotation also nicely demonstrates the second strength of the Harm2 study, which was that it
was applying a consistent methodology across all health boards in Wales such that data could be
compared, hospital by hospital, and aggregated with confidence.
The third added value of the Harm2 study lay in its independence. This implied less that the reviewers were
free from any suspicion of organisational pressure than that they were not blinded to problems that local
reviewers might accept as normal:
I think the other governance mechanisms have a greater risk of suffering from a cultural normalisation.
You know the windows are always broken so why would I complain about the windows being
broken. Nothing ever happens. What this has the potential to do is it’s relatively protected from that.
It is picking out harms where defects in care had been determined to have contributed to a death.
I cannot say with confidence that other mechanisms would so dispassionately come to such
a conclusion.
Health board 2
A fourth value was its external funding, which meant that the RF1 reviewers could devote more time to
the process than those who had to balance their reviewing work with patient care. Such was the work
involved in the admittedly sophisticated Harm2 review process, it was argued, that it put the tool out of
reach of clinicians for routine use for every inpatient death:
There is no way on God’s earth we could get our staff to do it. They are quite comprehensive. They
are really good for a research study by research nurses when it’s all they do but we could never use
that tool as a general tool . . . it is just not practical to use something as complex and detailed as that.
Health board 8
A fifth advantage of dedicated time for review was the thorough nature of the process. Although the RF1
reviewers had the time to track the patient journey through both medical and nursing notes, health
board reviews were largely a review of medical care only, unless something alerted stage 2 reviewers to
delve further.
The overarching mortality review thing is a narrative doctor type approach to was there any grand
problem in care and its very doctor focused as opposed to multidisciplinary. Some places are doing
multidisciplinary but generally it’s a kind of doctor focused thing as a prelude to the medical
examiner’s role.
Health board 7
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Not only do doctors think that pressure ulcers are nothing to do with them, they certainly don’t think
it’s their job to describe them in a case note. So I have to say that the most common and significant
harms that I know are not reported by doctors. I think the UK rate reported through [Hospital Episode
Statistics] is 0.1% whereas we know it’s 16% or something.
Health board 6
Finally, and by far the most useful addition to the information already held by health boards, was the fact
that the Harm2 study used the same tool to assess the rate and types of harm in the living and in those
who died, allowing comparison of the two rates. Given the significant amount of time that health boards
were investing in the mortality review process, it was important to know whether these findings could be
extrapolated to the 98% of patients who were discharged from hospital or whether the harm profile in
the dying was quite different:
We’ve very much focused on the death review off the back of Palmer12 but if the characteristics of
harm are the same then it’s potentially going to be extrapolatable (sic) back into the wider community
because we’ve got 1.5–1.8% of hospital episodes end in death in the acute sector. So one of the
problems I have is . . . if we’re focusing on the deaths what are we not focusing on? If the
characteristics are the same then the learning will be more widely spreadable if it’s the same pattern
whereas if we understand that there is a different characteristic of harm associated with death, then
we can focus on that characteristic and that would potentially have the biggest yield.
Health board 11
To me it is some sort of reassurance that our mortality reviews are not missing harm in the patients
that live. Because we do need to look at everybody. In a way this preoccupation with those that died
I can see why we do it but we need to be looking at those that live as well.
Health board 4
In addition to the plaudits, there were also some criticisms of the study. One related to the overall length
of the study and the lack of timeliness of the feedback. Part of this related to respondents receiving output
data neither directly from the research team nor from recipients within their own organisations, despite
having titles that indicated responsibility for quality and patient safety. The other related to the different
priorities of universities and health boards, and the latter’s perception of the former’s propensity to hold
on to data for too long:
The biggest criticism I have always had of researchers generally is their propensity to hold onto things.
It is a real danger. What they eventually try to do is create a product that they can own and sell and in
this type of environment I think we should use the study to prove what we need to know to tell us
what we need to do and then as organisations in health care we need to get on and do it. Not for
it to remain in the domain within the university. Let’s get it into organisations in parallel with
mortality reviewing.
Health board 1
One respondent pointed out that the screening tool included triggers that would seldom, if ever, be
reported as critical incidents. The respondent below cited criteria by numbers and, thus, the quotation is
reproduced in full with the addition of the explanatory wording:
Just yesterday I was asked by [name] to say which of these were harm incidents and which should
result in incident reports as we were kind of trying to cross-reference with Datix and that’s quite an
interesting question because number 1 [unplanned admission within 30 days] and 2 [unplanned
admission within 30 days post discharge] never get reported. Number 3 [hospital-incurred accident or
injury] nearly always. Number 4 [adverse drug reaction, side effect or drug error] sometimes. Number 5
[unplanned transfer to intensive care/high-dependency unit] never. Number 6 [unplanned transfer to
another acute care hospital] never. Number seven [unplanned return to theatre] never. Number eight
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[unplanned removal, injury or repair of organ or structure during surgery] very rarely. Number nine
[other patient complications to include MI, DVT, CVA (cerebrovascular accident)] never really, only if
the DVT arises as a lack of prophylaxis. Neurological deficit never. Unexpected death never reported
except by psychiatrists. Inadequate discharge planning – there have been one of two of those over the
years. Cardiac arrest hardly ever. I could go on. So what we consider critical incidents is nothing like
that list.
Health board 10
The respondent quoted went on to point out that when undertaking mortality reviews, unlike the Harm2
reviewers, clinicians would only ever identify actual, rather than potential, harm. Omitting medication
for several days was viewed as harm only if the patient suffered as a result. Other interviewees, while
acknowledging the value of alerts to potential harm, nevertheless struggled to interpret them:
You have to have the error and the consequence together before people treat it seriously. We should
be on the one in six drug errors, I agree, but the word harm means the patient’s been harmed, not
that the drug has been delayed. We get this argument all the time with our legal department.
Health board 10
I talked about the triggers in the Global Trigger Tool and the difference between the criteria and
whether it’s possible harm or an actual harm. When do you really need to worry about this because
the possible harm is a possible harm? So really getting your head around ‘is that something I really
need to react to?’ is also something that I struggle with more than I expected to.
Health board 4
Two reasons for the focus on actual serious harm were given. One was the size of health boards that were
likely to see hundreds of incidents a year across multiple sites. The other related to the modest staffing of
quality and safety teams who had to focus their efforts on the most important issues.
Management of the Harm2 outputs
What happened to the data on arrival varied from one organisation to another. In three health boards,
senior medical and governance staff responded instantly to data suggesting that patients had been
harmed in their care. In two organisations, respondents immediately located and reviewed the notes so
that they could answer the detailed questions that would inevitably be raised by the data. A third health
board compared the harm data in the outputs with information on the clinical incident recording system,
Datix, and also determined whether or not these cases had triggered a second-stage review within their
own mortality review process.
I just went through the G, H and I categories I thought we have a lot of Is here and so I had those
notes called so I could scrutinise them and draw some conclusions to discuss with the medical director.
Health board 5
What we’d agreed that we would do was marry up the information of the deceased cohorts with our
mortality review process and certainly in all instances check incidents on Datix.
Health board 9
Most of the comments from those who had carried out this checking review related to the point made
above – that harm in the dying is difficult to tease out from catastrophically compromised physiology:
One man died of uraemia but again had metastatic bladder cancer. He was 98 [years], had carcinoma
with multiple metastases, so this was an expected death. Yes, there was a delay in care but that was
caused by risk management. The researchers do not contextualise these issues they just identify the
criteria so from a research perspective they are right removing bias just looking for the criteria but the
delay in care was due to risk management but this is a man who was 98 [years] who became ill very
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quickly and died very quickly and we would not have wanted to handle it any other way. Family
involved and that sort of thing.
Health board 5
So that’s the bit I’m struggling with trying to quantify how much the hospital-acquired pneumonia is
just a failure to recognise the dying process and an inappropriate escalation of care and how much of
it is something we could potentially turn around. The trigger is the trigger but it’s understanding
what that’s telling us about the context. You could argue that inappropriate treatment is harm in
that situation.
Health board 11
In two health boards the data outputs as sent had been taken to committees, one to a mortality review
committee and one to an outcomes group. A third health board presented the data to the Quality and
Safety Committee and a fourth made reference to it within a more general report on mortality review.
Others had felt that the data, as presented, were unsuitable for presentation to a group that did not have
in-depth knowledge of the study, being difficult to grasp quickly and interpret meaningfully.
In the appendix most of the definitions are covered but I think it probably needs to be elaborated for
the uninformed reader. Given this has the potential to end up at a board and as such a public
document, it probably requires more of an easy read English explanation.
Health board 2
I think my only comment with things like that would be I know a fair bit about the study and so do
people around this table but if you put down that report to somebody completely cold they’d look at
it and just go, ‘what?’ There’s a lot of explanation they don’t understand what the criteria mean . . .
even our Medical Director looked at it and said you want to talk to me about this? . . . and he’s a
really bright bloke but it’s not intuitive, this, for people to understand. If you’ve been doing this sort of
research and you live and breathe it then its fine isn’t it, but it’s not something you could present to a
clinical group who didn’t have in depth knowledge of the project as data like that. I don’t think.
Health board 8
In three health boards, the data had been sent to clinical directors, but one medical recipient, who had
discussed it with colleagues, supported the view that it was too complex for them to assimilate
sufficiently quickly:
I think it’s brilliant work. I just wish it was more digestible to my average colleague. I kind of sat there
for half an hour looking at one sheet of paper going mmm mmm whereas some of my colleagues
would say oh it’s just another thing and it goes in the bin. You have to be understandable in
5 seconds what you’re trying to say.
Health board 7
What recipients really craved was unambiguous scientific data that would help focus their improvement
efforts proactively rather than, as was happening at present, following one directive after another:
In an ideal world you use semiscientific data to direct your resource to your biggest problem which
would be a nice world to live in because the world we live in at the moment is sort of fire fighting so
1 minute it’s dementia then the next minute it’s medicines error then it’s C. Diff [Clostridium difficile]
whichever hits the panic button and people rush around doing those things trying to improve safety in
those areas.
Health board 10
A number of respondents, from the WG to health boards, had been excited by the prospect of harm
signatures for each health board that would point to areas for improvement. For reasons of confidentiality,
DOI: 10.3310/hsdr05090 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mayor et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101
of course, health boards were sent only their own detailed data together with the all-Wales figures for
overall harm, and one criticism of the outputs was that they failed to give benchmarking data that might
alert organisations to the fact that they were outliers in respect of the presence of a specific harm criterion.
As an example, in the case of hospital-acquired infection, it would be useful to know whether or not an
individual health board or hospital was significantly above the Welsh average. This was a problem the
Harm2 study shared with other harm tools, such as Datix incident recording, which delivered numbers of
incidents that had occurred but left health boards wondering how to turn this into useful information that
would lead to meaningful improvement:
When [name] first talked about the results in the first part of the study she spoke about harm
signatures which is a great concept but it is most helpful and meaningful if you compare it to
something else. If you look at your own signatures you don’t know how different you are to anyone
else. I mean we all have health care associated infections and its most helpful knowing what are the
things where we are significantly different so I think doing this just on its own just looking at your
signatures yes you always look at your peaks you always want to know what those things are but if
you know you’re very different here that’s what really helps.
Health board 4
The Datix system, which has got thousands and thousands of cases in it, suffers from the same
problem which is if you ask it what themes are critical incidents it will come out with a graph and it’ll
say medication errors, falls, miscommunication la de dah de dah and that’s the same every month so
what do you do when you print off that report? You think OK nothing much has changed . . . that’s a
problem of databases universally isn’t it. You collect lots of data but how do you turn it into
useful information?
Health board 10
Reference was made above to the fact that independent review, while in many ways positive, had the
negative consequence of divorcing learning opportunities from clinical practice. In two health boards the
view was expressed that the centralisation of their own stage 2 review process was also guilty of this. In
these organisations, the stage 2 reviewing had recently been devolved to sites or directorates to maximise
the learning for clinicians, although it was recognised that persuading doctors to take on this onerous task
was not easy. An additional benefit of devolving review lower down the organisation was that, especially
in tertiary centres, it is difficult for non-specialists to make judgements about the quality of (medical) care:
What we then moved to doing was identifying the mortality needs for the specialties and feed the
notes to them. So we’ve taken some time to get to that but we’ve got that. There are a lot of
difficulties around support for that process. Very person dependent because we’re doing it manually
but we’ve got it up and running. The other thing that is a confounder is the different cultures on the
three sites but we’ve now got it down to a common process that has some outputs.
Health board 2
In a huge centre as we are there are so many tertiary specialties it would be very difficult for anyone
who did not have an in-depth knowledge of cardiac surgery to be able to critique that work. What we
do need to do, and we’re gradually moving there, is for individuals to be really enabled to be honest
and open about the care in which they are participating and to have that enquiry as a matter of
course. Have we provided the best care that we could and if not what do we learn from it?
Health board 5
Ultimately, respondents were looking forward to the establishment of a medical examiner who would
review all deaths in Wales. In addition, as indicated, respondents looked forward to the further
development of live and manipulable data on the Welsh Clinical Portal that would make case review
simpler and more meaningful.
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Although the statistical data provided by the Harm2 study were novel, their value in the early months was
tempered by the relatively small sample size at health board level. It was only after the accumulated data
for 1 year were distributed that respondents felt the numbers were such as to warrant serious discussion:
I think in terms of the numbers, I’m not saying individual patients aren’t of value but for the quality
steering group to really make any sense of it they don’t want ‘this month we’ve had three cases.’ They
are not going to be able to strategically steer on that basis . . . This [output data] is very helicopter –
It indicates what questions I would want to ask, like why is there a difference between the hospitals?
But then when I look at the absolute numbers they may be within confidence intervals so I’d want
somebody to tell me whether it was outside 0.05 p-values or whether and even then it could be still
by chance. What are the outliers here? Between our two hospitals – you know the numbers are
very small.
Health board 1
To conclude, at the level of individual boards (as opposed to country level) the study had just begun to
produce useful data as it came to an end:
And please do more of it, because this sort of data to me is gold dust – it needs to get into the culture
of everything we’re doing and I’d really hope for harm studies to expand and maybe get to be a
routine part of the way that we’re working. It’s been really useful from my personal perspective.
Health board 7
Summary of key findings
The reviewers found few problems in using the Harm2 tool, finding it clear and unambiguous, although the
judgement as regards preventability did present challenges that were relieved by discussion with colleagues.
The greatest difficulties, however, arose from the condition of the notes themselves which, particularly
in the case of patients who had died, were found to be in some disorder. The form of digitisation found in
one of the health boards, in which pages had been scanned onto the system as images, exacerbated the
problems and made it difficult to uncover the narrative of the patient’s stay and whether, for example,
actions prescribed by doctors had been carried out by nursing staff. The Harm2 data were well received by
those senior staff in health boards to whom they were sent, but were neither shared nor discussed to any
great or consistent extent beyond this group and it was thus not possible to trace any clinical changes to
practice as a result of the work. Rather, recipients used the data to assure themselves that serious AEs had
been picked up by their own systems and/or by retrieving the notes to determine whether the index event
had changed the patient outcome. In the vast majority of cases, where AEs had been identified in the
mortality sample, it was claimed that multiple pathology in frail individuals had made the outcome
inevitable. These respondents questioned the usefulness of mortality review in detecting harm in the wider
population. Although the health boards had no harm data that directly compared with those arising from
the randomly selected discharges review sample, respondents were reassured to find that the themes
coincided with those featuring in their own Datix systems and complaints records.
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Chapter 6 Summary of findings, discussion
and conclusions
Overall study findings
Adverse events are common in Wales and around half could potentially be prevented if care was delivered
to an expected standard in normal circumstances. The same proportion of AEs results in excess bed-days in
inpatient settings to manage the clinical complications. In Wales, where AEs resulted in prolonged hospital
stays of > 24 hours in duration, the median excess LOS was 6 days. In assessing the episodes of care in
which at least one AE was identified, the overall quality of care was still rated as being excellent or good in
71% of cases.
Measuring harm in Wales: phase 1, comparison of the Harvard and Global
Trigger Tool methodologies
In phase 1, the overall percentage of patients identified as having experienced an AE using the two-stage
retrospective review process was 10.3% (95% CI of 9.4% to 11.2%), with moderate inter-rater reliability
at the screening stage (κ = 0.47) and good inter-rater reliability at the AE determination stages (κ = 0.63).
The percentage of AEs from individual study sites ranged from 7.9% to 16.1% with an attendant reported
preventability of 40% to 87% (mean 51.5%, 95% CI 46.88% to 56.12%).
In this Welsh cohort of patients, length of hospital stay and being an elective admission (and, therefore,
more likely to undergo invasive surgical procedures) were independently statistically associated (p < 0.001)
with experiencing an AE. The case mix between medical and surgical patients appears to influence the
rates significantly, with events occurring more frequently in surgical admissions. Thus, the percentage of
patients affected was higher in sites whose sample contained more surgical patients. We did not observe
any seasonal trend in the determination of AEs across NHS Wales, although a small increase in AEs was
detected over the first 2-year period. It would be difficult to establish if this was an actual change or
related to the growing experience of the reviewers in detection over time.
The breakdown of problems in care underlying AEs revealed that failure in clinical monitoring (33.5%),
failure in infection control (29.4%), incidents directly arising from surgical and other invasive procedures
(21.2%) and incidents arising from the administration of drugs and fluid (18.7%) were key contributors.
Of these, 15.7% resulted in a level of disability not present on admission, 74.0% resulted in an extended
LOS and 8.9% were associated with, but not necessarily causally related to, the inpatient death. An
assessment of the psychological impact of the AEs identified in Wales was completed in only two-thirds of
cases by the research physicians (309/450) and 36% of patients were found to have experienced at least a
moderate degree of emotional trauma.
Comparison of the Global Trigger Tool and the two-stage retrospective review
process rates of harm across NHS Wales
We set out to compare two approaches to harm measurement: the two-stage retrospective review process
and a derivative of the IHI GTT. We conclude that, after comparing the extent and nature of AEs identified
by the two methodologies in matched-pairs analysis, the gold standard approach offered advantages
over the GTT in terms of the consistency of the approach, the frequency of AEs identified and the
categorisation of AEs from the spectrum of triggers identified. We detected a difference in overall rates of
2.3 percentage points, with the reported percentage of patients experiencing an AE being 10.3% and
8.0% in the two-stage retrospective review and GTT processes, respectively.
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The two-stage process was project managed across all sites, with the research team ensuring that
protocols were adhered to and problems addressed at an early stage. The GTT review, however, was an
independent NHS-led process and, although a national protocol for the use of the tool was available and
training provided to all organisations, there was considerable variation evident across NHS Wales in the
way the tool was being used, the composition of the review teams and the way in which the data
generated were entered and used. When implementation is not robust and as recommended, errors in
identification and therefore measurement may go undetected. When we examined the 153 AEs identified
through the GTT but not the two-stage process, we estimate that the research team potentially may have
missed < 10% of these, with the majority of the remaining AEs resulting from the inappropriate attribution
of multiple positive triggers to a single AE in an episode of care. The professional composition of the
review teams also influenced the determined rate. Strong multidisciplinary teams generated rates of harm
comparable to, or higher than, the research team. Teams led by non-clinically trained personnel typically
missed a significant percentage of AEs in inpatient records.
There are two primary purposes of investing in infrastructure to support case note review. The first is to
provide a level of assurance, at the corporate level, that the problems that patients commonly experience
as a result of care are not significantly higher than expected or commonly reported. The second is to
examine the outcomes of patients who experience AEs to learn from what happened and to raise
awareness, or inform improvement activity or remedial action. In terms of providing assurance, the data
provided by the Harvard method are comparable with previous studies. The GTT data can also be
benchmarked, but the findings in the Welsh context suggest considerable under-reporting and significant
variation in rates of harm reported across organisations, providing few data for assurance purposes. The
actual difference identified, of 2.3 percentage points, is not significant, as the internal validity of the tool in
this context is in question. Similarly, the GTT was limited in its scope to reliably identify recurring AEs
where improvement priorities could be generated, whereas the Harvard method provided a classification of
main problems in care, highlighting actual clinical harm and key areas across an organisation in which the
delivery of processes of care may be substandard.
Testing and understanding risk associated with screening criteria
Using a trigger list of criteria, which are indicative of risk of health-care-related harm, has been found to
be an efficient way of sifting out a selected group of cases for review. Experience with the GTT indicated
that reviewers tended to identify one or more of the same four or five triggers across cases, leaving the
other triggers virtually redundant.
Analysis of patterns of use of the criteria aligned with harm events indicated that a number of these, such
as transfer to another hospital, were ambiguous in that they could reflect both problems in care and also
good-quality care, if that transfer was part of good management. In-depth thematic analysis of four of
these criteria found that they were poor at picking up omissions in care or specific subcategories of harm,
and new categories of screening criteria were identified. Importantly, the new subcategories generated
include acts of omission, such as missed and delayed diagnosis or treatment, as well as breaking down
injury into categories such as falls, pressure ulcers and injury resulting from the use of equipment. This
subcategorisation, we believe, will make it more likely that harm risk and AE data will be used by a variety
of clinical and professional groups within organisations, thereby enhancing the opportunities for
organisational learning.
Furthermore, as we empirically identified acts of omission that were associated with the risk of developing
AEs in practice, we directly addressed criticisms of pragmatic tools that they do not identify acts of
omission and are sensitive only in picking up acts of commission. The new screening criteria were included
in the development of the Harm2 tool.
The development of the Harm2 tool
The Harm2 approach was developed in order to circumnavigate issues arising from using both the GTT
and two-stage retrospective review process in routine adverse event surveillance in Wales. In the
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meantime, NHS Wales made a decision to phase out the use of GTT from 2013 onwards. There were also
concerns related to the suitability of the two-stage retrospective review process as a tool for ongoing harm
surveillance. Information generated by this process is both quantitatively and qualitatively rich, but the
method is labour intensive in both physician and nursing time. Furthermore, the administration of the
review and subsequent data entry takes as long as the review of the inpatient episode of care, and the data
sets generated are unwieldy for routine use. The key time investment in case note review methodology is
the time taken to read and review the full episode of care. Our study showed that this can vary from 10
minutes, in the case of a straightforward surgical procedure, to > 1 hour in a complex episode of care. In
the two-stage process this reading and review process is undertaken twice (once by the nurse who screens
the notes and once by the physician reviewer) for each episode of care assessed, an approach judged not to
be viable in a routine surveillance programme.
Key considerations in the development of the Harm2 tool was the need for a one-stage process, which
would provide a robust measurement of AEs and their preventability and to provide adequate detail of this
harm in the form of a narrative account to allow its contextualisation. The tool was designed to provide
hospitals with key information that would drive change in clinical processes and practice through the
identification of common problems in care. The Harm2 tool is a condensed version of the traditional gold
standard two-stage approach. As in the GTT, cases are initially screened to detect those that are at higher
risk of health-care-related harm, with the reviewer going on to identify if a harm actually occurred in the
high-risk cases. Unlike the GTT, the reviewer reviews the entire case record and also provides a narrative
account of any AEs found.
Measuring harm in Wales: phase 2, the Harm2 tool
In phase 2, the percentage of patients identified as experiencing an AE was 11.3% (95% CI 10.22% to
12.40%) in the sample of randomly selected discharge reviews and 30.1% in the randomly selected
deceased patient reviews (95% CI 28.13% to 33.82%), with 59.6% (95% CI 55.29% to 63.91%) and
61.7% (95% CI 57.49% to 65.91%), respectively, being identified as preventable. The inter-rater reliability
of the Harm2 tool was moderate in both the randomly selected discharge reviews (κ = 0.50) and the
randomly selected deceased patient reviews (κ = 0.54) cohorts. Comparison of a 10% sample of nurse-led
reviews with two-stage physician reviews also indicated moderate reliability (κ = 0.45). Comparing the
breakdown of problems in care categories in randomly selected discharge reviews and randomly selected
deceased patient reviews, problems in assessment, investigation and diagnosis (p = 0.036), problems in the
administration of medications including i.v. drugs and bloods (p = 0.0042) and problems arising from
surgery and other invasive procedures were less common in the randomly selected deceased patient
reviews cohort than in the randomly selected discharge reviews. In addition, infection control problems
were significantly more common (p < 0.0002) in patients who had died.
Identification of patient-level factors predisposing individuals to risk
Attempting to predict which patients are most likely to experience AEs in inpatient care is both attractive
and risky, as we, and others, have consistently demonstrated that AEs occur across the age and inpatient
spectrum.14,16,32–39 Risk factors have been proposed but, to date, little work has been undertaken to test
theoretical assumptions.60 For example, physiological reserves have been proposed as an alternative
hypothesis to age per se.60–62 Work undertaken to date has been dependent on hospital administrative
data sets to generate variables to test in regression models with varying outcomes.35,63
Elective admission and length of hospital stay was independently statistically associated with experiencing
an AE in phase 1 of the study. However, longer length of hospital stay, associated with a nearly 40%
increased risk of incurring an AE, is a difficult variable to interpret as a risk factor for AEs. The increased
LOS may arise from longer duration of exposure or may just reflect the fact that the LOS was longer
because the patient was injured and required further inpatient management. Similarly, being an elective
admission and, therefore, more likely to undergo surgical intervention was associated with a 17%
increased risk of AE determination.
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In phase 2 we prospectively collected Charlson Comorbidity Index chronic disease data from all patient
records included in both samples. Dementia, PVD or hemiplegia was associated with at least a twofold
increased risk of experiencing an AE. Also significant were age and Charlson Comorbidity Index scores,
with ORs of 1.12 and 1.10, respectively. Further examination of the nature of the events in patients with
dementia, PVD and hemiplegia indicates that the majority of events, in all likelihood, probably result from
underlying physical and cognitive impairment and comprise falls and pressure ulcers, with a smaller
number of other events arising from drug administration or reactions or hospital-acquired infection. The
crude AE rates in these groups were 22% in patients with dementia, 24% in patients with PVD and 22%
in patients with hemiplegia. The current assessment of risk in these patients, compounded with failings in
providing a safe inpatient environment, appears to predispose these patients to ward-based AEs.64
In the sample of deaths, age was not a significant factor, with the mean age of inpatient deaths being
78.9 years, and no chronic disease category was associated with increased risk in patients who died
during the inpatient episode. Furthermore, the risk associated with elective admission, rather than being
increased, was twofold lower than the risk associated with emergency admission, reflecting the lower level
of surgical-related AEs in this cohort.
Difference in the composition of adverse events in the sample of randomly
selected discharge reviews and deceased patient reviews using the Harm2 tool
In phase 2 of the study, we explored differences in the extent and composition of AEs in patients who
constituted a random sample of all hospital discharges and a random sample of patients whose
hospitalisation ended in death. Significant differences arise in the comparative analysis of the breakdown of
problems in care categories in these independent cohorts. A number of striking differences are evident,
particularly in problems in care relating to problems with infection control and problems arising from
surgical or other invasive procedures. Furthermore, the areas in which significant differences were not
detected were in failure in clinical monitoring and failure to respond to changes in the patients’ conditions.
These problem in care categories include aspects of care such as venous thromboembolism, prophylaxis,
falls and pressure sore risk management and monitoring, the monitoring of vital and neurological
observations and monitoring food and fluid intake and output, in which differences would not be expected.
Innovative methods highlighting organisational risk and patient experience
Organisational signatures of harm
As part of the quality assurance process of checking the RF1s as they came into the research office, we
became familiar with the types of AEs identified across individual NHS hospital sites. Distinct patterns
emerged that indicated to us that AEs might be characterised at the individual hospital level and could be
used to highlight areas in which improvement may best be targeted for both patient and organisational
benefit. We termed this notion ‘organisational signatures of harm’. Signatures of harm are generated from
the top criteria screening positive and then subsequently converting to determined AEs. These are then
simply illustrated in a pie chart or a Pareto chart. This process highlights to organisations the origins of
harm to patients and can be strikingly different across NHS sites. Harm signatures had immediate
resonance with study sites, as they were recognisable issues to some individuals in leadership roles within
organisations, and this in itself we believe may heighten accountability and responsibility for addressing the
problems they highlight.
Signatures of harm have the potential to inform and subsequently monitor AEs in organisations over time.
It is difficult to demonstrate quantifiable changes in AEs rates over time and, therefore, the beneficial
impact of programmes of quality improvement and patient safety. Signatures of harm may be a simple
methodological approach whereby quality improvement can be assessed by changes in the composition of
AEs as a result of improvement efforts, which can subsequently be tracked over time.
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Similarly, right at the start of the study we introduced a narrative on each record reviewed. Despite not
describing the events in the way an incident report would, we believe that this form of narrative brings
something of the patient story, and, therefore, context to the impact of harm events on patients, families
and organisations. Pressure ulcers, for instance, are an area in which there is universal recognition that
improvements can be made.65,66 If captured through case note review, as they are generally noted in only
the nursing records of care, they are generally classified as minimal impairment and no psychological
injury. Narrative brings context to specific events, such as the man in his thirties who acquired grade 3
pressure ulcers on his heels after extensive surgery for oral cancer. His main complaint at follow-up was
the pain and immobility he was experiencing from this tissue damage. The use of both data showing the
extent of a problem and narrative that shows its impact can play a role in highlighting the impact that
common AEs have on patients and their families.
From ward to board, narrative in a useable format has the potential to become a mechanism in which a
wide range of patient experiences can raise the profile and relevance of patient safety issues in clinical
practice and contribute to improvement priorities.
Study strengths and limitations
Study strengths
We report on AE rates in a UK setting generated from a sample eight times larger than the samples from
which AEs rates have been determined previously.14,16 The sample was derived from every health board
providing acute service across NHS Wales and was longitudinal in nature, with a duration spanning 4 years.
The rate of AEs reported is in line with previously reported AE rates and attendant preventability and severity
in smaller UK settings and the mid-point in the rates reported in epidemiological studies internationally.14,16,32–39
The infrastructure supporting the review teams came from both the academic study team and the clinical
research infrastructure of the National Institute of Social Care and Health Research. Training and support
was also longitudinal with regular face-to-face meetings with regional leads and teleconference meetings
with review teams in which progress against objectives was assessed, problems described and difficult cases
discussed, promoting learning and ongoing professional development. The expertise within the review team
grew over the study period and the inter-rater reliability we report is consistent with other studies of this
nature.14,16,32–39 The collaboration the study team had with NHS colleagues was instrumental in informing
the development of the Harm2 tool, but input was provided from a wide range of stakeholders.
Study limitations
The methodological limitations of using a retrospective case note methodology to identify AEs in health
care are well rehearsed.17,56,67 Information bias, moderate reliability and hindsight bias are commonly cited
issues and would have influenced this study in the same ways as previous studies. This study differed from
most other epidemiological studies on AEs undertaken to date in a number of ways. All previous studies
using the two-stage methodology examined prevalence in snapshot random sample surveys. The Dutch
group has undertaken significant longitudinal assessment but in three distinct prevalence surveys39,68,69
rather than a quota of records reviewed monthly over a period of several years. Our sample in phase 1 was
longitudinal over a 2-year period and was drawn from all health boards providing acute inpatient services
in NHS Wales.
We were, however, reliant on a sampling strategy of inpatient notes that underpinned the measurement
of harm as part of a National Patient Safety Campaign. The method identified and reviewed a randomly
selected set of 20 inpatient notes out of a pool of 30 identified records on a monthly basis and the
research team reviewed the same notes. The notes were unavailable to the study team if a GTT review
team was not convened or because of resource constraints in medical records departments. The number of
GTT reviews therefore undertaken by an individual health board was dependent on commitment to the
methodology and study, in addition to its capacity to bring together senior health-care professionals to
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undertake the reviews. The range in the individual site sample size was considerable (from 174 to 560)
and this, along with the robustness of each organisation’s randomisation process, was influential in
determining the rate of AEs detected site by site. One study site provided < 200 reviews, with the
remaining 10 providing > 300 and six sites providing > 400 reviews. Two sites were identified as having
problems with their randomisation, which was described by the review teams and amended on request.
The robustness of the randomisation process has implications for the study’s generalisability. This,
however, was acknowledged from the outset of the study as we followed the quality improvement
methodology and sampling strategy already adopted by NHS Wales.
The highest AE rate at an individual study site was double that of the lowest rate (16.1% vs. 7.9%).
We cannot rule out that this variability was, in part, a result of differences in sample size along with
differences in sampling strategy. An additional bias was introduced because the sampling strategy did not
take into account the size of the hospital and the nature of the services provided. We did not identify
any discernible patterns in the rates of harm by level of care provided in district general hospitals or
tertiary-level provision. These findings have significance for operationalising a system of AE surveillance,
but do not have significance in relation to the overall rates of AEs that we report.
We encouraged the RF1 screening process to be more than a tick-box exercise by encouraging the use of
free-text boxes aligned with each of the 18 criteria to highlight why a particular criterion had screened
positive. We rationalised MRF2 referral, as it is logistically difficult to pull sets of notes twice for review as
well as being labour and resource intensive for physicians. Similarly, we did not assess a percentage of all
negative screens. We cannot rule out that this process resulted in an underestimate of the rate of harm
across NHS Wales, as physicians may have identified AEs that nurses did not, but we do, however, suggest
that it is unlikely that significant harm is underestimated, given the experience of the reviewers and
research team who made an individual assessment of all review forms.
Limitations of the service evaluation element of the study relate to its restriction to the key contacts in
health boards. However, in view of the lack of wider circulation of the harm data, it is clear that a larger
group of interviewees would have yielded no further information. We did, however, approach the
entire known population of reviewers, and interviewed as many as were willing and available within
the timescale.
Challenges in current case note review methodology
The reviewers’ experiences suggest that maintenance of patient records is, with a few exceptions, poor,
which makes case note review difficult and puts health boards at risk of reputational damage. Both
reviewers and health board audit staff found digitised notes involving non-searchable images difficult to
use, which raises questions about their efficient use by clinical staff if and when a patient is readmitted,
or admitted to another facility.
Reviewers stressed that collaborative notes made the retrospective assessment of interprofessional
communication easier for reviewers, which suggests that they are also likely to aid such communication in
real time.
In undertaking the research, reviewers found the Harm2 document easy to use on the whole. The main
difficulties experienced related to judgements of preventability and severity of harm.
The assessment of preventability
The level of preventability was categorised according to the level of evidence, supporting the reviewer’s
judgement in a scale originally derived from the legal definition of negligence.70 The scale ranges from
virtually no evidence for preventability to virtually certain evidence of preventability, and just under
one-quarter of all AEs identified were at least ‘probably preventable’ and defined in the scale as ‘more
than 50–50 but close call’. As assessment is restricted to information documented in the record of care,
it is subject to both information and hindsight bias and it may be that, rather than an assessment of
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evidence, the level of reported preventability reflects the level of certainty of the reviewers.16 Given these
limitations, however, our assessment of preventability lies on the mid-point of rates of preventability
reported previously.14,16,32–39
Reviewers found the assessment of preventability challenging, and this may reflect the limited empirical
evidence on the validity and reliability of the available definitions of preventable harm. Nabhan et al.,71 in a
systematic review, concludes that no single definition is supported by high-quality evidence, and synthesis
of the literature suggests that preventable harm can be best defined by three criteria: (1) the incidence
that can be reduced by detecting and intervening or preventing a causal event or chain of events; (2) the
causal event or chain of events by its nature can be detected before the harm takes place; and (3) there is
evidence that an intervention is efficacious in reducing or eliminating the harm by virtue of eliminating
the offending cause or disrupting a harmful chain of events.71 The definitions of preventable harm in
two-stage retrospective review studies are generic and mostly aligned to statements about ‘best practice’
and there is a case for reiterating the conclusions of Sari et al.16 that ‘further research is needed to assess
the effect of using summaries or the full medical record to assess preventability and these other factors on
the degree of agreement in assessing preventability’.
The severity of harm rating system
Other challenges in deriving a full assessment of the impact of AEs in health care through case note review
is seen in the assessment of emotional or psychological harm. Although physical impact is well described,
the psychological impact on patients is poorly described in the literature, with more written in this respect
about the second victims of severe AEs, namely the health-care professionals responsible for providing or
overseeing care.72–74 An assessment of the psychological impact of the AEs identified in Wales was only
completed in two-thirds of cases by the research physicians (298/450), and the same proportion was
expected to have experienced minimal or no emotional trauma (183/298). This is a finding that does not
conform to the reported physical and organisational outcomes of AEs and reiterates the need for both
researchers and health-care organisations to understand, from the patient’s perspective, the wider and
societal impact of harm in health care.
The NCC MERP’s Categorizing Medication Errors Index44 was used to classify the severity of the AE and, in
the second phase of the study, the percentage of patients who experienced disability and whose AEs was
associated with, but not necessarily causally related to, the AE were significantly lower than expected and
reported in the first phase of the study. This is surprising given that other end points (such as preventability
and the breakdown of problems of care) are in line with both phase 1 findings and the wider body of
literature. Furthermore, issues become apparent with this classification when identifying problems in care
in patients who die in hospital. When an AE occurs in a terminal episode of inpatient care, there are
limited options on how the impact on the patient can be described, with classifications such as temporary
harm, prolonged hospitalisation and permanent harm having no relevance. Although not posing issues
across all ‘problem in care’ categories, this is challenging if the patient dies within a short period of time
of acquiring, for example, HAP. In the deceased patient cohort, we identified 525 events in 315 patients
and > 100 of these were HAP. As a result, with no classification system that considers issues of
preventability, in 34.4% of cases the non-physician reviewers classified the AE as leading to death. On
review, it is evident that in specific situations it is not possible for the reviewers to differentiate between
NCC MERP’s Categorizing Medication Errors Index44 classifications in the event of death and it was not a
component of the training delivered. This also conforms to the abovementioned reports from health
boards that there is high-level noise from the dying process that could be misattributed to failures in care
and AEs. We therefore recommend that the NCC MERP’s Categorizing Medication Errors Index44 is not
used in assessing the attribution of AEs to patient outcomes, such as death, from case note review,
particularly in the event of no assessment of preventability as a result of the risk of misclassification.
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Comparison with previous findings
The interpretation of headline findings in relation to other studies undertaken internationally is not
straightforward. Different studies emphasise different end points in their reporting and these include the
level of preventability36 and confidence in management causation.39 The percentage of AEs detected
across NHS Wales is 7.7% (95% CI 6.91% to 8.49%) when events classified as being caused by
health-care management are reported and therefore complications are excluded, and 5.29% (95% CI
4.67% to 5.99%) when AEs that are deemed to be preventable are reported.
At the individual hospital site level in phase 2, there was less variability in the organisational percentages of
AEs, probably because of improved randomisation and, while these percentages are higher than those
reported in phase 1 of the study using the two-stage retrospective review process, they are lower than the rate
and levels of preventability in a random sample of 28 Swedish hospitals36 reporting a physician-determined AE
rate of 12.3% and attendant preventability of 70%. All end points we report are consistent with other studies
and this gives us confidence that the gold standard approach, which was amended in phase 1 and condensed
in phase 2, generated valid and reliable information providing a platform for improvement work in Wales.
The ongoing measurement of AEs is important and a consistent message across AE studies is clear:
AEs have a considerable impact on patients, families and health-care providers.14,16,32–39 In the largest study
undertaken to date across the Dutch health-care system, Zegers et al.39 report that 12.8% of all AEs result
in permanent disability or are associated with death. Excess LOS arising from the management of AEs is
significant and our Welsh estimate of 6 days is in line with other European studies reporting 6 days in
both Sweden36 and Spain.38 Furthermore, readmission is common and we found a readmission rate of
approximately 2.5 readmissions for every 100 patients managed within a secondary care setting.
The comparison of the Global Trigger Tool and two-stage retrospective
review process
The harm rate of 9% in Wales using the GTT is considerably lower than any of the US-based studies
examining harm in secondary care settings4,21,41,75 and it is very unlikely that this reflects a true difference
in AE rates between the US and UK health systems. Some GTT studies do not exclude AEs present on
admission and it remains unclear what the GTT is actually measuring. Although the GTT undoubtedly
identifies significant problems in processes and clinical care in order to prioritise improvement efforts,21,75
it may also detect signal noise, which does not translate into actual AEs. This may be compounded
by the limited time to examine the notes, which prevents contextualising these triggers and subsequent
overestimation of harm rates. In the Welsh context there was significant variability in the GTT rates
reported across Welsh health boards and less variation when the Harvard method and Harm2 tool
were used.
Assessing risk for adverse events in inpatient settings
Previous studies report around a twofold increased risk of AEs in adults over the age of 65 years37,76 and we
confirm that increasing risk is concomitant with increasing age. The assessment of comorbid states on the
risk of being injured in health-care management is, however, more complex. In a US setting, Naessens et al.77
examined the effect of illness severity and comorbidity by using patient safety indicators and reported AEs
through incident-reporting systems. They assessed association with chronic diseases generated from
diagnoses coded for Charlson Comorbidity Index chronic disease classifications, concluding that at admission
underlying disease severity increased the likelihood of all types of AEs and increased incremental costs and
LOS. The Dutch group also examined the role of chronic disease and comorbidity by supplementing their
original data set from their first National Prevalence Study, with comorbidity generated from diagnosis data
from the national hospital administrative database, enabling the calculation of Charlson Comorbidity Index
scores. All variables were modelled using multiple regression and they concluded that it was not possible
using inpatient data available on admission and collected during the course of the two-stage process to
develop a satisfactory predictive model for AEs in older patients. The variables that remained significant
in the model were age (OR 1.04), elective admission (OR 1.65) and management within the surgery
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department63 (OR 1.53). Similar findings using similar methodology were generated from the Spanish study
of AEs, the conclusion drawn being that the true risk of AEs depends on the number of exposures to
potentially iatrogenic actions rather than age or the presence of comorbidities.76 We would concur with
previous national studies that comorbidity in itself does not play a significant role in increasing an individual’s
risk of experiencing an AE. There are interactions, however, that remain to be explored, and increased risk is
evident in patients who have heightened vulnerability as a result of physical or cognitive decline. Relying on
the use of the Charlson Comorbidity Index as a measure of comorbidity, however, we cannot rule out that
any associations we report may have been underestimated.
Comparison of live discharges and mortality admissions
The Dutch study recently retrospectively compared the rates and distribution of AEs between these two
groups of hospitalised patients and reported an AE rate that was twofold higher in the deceased patient
cohort. Aligned with our findings, AEs were more common in patients who were emergency admissions
and were less frequently associated with surgical procedures than in the live discharged patients.67 We
report a threefold higher rate of AEs in our deceased cohort and propose that this may be a result of the
composition of the AEs analysed. We report on all AEs arising from inpatient management, whereas the
Dutch study removed all AEs from their data set when management causation was not rated as 4–6 on
the management causation scale. This means that a significant number of events, such as HAP, would not
have been included in rates reported along with harm associated with known complications of surgery.
The composition of problems in care in the discharges sample and the deceased sample is significantly
different and we concur with the Dutch experience that the yield of AEs is greater in deceased patients but
that the distribution of events across the problem in care categories varies. This is a result, in part, of the
lower percentage of surgical procedures undertaken in this group but, in our experience, the relative
differences in the importance of infections, specifically the predominance of HAP in the deceased cohort, is
also very significant. Baines et al.67 concluded that mortality review is an efficient way of studying AEs, but
it is important to be aware that some events are underexposed and others are overexposed, and caution
should be applied if data generated are being used to inform programmes of quality improvement.
The assessment of the Harm2 tool and the practicalities of case
note review
The Harm2 tool was developed from tools in existence, but the key properties, along with an assessment of
its performance in routine use across NHS Wales, are outlined in Table 53. In summary, the Harm2 tool is a
condensed version of the Harvard method but can be operationalised pragmatically. It has a clear remit in
filling currently unmet need in clinical practice for a harm surveillance tool that is easy to use, has face validity
with clinicians and stakeholders, and can be used at the organisational and national level for both assurance
and organisational and professional learning purposes. The measurement outcomes are aligned with
international findings using the Harvard method and we report an acceptable level of inter-rater reliability.
Subject to a few minor changes to the tool, such as the replacement of the NCC MERP’s Categorizing
Medication Errors Index44 with the classification of severity from the MRF2 and the removal of components
such as the Charlson Comorbidity Index (which are of ongoing value only in a large national study such as
this), the tool is ready for application in clinical practice. The Harm2 tool has a non-time-limited approach to
case note review as this facilitates deeper understanding of the circumstances surrounding the AE and robust
assessment of its presence, preventability and impact both on the patient and on the organisation.
The Harm2 review teams and training
The Harm2 tool is pragmatic and the non-physician reviewers found it straightforward to use in this
research setting. Our reviewers were nurses conversant with research methodology and experienced in
data retrieval from inpatient records. This had obvious advantages within this study setting but with
training on the principles of AE identification and the assessment of preventability and categorisation,
it is a process that could be undertaken effectively by experienced nurses from a clinical practice setting.
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TABLE 53 Key characteristics of the Harm2 tool
Characteristic assessed Key points arising from assessment
Aim The aim of Harm2 was to develop a tool to measure harm in health care that was aligned in
definitions and epidemiological end points to previous studies, thus facilitating benchmarking
both in the monitoring of trends within an organisation over time and with other studies
reporting AE rates nationally
Principles of design A review of existing measurement tools for AEs was undertaken and triangulated with
experiential knowledge of how these tools actually work in practice, along with an assessment
of data outputs with their relative strengths and limitations
Item selection and
instrument development
All core elements of the tool were taken from one of three tools: the GTT, the Harvard method
(elements of both had previously been psychometrically tested) and the PRISM tool. Other
additions to Harm2 in phase 2 were included purely for research purposes and this included
the Charlson Comorbidity Index and a measure of avoidable mortality
The tool was constructed so it followed a logical flow of demographic and clinical information,
identification of the AE, assessment of the preventability and severity of the AE, the identification
of contributory factors, points for organisational learning and assessment of overall quality of care
Criterion validity We compared the outcomes of the Harm2 tool with phase 1 outcomes
The percentage of service users with AEs identified was 10.3% (95% CI 9.4% to 11.2%) using
the Harvard method and 11.3% (95% CI 10.22% to 12.40%) using the Harm2 tool
There is no gold standard measure of AEs that we can correlate our findings with. Few studies
have assessed criterion-related validity and, when they do, they propose implicit professional
judgement, such as overall assessment of quality of care. Lower overall assessments of quality
of care were associated with preventable AEs in both the Harvard and Harm2 data sets
Construct validity AEs identified using the Harm2 tool were associated with a number of factors and patient
variables that conform to theoretical and construct expectations. AEs increase with age and
are associated with increased LOS and readmissions, are different in medical and surgical
specialties and are more common in patients who die in inpatient settings
External validity The perceived benefit by stakeholders of the measurement structure in Harm2 was its alignment
with previous UK studies such as those undertaken by Sari et al.16 and Vincent et al.14 in England
and other national studies such as the Dutch and Spanish AEs studies. The common end points
and measurement structure used in Harm2 will make outcomes reported familiar to the quality
improvement community internationally
Reliability The inter-rater reliability of the Harm2 tool was 0.50 (95% CI 0.38 to 0.65), with agreement
being achieved in 88.4% of cases, and the intermethod reliability was 0.45 (95% CI 0.07 to
0.62), with agreement reached in 78.4% of cases
The Harm2 tool in this setting performed as well as the GTT and Harvard method previously
reported in a wide variety of settings
Errors of measurement The percentage of AEs detected is very dependent on the robustness of the sampling strategy,
which influences outcomes
The NCC MERP’s Categorizing Medication Errors Index44 did not provide the granularity
required to fully assess the impact of AEs on patient populations
Instrument data
preparation
Data entry is timely and simple and datasheets generated are easily manipulated and analysed.
Codes were applied to data fields for entry into an Microsoft Excel spreadsheet
Availability Feedback from organisational leads indicates that the feedback mechanisms need to be honed
but the notion of organisational signatures were universally welcomed. One area for future
development includes the further in-depth study of preventable AEs at individual study sites
improving the face validity of information being reported on. There is scope to further develop
summary data from Harm2, including the separate reporting of AEs that were preventable in
nature and resulted in significant clinical impact to the patient
Interpretation of data
collected
Both organisational percentages of harm and the flagging of case notes for further
investigations were well received. Furthermore, organisations like to see their percentage of
harm events in relation to a national average as some kind of assurance mechanism
Clinical usefulness Data on AEs that are directly related to clinical care will increase the likelihood of continued
measurement and monitoring of patient outcomes, which can lead to the prioritisation of
quality improvement targets and professional development activity both organisationally and
nationally
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In our study, we found it possible for four nurses to undertake a sample of 20 reviews in one afternoon
or morning, which has realistic resource implications. In addition, the Harm2 form takes between 5 and
15 minutes to input, and 1 month’s worth of data can therefore be entered into the organisational data
repository in 5 hours. Harm2 is less resource-intensive than GTT reviews as per the IHI recommendations,
which require two independent reviewers per case note review.
Table 54 outlines an indicative estimate of the cost to run a harm-monitoring programme using the
Harm2 tool in an individual organisation. The time allocation in the example has doubled from what our
experienced reviewers were able to complete within their allocated schedule and allows for training time
and discussion in the early phases of implementation.
The basic staffing resources required without on-costs for a routine surveillance programme at an
organisational level will run at around £8000 if completely nurse led but could rise to £20,000 per annum
if on-costs and consultant time to confirm complex AEs and respond to any clinical queries are included.
This equates to around 0.5 whole-time equivalent of a band 7 nurse per organisation, per year. The NHS is
well resourced with patient safety advocates and experts and, whether used as continuous surveillance or
periodic monitoring, the Harm2 process is one that NHS organisations can prioritise, adopt and integrate
into their patient safety and quality activity.
The training methods we employed included both didactic teaching and experiential learning and this is an
approach that worked well in our context. Novice reviewers gained from being paired with experienced
reviewers. Once teams were undertaking reviews in practice, peer supervision was an invaluable process.
Expert reviewers are not ‘taught’, but learn through experience and the experience of their colleagues.
Our phase 1 and 2 reviewer cohort benefited from a collegial approach and the bringing together of the
regional teams on a regular basis promoted learning and development. We had a reasonably stable
reviewer workforce and most found it a challenging, interesting and enjoyable experience over the 4 years
of active data collection. If this work is undertaken routinely within an organisation, we strongly advocate
stability within the case note review teams, as experience will improve reliability and highlight patterns and
trends over time which will highlight local learning, which in turn will drive improvement. A team approach
within organisations is recommended as it is more sustainable and reliable given the intense, reflective
and emotionally draining nature of the task.
The importance of a robust sampling strategy
Other important points of learning arise from our data. First, understanding the context and sample from
which AEs are identified and subsequently quantified is essential. Reviewing notes from convenience
samples in medical records departments will influence the breakdown of problems in care significantly and
the number of AEs detected. Our sampling strategy of 20 records per month was adequate for surveillance
purposes but, if new to the practice, organisations may wish to frontload more reviews early on, to
TABLE 54 Estimate of resources required to implement Harm2 within an organisation
Resource required
Cost (£)
Per month Per annum
Two band 7 nurses costed at top of scale to complete 20 reviews and all relevant
documentation over a 2-day period
465 5586
Administrative support costed at the top of band 2 for pulling and filing notes for 2 days a
month
102 1214
Optional support in the preparation of notes for review and data entry 102 1214
Total nurse and administration time 669 8014
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generate an initial signatures of harm within their organisations. It is possible to begin to observe trends
and patterns and develop an initial harm signature within 200 reviews.
Second, the sampling strategy we employed taken from the IHI GTT methodology is one that meets the
need of organisational learning and monitoring but may lack the generalisability found in other sampling
methods. Smaller samples generated from individual hospitals can appear to be outliers in terms of their
AE rate and caution is needed when interpreting reported rates in any assessment of organisational quality
or safety. Hospital comparison may be possible if (1) the samples are truly random and (2) the surveillance
of AEs is undertaken longitudinally and the sample size increases over time. Attention, however, may be
more appropriately directed to the organisation’s response to AEs rather than crude AE rates. This shifts
the focus to the information generated from the process to highlight areas of clinical or management
concern that can be addressed through local programmes of quality improvement with subsequent
follow-up and monitoring of challenging or problem areas.
The development of data outputs
The organisational reports that we developed had a mixed reception in practice but the concept of pie charts
showing graphically where harm is occurring within organisations is attractive and can be used regularly in
committees and boards to promote discussion and assessment. Reasons for the different perceptions of data
outputs varied. As the data were cumulative, the small numbers at the outset discouraged recipients from
sharing the outputs and this seemed to become a pattern that did not change as the numbers grew, which
may indicate that regular incremental feedback has less impact than final results.
For some, the information we provided did not provide the granularity of information necessary to focus
on AEs that (1) were flagged as preventable and (2) had the greatest impact on patients. Furthermore,
because this was an external process, organisations had to re-pull the notes to generate any learning or
triangulate with other patient safety data, factors that clearly depended on organisational resource and
commitment to follow-up. If such a methodology were undertaken within the service, these issues would
not arise, as points of learning or concern would be fed directly into the clinical governance structures at
the time the reviews were being undertaken. Similarly, data would be organised and summarised to meet
the ongoing needs of the organisation. Signatures of harm accompanied by examples of narrative
describing the episode of care could be an effective mechanism in raising awareness of the problems
encountered by patients within individual organisation. Similarly, reviewers often find examples of excellent
care and identify when patient pathways or teams are working well and this could be a mechanism
through which best practice can be identified, celebrated and spread at the organisational level.
The importance of preventability
We consider the robust assessment of preventability to be important, and the clinicians and managers
within Welsh health boards find it even more important. If potential targets for improvement cannot be
identified and interventions proposed with potential short- to medium-term impact, there is little to be
gained in undertaking routine labour-intensive review of inpatient episodes of care. Aranaz-Andrés et al.38
report that the measures of frequency, severity, impact and preventability are the most efficient strategies
to inform improvement, in order to improve the safety of care for patients. To engage clinical teams and
managers in the process of quality improvement, it is important that AEs identified have face validity in
order to identify opportunities to mitigate impact in patients. While we recommend that all AEs are
recorded as every patient injury or complication is important, further organisational breakdown of those
with high levels of preventability will ensure the identification of areas in which targeted action and active
monitoring may lead to short-term gains in patient safety work.
The record of inpatient care
The condition and organisation of case notes was found to be almost universally poor across NHS Wales.
One organisation had already addressed this internally prior to the study and had significantly better
records of care than the other health boards in Wales. Organisations are transitioning to digital records,
which also posed challenges to external reviewers when these electronic files could not be manipulated
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and searched, or when timely information was not to hand, to review and assess care. The implications
for health boards are significant and if external reviewers cannot undertake comprehensive assessment
of care there is a risk of attendant clinical harm to patients. As work on the quality and organisation of
medical records needs to be a national-level priority, in the shorter term case note review processes can be
facilitated by an administrative assistant who organises the notes prior to the review session. Administrative
staff can, in addition, populate fields of the Harm2 form ahead of the review session so that the reviewer
starts completing the form at the stage of harm screening and determination, thereby increasing the
efficiency of the process.
Implications for practice
Despite growing awareness of patient safety issues across NHS health-care systems and internationally,
there is little evidence of a commitment to the monitoring of patient safety outcomes. The NHS is heavily
dependent on voluntary reporting of unspecified patient safety incidents into a system that is characteristically
flawed by design, by under-reporting and by its inability to generate data to drive patient safety.78 We have
demonstrated that organisations can introduce into their patient safety measures a monitoring tool that will,
over time, provide a level of organisational assurance, giving summary estimates of current risk to specific
inpatient populations. This monitoring, whether undertaken monthly or periodically, is both inexpensive and
efficient. As an example, the cost of treating a pressure ulcer varies from £1214 (category 1) to £14,108
(category 4)79 and the median cost of managing a surgical wound infection in an English hospital is £5239.80
A very modest reduction in these AEs will make such monitoring cost neutral.
The Harm2 tool is not complex and with the research elements such as the Charlson Comorbidity Index
removed, it is a logical and easy tool to use. When training Harm2 reviewers, they reported that the
determination of AEs was easier when guided through the form to consider issues such as where did the
event take place, what was the level of preventability and what were the contributory factors and points
of learning for the organisation or health-care providers. What is very clear is that perception of both
complexity and resources seem to be related to both organisations’ and individuals’ commitment to the
patient safety agenda. Some organisations used the study harm to investigate their own processes and
practices and were open to the role of academia in effectively measuring harm in the system. Others noted
that there is ‘no way on God’s earth we could get our staff to do it’, highlighting that no improvement
activity is without its challenges in implementation.
The implications for patient safety are clear; knowing both the percentage of inpatients experiencing an
AE and the proportional breakdown of the attendant identified ‘problems in care’ allows for crude
extrapolation of how big an issue is within a health-care system. This facilitates assessment of problems,
prioritisation of interventions and assessment of progress. Areas of risk deemed to be important can be
triangulated with other organisational data and an appraisal instigated of current monitoring and
intervention efforts. Harm2 offers an organisational response to common issues in practice that are
identified corporately, but when named, accountability for action both in terms of their assessment and
any required intervention can be distributed to relevant clinical areas and teams. In the longer term, it is
feasible that raising awareness of current organisational priorities for patient safety activity through the use
of harm signatures and effective organisational communication could improve reporting and increase the
learning generated from specified incidents, such as harm caused by hospital-acquired infections, inpatient
falls or failures in thromboprophylaxis.
Looking ahead: monitoring benefit and harm for patients and populations
Many countries, and Wales in particular, have made enormous progress in the last 20 years in developing
measures of clinical outcome and routinely monitoring those outcomes. In contrast, the measurement of
harm has been sporadic, inconsistent and has not achieved the same level of rigour. We have relied
instead on incident reporting systems, which, despite being valuable as safety warning systems, have
conclusively been shown to be completely inadequate as a measure of harm. The studies described here
DOI: 10.3310/hsdr05090 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 9
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mayor et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
have shown the potential value of ongoing systematic and rigorous evaluation of the harms of health care
alongside the many benefits. As one participant commented:
And please do more of it, because this sort of data to me is gold dust – it needs to get into the culture
of everything were doing and I’d really hope for harm studies to expand and maybe get to be a
routine part of the way that we are working. It’s been really useful from my personal perspective.
We believe that Wales, and indeed other countries, now need to consider how harm can be routinely
monitored within health-care systems. We appreciate that we cannot necessarily continue to carry out
record review on the same scale and with the same intensity as in the current studies. We do, however,
believe that an ongoing assessment of harm within health-care systems is absolutely essential, and in
Wales it would be relatively simple to devise. It would be relatively straightforward to devise a means of
continuing the current approach by sampling across the country on a regular basis. This would have
huge benefits for both local and national learning, for the prioritisation of safety programmes and for
monitoring change over time. Wales would become, if this was instituted, an immediate international
leader in patient safety. Over time this approach could evolve into a system in which both benefits and
harm were monitored within electronic medical records.
Harm in health care reflects an incomplete view of patient safety issues, and future studies would benefit
from setting measures of harm alongside measures of the beneficial effects of health care, first at the level
of populations and then, more ambitiously, for individual patients. Ultimately, the aspiration should be
to mirror our experience as patients and be able to reflect for any one individual the overall balance of
benefits and harms of health care and the accompanying experience for patients and families.10
Finally, this work would not have been possible without the input of many individuals in the WG, and the
many hospitals across Wales, which are committed to patient safety and the principles we promote to
identify risk in order to mitigate it. The operationalisation of a research study is, however, very different
from the operationalisation of an improvement programme. As significant development has been made on
the tools and methods of AE surveillance, there is significant work remaining on embedding processes in
practice and ensuring that data and narrative generated meet the service needs in individual journeys
of improvement.
Conclusions
Some health boards in Wales have been monitoring patient safety outcomes for the last decade using a
variety of tools. Working in collaboration with NHS Wales, we report percentages of AEs using the gold
standard Harvard methodology, which conforms to previous studies in a UK setting and national studies
undertaken in Sweden, Holland and Spain. We confirm the 1 in 10 finding of AEs in inpatient populations,
half of which are potentially amenable to intervention. If the occurrence of these common events
identified through case note review is crudely extrapolated across the total number of hospital discharges
in Wales per annum, they would equate to around 19,900 events relating to failures in clinical monitoring,
17,500 AEs resulting from failures in infection control, 12,650 events relating to problems with operations
and procedures, and 11,000 AEs relating to the administration of drugs, fluids or blood. Given the impact
of these common problems on patients, health-care professionals and service providers, there is much to
be gained from reducing their current levels.
There are groups of patients in whom the risk of AEs is greater than in the general inpatient population,
and these include older patients with physical and cognitive impairment as a result of pre-existing
diagnoses, such as dementia or PVD. AEs in these groups probably result from underlying physical and
cognitive impairment and comprise falls and pressure ulcers, with a smaller number of other events arising
from drug administration or reactions or hospital-acquired infection. The current assessment of risk in
these patients, compounded with failings in providing a safe inpatient environment, appears to predispose
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these patients to ward-based AEs. Our data suggest that these groups could be targeted in organisational
quality improvement efforts to improve the safety of the ward environment and thereby reduce the high
levels of AEs in vulnerable groups.
Both the Harvard and the IHI GTT use multidisciplinary teams involving nurses screening episodes of care
for AEs, before physicians confirm the presence of an AE. We have demonstrated that with training, which
in most cases did not exceed 2 days in duration, nurses can determine the presence of AEs that generate
findings that conform to other methods when this element of the case note review process is undertaken
by physicians.
Our data demonstrate consensus between professional groups on the determination of harm events in
around 80% of reviews undertaken. Differences are noted, however, and a number of AEs that clearly were
events were not deemed to be significant by the physician reviewers, and vice versa. This has important
implications for the composition of review teams and we suggest that, although experienced nurses with
administrative support can undertake the majority of the review process, the presence of a physician in a
review team will bring clinical expertise and a more holistic assessment of the health-care management
process and clinical aspects of care. AE determination involving a single professional group will lead to
underdetection of the spectrum of AEs commonly seen in clinical practice.
There were problems with both the GTT and Harvard methods of case note review when implemented
across Wales. The GTT under-reported AEs and the Harvard method is labour intensive in both review and
data management time. We developed a nurse-led hybrid tool of the GTT pragmatic process and Harvard
methodology measurement structure, the Harm2 tool, which we implemented in six Welsh health boards.
The reported extent and nature of harm conform to phase 1 findings when the Harvard methodology was
used. The Harm2 tool performed with the same levels of moderate reliability as the GTT and Harvard
method in the determination of AEs/problems in care. Harm2 can be further streamlined without changing
measurement structure for routine implementation in clinical practice. A pragmatic approach with a robust
measurement structure offers the potential for routine monitoring of AEs in NHS organisations to offer both
organisational assurance, opportunities for learning and the identification of priorities for improvement.
We compared the rate and composition of AEs in two independent samples: a random sample of hospital
discharges and a random sample of inpatient deaths. The rate and composition of AEs in these groups are
significantly different and the composition of the sample in case note review examination will influence the
findings generated. Surgical events occur infrequently during final episodes of care, but infections are
common. We therefore report that AEs occur three times more frequently in patients who die in hospital
but they are different in nature from the AEs that occur in a random sample of inpatient discharges and,
furthermore, commonly occurring events, such as HAP, may be misclassified as AEs during the dying
process. Careful consideration must be given to desired measurement end points and what the data
generated are intended to inform before samples are drawn for case review studies. AEs occurring in
patients who die in hospital are not representative of AEs occurring in 98% of the inpatient population
who are discharged from acute care. We report that AEs arising from surgical and other invasive
procedures are significantly under-represented and this group may not be an appropriate inpatient
population to inform quality improvement priorities.
A harm-monitoring or surveillance programme can be realised in NHS settings with modest resources and
will provide reliable estimates of the extent and nature of AEs either periodically or longitudinally. In
addition, from data generated from the screening component of the Harm2 process, we have developed
simple visual methods in the form of signatures of Harm to profile the origin of harm events at the
organisational level. Harm signatures, when tested with organisations, have face validity and confirmed
organisational priorities for improvement. Furthermore, they can be used to prompt assessment,
intervention and ongoing monitoring over time, enhancing the breath of information generated through
the quantification of AEs found.
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Reviewing the record of care generates a rich source of information on how clinical managerial and
organisational processes may impact on patient outcomes. They are, however, an imperfect source of data
and the difficulties faced by reviewers in navigating and finding information in case notes highlights the
difficulties that may be encountered in navigating them in clinical practice. The written record of care
needs to be an improvement priority across NHS Wales.
Future work
The concept of risk signatures is developmental but promising. Public Health Wales intends to provide
support to Welsh health boards in order to understand patient safety issues at the organisational level
through risk signatures, and an in-depth evaluation of this approach is warranted. Formal testing of their
alignment with other patient safety data, such as incident reports and current improvement efforts, will
provide a level of validation and an assessment of their utility in quantifying ongoing risk or progress made
over time.
Our experience of three harm identification and measurement tools in Wales suggests that the
determination of preventable harm is challenging for reviewers and may reflect the current definitions in
use, which are not theoretically underpinned and do not consider the causal mechanisms through which
AEs occur. This limits the direct clinical applicability of the quantification of AEs in health care and work is
needed to explore the issue of preventable harm aiming to provide guidance and a more theoretically
underpinned classification system. Drilling beneath headline rates to understand the how and the why of
commonly occurring AEs could significantly improve our understanding of how to use harm and mortality
data to prioritise where efforts are best targeted to realise quantifiable improvements in patient and
organisational outcomes.
Future large-scale studies should attempt to specify in advance at least a large percentage of specific types
of AEs, which should enable more precise tracking of both specific types of harm and the overall level of
AEs. This will never be a complete solution, as there will always be problems that are rare or elude precise
definition and that will require a generic ‘other’ category.
There are areas of clinical practice that have not benefited from the range of quality improvement
initiatives and patient safety work seen in the general inpatient population. These include child health,
maternity services and mental health, yet much of the risk described through the Harm2 tool is pertinent
to these population groups. Small-scale studies are needed to test the utility of this approach within
these specific patient groups and to ensure inclusion, rather than exclusion, as is currently the case, from
patient safety monitoring.
Iatrogenic injury is challenging for health-care organisations, staff, patients and their families and carers
and there is a paucity of information on how organisations respond to the emotional and psychological
impact in their aftermath. With calls for increased openness and candour and national policy on ‘Putting
Things Right’ for patients, there is a need to assess how these systems currently operate and what support
patients and their extended families articulate as being needed, mapped against what they were offered
during the period following a preventable AE.
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Appendix 1 Modular review form: doctor
assessment of harm from the Harvard method
Reproduced from Case record review of adverse events: a new approach, Woloshynowych M, Neale G,Vincent C, vol. 12, pp. 411–15, 2003, with permission from BMJ Publishing Group Ltd.30
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Appendix 2 Review form 1
MEASURING HARM AND INFORMING QUALITY IMPROVEMENT 
LONGITUDINALLY IN THE WELSH NHS 
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Appendix 3 Overlap in the identification of
adverse events using different tools and methods
In 3504 matched GTT and two-stage retrospective review cases, the nursing cohort identified 617 AEs,of which 341 were subsequently confirmed as AEs in the physician review. In the same records, the
GTT identified 294 events through the NHS-led process, of which 153 were not identified through
the two-stage retrospective review process (Figure 37). There is no direct overlap between MRF2- and
GTT-identified AEs, as MRF2 assessment is not an independent process from the RF1 process.
On review of the 153 AEs picked up by the GTT and not the Harvard method, we determined that around
15 AEs could have been missed by the Harvard method, but the remainder of the events were accident
and emergency department misclassifications mainly arising from multiple triggers being classified as
multiple AEs.
n = 95
GTT
n = 153
RF1
n = 230
MRF2
n = 46
n = 246
FIGURE 37 The overlap between the identification of inpatient harm using the RF1, MRF2 and GTT as
measurement tools.
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Appendix 4 Global Trigger Tool triggers
Reproduced with permission from Global Trigger Tool How to Guide.81
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Appendix 5 Failures in care and their association
with readmissions across NHS Wales
TABLE 55 A summary of the derived themes under ‘failure of care’ with an associated definition and example
Theme Definition of theme Example from data
Failure of care
Diagnosis
l Delayed diagnosis
l Misdiagnosis
A diagnosis that was not made on the
index admission therefore resulting in
repeated readmissions with the same or
similar symptoms
Pneumothorax missed during two
previous admissions
An incorrect diagnosis made on the
index admission which resulted in a
readmission with the same or similar
symptoms
Patient admitted via fracture clinic . . .
diagnosed with arthritis as per X-ray . . .
readmitted and diagnosis changed to
a fracture
Ineffective symptom
management
l Pain
l Cardiorespiratory
l Neurological
l Gastroenterology
l Genitourinary
l Orthopaedics
The management of symptoms that
was not performed adequately on a
previous admission therefore resulting
in a readmission
Admitted with acute exacerbation of
COPD . . . frequent admissions pre and post
this episode . . . ‘there appears to be no
cohesive management in place’
Drug toxicity Symptoms that arise because of the
patient falling outside the advised drug
therapeutic index therefore requiring a
readmission
69-year-old patient with AF on warfarin
admitted on two occasions with epistaxis
Communication Breakdown in communication between
health professionals which contributed
to a patient readmission
Patient transferred between hospitals . . .
‘no documents regarding this admission in the
medical records’
Falls outside the hospital A patient known to be susceptible to
falls who is readmitted after a further fall
Patient admitted on three occasions suffering
several falls at home, resulting in dislocations
and fractures after undergoing a total
hip replacement
Post operative
l Infection
l Bleeding
l Pulmonary embolism
l Pain
l Faecal leakage
Complications that occur following
surgery which result in a readmission
Patient underwent a laparotomy during index
admission . . . 4 weeks later they were
readmitted with breathlessness, right calf
swelling and hypotension . . . ECHO revealed a
massive pulmonary embolism
Prolonged waiting times A readmission while waiting for a
procedure or outpatient appointment
Numerous admissions in the past 12 months
for recurrent vomiting while awaiting input
from another hospital appointment
Social care inadequacy Social care package that is inadequate
for the patient resulting in a readmission
Patient admitted with basal pneumonia and
confusion . . . discharge with care package . . .
readmitted 2 months later with deterioration
in confusion
Hospital-acquired infection A readmission because of an infection
that presented post discharge from the
index admission
Patient admitted with general deterioration
. . . treated for hospital-acquired infection as a
result of his recent discharge the day before
continued
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TABLE 55 A summary of the derived themes under ‘failure of care’ with an associated definition
and example (continued )
Theme Definition of theme Example from data
Premature discharge
l Up to 24 hours before
readmission
l 24–48 hours before
readmission
Discharging the patient when their
symptoms had not been managed
adequately therefore resulting in a
readmission with the same or similar
symptoms
Patient had been admitted at 00:45 with
diarrhoea and vomiting and was discharged
by 10:00 . . . subsequently readmitted later
the same day with recurring symptoms
AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; ECHO, echocardiogram.
TABLE 56 A summary of chronic disease management and its association with readmissions and AEs across
NHS Wales
Theme Definition of theme Example from data
Nature of disease
Routine disease
management
A readmission that occurs because of
the natural management of a disease
Patient diagnosed with breast cancer required
further surgery owing to spread of cancer to
axillary lymph nodes
Unrelated to index
admission
A readmission that consisted of
different symptoms compared with the
index admission
Patient was admitted with a severe sore
throat and diagnosed with quinsy . . .
readmitted following a fractured ankle
Hospital transfer An unplanned readmission as a result
of the transfer of a patient to another
hospital
Patient admitted with chest pain and
transferred to another hospital for
an angiography
Patient factor Factors relating to the patient declining
the advised medical treatments or the
non-attendance of patients to booked
clinic appointments
Patient admitted with a fracture of the left
tibia but patient absconded . . . subsequently
readmitted owing to worsening pain but
self-discharged against medical advice
Procedural issue An issue relating to a procedure that
requires the patient to be readmitted at
a later date
Patient discharged after first per oesophageal
gastric tube failed to insert . . . readmitted
6 days later for a second attempt under
radiological guidance
Planned readmission Patients who have been readmitted as
planned in advance
Patient admitted from outpatient department
for gastric outlet obstruction and was
readmitted as planned for a blood transfusion
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Appendix 6 Summary of the derived themes
under criterion 18, other undesirable outcomes with
an associated definition and example
TABLE 57 A summary of the derived themes under ‘other undesirable outcome’ with an associated definition
and example
Theme Definition of theme Example from data
l Delayed treatment
l Resource constraints
l Staff shortages
l Staff clerking
Issues caused by staff shortages, and
those caused by delays in the process of
clerking, including delay in medication
prescribing and response by the on-call
team
30-year-old female. Laparoscopic
cholecystectomy. Operation cancelled in
anaesthetic room because of unavailable
equipment
Resource constraints include bed
availability, drugs and procedures, which
contributed to the experienced delays
either directly or because of cancellations
59-year-old male. Aspiration of infected knee.
Post-operative blood transfusion commenced
late because of shift staff shortage
80-year-old male. Admitted due to TIA.
Inappropriate referral to dermatology leading
to treatment delay
l Decisions
l Stigma
l Treatment
Issues related to the decision-making
process of health-care professionals
involved with the patient journey. The
majority of reports were inappropriate
decisions made relating to the treatment
or intervention the patient received
30-year-old male. Admitted for i.v. antibiotics.
History of i.v. drug abuse, clean for 5 months
in rehabilitation. Patient prescribed
Oramorph® (Boehringer Ingelheim, Bracknell,
UK) over methadone, the drug of choice for
patients in rehabilitation
21-year-old female. Admitted with pain and
diagnosed with appendicitis. Discharged
and treated conservatively with elective
appendectomy booked. Patient readmitted
three times before surgery was performed
Communication
l Verbal
communication
Ineffectual communication between
patient and professional, giving rise to the
potential for the behaviour of staff to
impact on psychological well-being,
as well as the health-care process
19-year-old female. Admitted with
anaphylaxis. Patient had been previously given
Epipen® (Mylan, Maidenhead) but stated they
had not been told how to use it properly
55-year-old female. Fractured ankle from fall,
required surgical fixation. Patient’s first
language is Polish, causing issues with
preoperative understanding but no formal
interpretation was sought
l Written
communication
Problems in the documented word that
included insufficient records, discrepancies
between notes, and notes that were
missing
85-year-old male. Admitted after 2 days of
vomiting, history of bowel cancer. Cardiac
arrest on third day of admission, unable to
resuscitate. No medical notes written during
admission until arrest. Lack of observations on
chart and missing blood test results. No
documented referral to acute care team
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TABLE 57 A summary of the derived themes under ‘other undesirable outcome’ with an associated definition
and example (continued )
Theme Definition of theme Example from data
l Failure of follow-up Problem in the organisation and
facilitation of further assessment or
treatment
35-year-old male. Seen in clinic after acute
admission of abdominal pain. Prescribed
steroids and urgent follow-up requested.
Patient never received urgent colonoscopy
and remained on steroids and not monitored
for 11 months. Was then admitted with
acute pancreatitis
l Missed or delayed
diagnosis
Issues arising as a result of insufficient
investigations being carried out or by
submitting patients to unnecessary
treatments or interventions
47-year-old male. Admitted with sore throat.
Diagnosed with lower respiratory tract
infection. Patient became septic during
second week of admission and neck abscess
found. Correct diagnosis took 9 days to
be identified
60-year-old female. Admitted with sepsis,
pain, diarrhoea and vomiting. Had been
discharged recently with treatment for
atypical flu. Further investigations found pelvic
abscess. Correct diagnosis missed during
first admission
TIA, transient ischaemic attack.
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Appendix 7 Harm2 tool
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Appendix 8 Example of the description used for
screening criteria in the Harm2 manual
Definition: an infection is considered to be hospital acquired once the patient has been in hospital for72 hours or more. The evidence of infection may be clinical (local or systemic evidence) or combined
with a positive microbiological culture.
Exceptions: infections acquired prior to admission to hospital unrelated to health-care management, for
example a patient admitted with a chest infection with no previous health-care intervention.
Discussion and data retrieval: for patients admitted with infections check for evidence of prior health-care
management and where infection may have been acquired; for example, a patient transferred from one
hospital to another for ongoing management of a wound infection acquired during hospitalisation should be
recorded as YES.
For infections manifesting themselves 72 hours post admission, check for evidence of an invasive
procedure. Note any breeches in asepsis or any other potential infection risks a patient may be exposed to.
Note if antibiotic prophylaxis is used in prosthetic surgery and look for delays in diagnosis and treatment of
infections. The reviewer needs to look at the microbiology reports and the corresponding dates in the
progress notes to identify both clinical and laboratory evidence of infection. What to look for as
confirmation of infections:
1. Urine microbiological reports; look at the white cell count (WCC) for clues of contamination versus
infection. A WCC of > 100 suggests infection. Epithelial cells > 100 suggests a high probability of
contamination. Positive nitrates suggest possible infection. Therefore, the following are all good
indications of infection:
i. WCC > 100
ii. epithelial cells < 10
iii. nitrates positive.
More than three organisms cultured generally indicates a contaminated specimen. Wound infections
will have:
Clinical evidence (i.e. redness, discharge, etc).
Systemic evidence (i.e. fever of > 38 °C for more than 2 days following a procedure and an increased WCC
with a positive wound culture reported as microbiological evidence).
Other infections including blood, chest, etc. will appear with similar signs and symptoms and
microbiological confirmation. The reviewer should describe the event to include the date, the nature of the
infection and the treatment.
Examples: wound infection and elective admission for cardiac surgery. Postoperatively the patient’s sternal
wound developed an infection requiring return to theatre for debridement and resuturing.
Hospital-acquired pneumonia: elective admission with mutilating rheumatoid arthritis. Treated with
antibiotics and epoprostenol infusion. Wounds redressed. Reviewed by registrar prior to discharge and
noted to be hypotensive 94/50. Stat gelofusion given i.v. Last entry in nursing notes 23 March 2011.
Doctor’s notes confirm patient discharged same day. Patient readmitted 26 March 2011; diagnosed
with HAP.
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Clostridium difficile: patient on chemotherapy. Hospital admission with fever and diagnosed with
neutropenic sepsis. Also complained of diarrhoea and diagnosed with Clostridium difficile from inpatient
stool sample. Treated with antibiotic therapy and chemotherapy treatment suspended temporarily.
Sepsis: admitted for Hartmann’s procedure for cancer. A week later became septic (pelvic collection and
pneumonia) and had a cardiac arrest. Went to ITU for 3 days. Monitoring in atrial fibrillation (AF) – treated
with amiodarone. Also chronic cardiac failure exacerbation. Treated with i.v. antibiotics. Poor glycaemic
control. Transferred to community hospital.
Other: developed norovirus while on the ward. Ward was closed due to norovirus infection.
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Appendix 9 Examples of Harm2 adverse events
falling into the NCC MERP’s Categorizing Medication
Errors Index in the randomly selected discharge
reviews
TABLE 58 Examples of Harm2 AEs falling into the NCC MERP’s Categorizing Medication Errors Index in the
randomly selected discharge reviews
Severity code Summative overview of episode of care
E Patient admitted for a suspected DVT 2 weeks after discharge for total left hip replacement. DVT
confirmed and warfarin started. Referred to OT physiotherapy and INR clinic prior to discharge. There
was a delay in DVT confirmation, 4 days, because no one was available to perform Doppler. Previous
admission for THR appeared uneventful and patient discharged on rivaroxaban, DVT was noted as a risk
on consent form
Elective admission for right total knee replacement. Uneventful procedure, but patient experiencing
nausea, vomiting and poor pain control postoperatively. Treated for dehydration and suspected HAP
following an episode of tachypnoea, pyrexia and raised heart rate on postoperative day 2. Continued to
feel unwell and diagnosed with withdrawal from gabapentin on postoperative day 3 (drug had been
omitted since surgery and patient usually takes high dose). Gabapentin re-introduced prior to discharge
F 82-year old female admitted with sudden-onset dysphasia. Known to have AF previously. In 2012
was started on bisoprolol for rate control. Documented in notes previously that ‘may need warfarin’;
however, on discharge says ‘no follow-up’, so limited information on why patient not anticoagulated
and noted on most recent admission. SHO discussed with GP whether patient had been on warfarin in
the past but no record of this either. Diagnosed with PAF and prescribed rivaroxaban on discharge
Acute admission owing to 6-week history of vomiting and nausea. Bloods revealed acute kidney injury
and hypernatraemia
l Event 1 – vomiting was thought to be due to the opioid she was given following a right
humerus fracture
l Event 2 – she was also diagnosed with SIADH due to hypernatremia because of medications.
Medications (bendroflumethiazide and omeprazole stopped and ramipril reduced). Renal function
and sodium improved
l Event 3 – started on amlodipine, but felt unwell after taking amlodipine – stopped
l Event 4 – developed bronchitis while admitted, treated with salbutamol became ‘shakey’ and
tachycardic (pulse 124 b.p.m.), reviewed by doctor, treatment stopped
G Patient admitted with exacerbation of COPD and pneumonia. GP had commenced antibiotics, but
patient was yet to start them. When in A&E it was decided to commence patient on urgent BIPAP.
Taken to ITU and intubated, NG feed commenced and i.v. antibiotics given. Once extubated patient
did well, repeat chest radiography showed an improvement in consolidation. Seen by respiratory nurse
and commenced on Tosca transcutaneous monitor (Radiometer, Bronshoj, Denmark). Discharged home
once improved with repeat radiographs and follow-up. Lung cancer diagnosis made within weeks of
discharge
This 94-year-old, who was normally very fit (with no significant previous medical history) was admitted
generally weak and unwell and aching. Mobility poor and completely lethargic. She had not responded
to a 7-day care course of steroids (prednisolone). Suffered a fall (slip) backwards on day 3 of admission
at the bedside and suffered a head wound. Incident report form completed and family informed of fall.
Deteriorated from this point and transferred to rehabilitation. No ECG or CT scan of chest, abdomen
and pelvis had been ordered despite earlier reference to these being awaited. Subsequently had a
vasovagal episode while mobilising, no actual LOC. Also complaining of mild supra pubic discomfort.
CT ordered and mention of DNCPR decision in notes. Four days later, CT completed, evidence of
retroperitoneal lymphoma, with gas in abdomen from unidentified site. Not for surgical intervention –
deterioration over next few days and passed away peacefully
continued
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TABLE 58 Examples of Harm2 AEs falling into the NCC MERP’s Categorizing Medication Errors Index in the
randomly selected discharge reviews (continued )
Severity code Summative overview of episode of care
H This patient was admitted from A&E with a history of recently being discharged from ** where he had
a right hip replacement. Following this he had a cardiac arrest due to increased potassium levels and
also needed temporary pacing wires because of ventricular standstill. He also had a history of weight
loss and indigestion pain and since going home has been experiencing coughing and increasing
shortness of breath and chest pain. On admission, ECG left bundle branch block referred to cardiology
and sent to CCU. Echocardiography showed pleural effusion secondary to chest infection. Patient put
on i.v. antibiotics. Pericardial effusion not drained initially because of infection. Patient in and out of AF
during admission and treated appropriately. Temperature kept increasing therefore blood cultures were
taken and another set of antibiotics started. CT also showed pericardial effusion. Chest drain inserted
later as patient increased shortness of breath drained and then removed then transferred to ** ward
then home 4 days later
86-year old lady with dementia and recurrent UTIs admitted with fractured femur having fallen at
home. She underwent a left hemiarthroplasty in theatre. Recovery was slow postoperatively, although
the surgery was successful she was found to be unresponsive on the commode 5 days post operation.
The arrest team was called and she made full recovery. This was thought to be because of dehydration
and low HB for which she was already receiving i.v. fluids and blood transfusion. She fell in the ward
while trying to mobilise without assistance. She developed a rash secondary to her antibiotic, which
then cleared when antibiotic was discontinued. It was noted that her mental capacity had deteriorated
considerably and she was eventually discharged to a nursing home once medically fit, but was deemed
as lacking capacity
I Admitted from home via A&E h/o collapse and severe pain. Analgesia, fluids and i.v. antibiotics
administered. CT undertaken. Catheterised. ECG. Transferred to theatre – ruptured right iliac aneurysm
and small AAA. Transferred to ITU. Sedated and ventilated. Day 4/7 faecal matter aspirated from
mouth. NG replaced remains on dialysis. Left leg ischaemic. Hypotensive. Returned to theatre on day 9
of the hospitalisation as a result of a nick/suture during AAA repair procedure. Gross faecal peritonitis.
Remained hypotensive. RIP
Patient elective admission for gastrojejunostomy because of duodenal lesion, background of chronic
pancreatitis due to alcoholism. Found not malignant but chronic inflammation patient suddenly
deteriorated on admission because of arterial embolus, likely cause was poor management of CVP line.
Booked for elective surgery but unable to have as ITU full. Readmitted for surgery, but patient died
when waiting for surgery
A&E, accident and emergency department; AAA, abdominal aortic aneurysm; BIPAP, bilevel positive airway pressure;
b.p.m., beats per minute; CCU, coronary care unit; COPD, chronic obstructive pulmonary disease; CT, computerised
tomography; CVP, central venous pressure; DNCPR, do not cardiopulmonary resuscitation; ECG, electrocardiogram;
HB, haemoglobin; h/o, history of; INR, international normalised ratio; LOC, loss of consciousness; NG, nasogastric;
PAF, paroxysmal atrial fibrillation; OT, occupational therapy; RIP, rest in peace; SHO, senior house officer; SIADH, syndrome
of inappropriate antidiuretics hormone secretion; THR, total hip replacement; UTI, urinary tract infection.
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Appendix 10 Examples of Harm2 adverse events
falling into the NCC MERP’s Categorizing Medication
Errors Index in the randomly selected deceased
patient reviews
TABLE 59 Examples of Harm2 AEs falling into the NCC MERP’s Categorizing Medication Errors Index in the
randomly selected deceased patient reviews
Severity code Summative overview of episode of care
E Patient admitted to frail elderly care unit from A&E. Short history of confusion and out of character
behaviour with agitation and delusional ideas. Wife, unable to cope or manage him at home. Seen by GP
previous day and prescribed trimethoprim for possible UTI. Patient previously well and independent prior to
admission. Documented to have high alcohol intake and history of DVTs, AF and MI. On warfarin. Nursing
notes only in this record. Patient nursed 1 : 1 and 2 : 1 because of aggression and unpredictable behaviour.
Incident recorded where patient complained of being restrained by his carers, which caused bruising. This
incident was investigated pending medical assessment of bruising – outcome not recorded. Patient had CVA
during day 2 of admission. Treated conservatively – residual left-sided weakness and slurred speech. Patient
had witnessed cardiac arrest on ninth day of inpatient stay and died following failed attempt at CPR
Acute admission recent discharge from hospital with history of TIAs. Since previous admission, son had been
living with mother in flat. This admission found unresponsive and ongoing UTI and urosepsis diagnosed but
was on trimethoprim on admission and so not hospital acquired. Decreased mobility. Discharge planning
was evident throughout but patient’s condition deteriorated – became weaker and decrease in appetite,
confused, decrease in health. DNR form completed. Passed away. Pressure sore on heel noted – hospital
acquired
F Readmission from home (inpatient due to chest infection 7 days previously). Found by neighbours who
raised alarm and patient found to be unresponsive. Consciousness level decreased and patient developed
dense hemiplegia while under observation in A&E department. Diagnosed with CVA but chest infection
not ruled out as possible cause for symptoms. Treated with i.v. antibiotics but failed to improve from
respiratory and neurological point of view. Supportive care provided up until patient’s death. Decision
made for no active treatment (ventilation or CPR in event of patient’s demise) with family members. Drug
error with insulin infusion occurred during patient’s stay, which was not reported to one consultant or the
coroner until death certificate issued but coroner was satisfied this did not directly contribute to death
94-year-old lady with dementia and learning difficulties admitted from care home with dehydration and
urosepsis. Pressure sore prevalent on admission – patient seen by tissue viability team. Patient treated with i.v.
antibiotics – cannula tissued many times and patient developed cellulitis. Patient treated with sliding scale to
control blood sugar and i.v. fluids. Patient became oedematous +++ before i.v. fluids stopped. Missed i.v.
drug administration due to ward pressures/demands. Patient S/B dental service and radiograph requested –
but not performed? Why? Minimal oral diet and fluid intake throughout admission – no evidence of dietitian
input. Patient’s condition deteriorated during admission. Patient failed to respond to i.v. antibiotics. Patient
commenced on all-Wales integrate care priorities for the last days of life
G Patient with numerous comorbidities attending hospital for routine dialysis appointment. Sustained a fall
in a car park, found by staff with fractured hip and required transfer to A&E. Hip arthroplasty performed
that night under care of orthopaedics. Following successful surgery patient had an episode of coffee
ground vomit. Refused OGD investigations in spite of warning of seriousness. Remained an inpatient for
several weeks, attended for dialysis appointments but generally non-compliant with nursing and medical
care including pressure area care and mobility. Developed pressure sores in spite of appropriate
assessment and intervention by tissue viability service attempts. Required wound debridement and
continued to deteriorate and developed wound infections and chest infections. Treated with antibiotics
and continued to refuse nursing care, nutritional support and medication. Discussion with family and
decision made not to escalate care. Died on ward
This review involved the death of a 52-year-old woman from documented cervical cancer and metastases
of bone, liver and lung. The care she received during the final inpatient episode was excellent; however,
her initial diagnosis was delayed by 5 months because her referral did not reach the obs and gynae team
here at the HB. It is important to state the consequences of this delayed diagnosis, as she was symptomatic
on presentation to the GP
continued
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TABLE 59 Examples of Harm2 AEs falling into the NCC MERP’s Categorizing Medication Errors Index in the
randomly selected deceased patient reviews (continued )
Severity code Summative overview of episode of care
H Complicated case of an 87-year-old with RA and HF being admitted from a nursing home with a
fractured NOF. Initially due to poor underlying health status was poor anaesthetic risk and treated
conservatively. Became septic from chest and prescribed Tazocin® (Pfizer, New York City, NY, USA),
acknowledging C. diff risk. Became C. diff positive and treated with metronidazole. Condition improved
and hemiarthroplasty performed – risk considered, P.POSSUM risk score calculated and mortality was
40–46% and morbidity was 92–3%. The family was aware. Complicated postoperative period with two
further episodes of sepsis and sub-acute obstruction. Notes are chaotic and difficult story to follow, but
mortality seemed to be an inevitable end point for this gentleman
Male with history of myelodysplasia. Had received first cycle of chemotherapy and discharged. Follow-up
arranged at local chemotherapy day unit 3/7 later. Acute admission via A&E following 999 call in the
early hours. Complaining of sudden temperature of 38 °C, PR bleeding and urinary frequency. Neutrophil
count, 0.0. Diagnosed with neutropenic sepsis, suspected diverticulitis and urinary retention. Platelets
low. Neutropenic sepsis regime initiated – i.v. fluids and i.v. antibiotics. Platelet transfusion and patient
catheterised. Admitted to medical/oncology ward. Patient very unwell – hypotensive, acidosis – transferred
to HDU later that day. Remains very unwell, exhausted and decision to incubate, also NG tube passed.
Medical team receiving advice from local haematologist and also haematology at XXXX. Clinically
continues to deteriorate – prognosis poor. Family aware of situation. Iatrogenic incident involving syringe
pump failure to deliver inotropic agent and patient arrested, patient chest radiography performed and no
rib fracture following chest compressions. Blood pressure became very variable – unstable requiring
intensive support but continues to deteriorate. Discussed with family – DNAR and d/w family again
regarding prognosis and possibly of withdrawing treatment. Blood pressure low, 50/33 mmHg, heart rate
50 b.p.m. Reviewed by clinicians. Decision made to withdraw treatment. Noradrenaline and adrenaline
discontinued. Patient appeared comfortable and died soon after
I This patient was admitted acutely with back pain following a fall. She had been assessed in **
immediately following the fall 5 days previously, radiograph showed no bony injury. Her mobility had
been decreasing following the first week of chemotherapy for Ca brain. She was admitted for pain
control. E.coli UTI diagnosed after 5 days as inpatient – treated with antibiotics. Became rapidly unwell
and pneumonia diagnosed following chest radiography. Patient’s relatives voiced concerns over care,
regarding pain relief and patient’s constipation not being addressed. Patient passed away following day
Recent excision of BCC × 3 to leg and SCC to arm. Two days post discharge from surgery banged leg
and wounds bled uncontrollably. Admitted and bleeding controlled. Wounds found to be infected.
Infection managed – reviewed by tissue viability and surgical team. Become anaemic and transfused
some blood. Patient initially responded well. Chose to remain in hospital as unable to cope at home.
Discharge to community hospital planned. Patient suddenly became unwell. HAP – deteriorated and died
within 2 days
A&E, accident and emergency department; BCC, basal cell carcinoma; b.p.m., beats per minute; Ca, carcinoma;
C. diff, Clostridium difficile; CPR, cardiopulmonary resuscitation; CVA, cerebrovascular accident; DNR, do not resuscitate;
d/w, discussed with; E. coli, Escherichia coli; HB, Health Board; HDU, high-dependency unit; HF, heart failure; NG, nasogastric;
NOF, neck of femur; obs and gynae, obstetrics and gynaecology; OGD, oesophagogastroduodenoscopy; PR, per rectal;
RA, rheumatoid arthritis; S/B, seen by; SCC, squamous cell carcinoma; TIA, transient ischaemic attack; UTI, urinary tract
infection.
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Appendix 11 Examples of adverse events
identified through the Harm2 tool at different points
in the process of care
TABLE 60 Examples of AEs identified through the Harm2 tool at different points in the process of care
Origin of A&E Summative overview of episode of care
Pre admission 58-year-old lady admitted with painful NOF. Mechanical fall 9/7 prior to admission had visited A&E
following fall. O/E full ROM, no radiography. Diagnosed with soft tissue injury and discharged. On
admission, radiograph showed undisplaced fracture NOF. Listed for fixation. Uneventful procedure and
good recovery and mobilisation prior to discharge
Patient attended A&E with increasing abdominal pain and vomiting over past 2 days at home. Visited by a
GP the day before this admission and told he had gastroenteritis. O/A kept NBM and seen by surgeons?
Appendicitis. Taken to theatre diagnosed with ruptured appendix. Patient recovery slow but found to have
infection in tip of drain. Discharged home on oral antibiotics on the advice of microbiologist for 6 days
Early in
admission
The patient was admitted with a 4-day history of RIF pain associated with nausea, pyrexia and anorexia.
Clinically presented as appendicitis and underwent a laparoscopic appendectomy, good postoperative
recovery and discharged home with DN follow-up. Histology shows non-specific reactive changes
(normal). Subsequent admissions over 2 months with similar symptoms and diagnosed with ovarian cyst
on CT scan. Followed up by obs and gynae
Patient admitted due to generally unwell with less mobility and cough. Seen by GP and antibiotics
prescribed. Oral antibiotics changed and continued on admission. Patient experienced witnessed
collapse due to missed epilepsy medication not written on prescription chart
During
procedure
Admitted for elective radical nephrectomy for renal tumour. In theatre following removal of an
adhesion a 7-cm defect was noted between the diaphragm and pleura. Chest drain inserted and defect
was closed. Postoperatively the patient experienced pain at the chest drain site, but this was managed
well by the pain team. Discharged home postoperative day 6 with outpatient follow-up
Admitted for elective thyroidectomy with cervical lymph node resection. Returned to theatre
approximately 90 minutes after operation because of wound swelling and respiratory distress. Returned
to theatre, wound re-opened, fresh clot and blood found, clot removed and bleeding controlled.
Nursed on ITU post procedure then transferred to the ward. Discharged home with outpatient
follow-up. Magnesium and calcium low post surgery – replacement therapy given. Found to have
Clostridium difficile – commenced antibiotics. Discharged home with outpatient follow-up
Admitted as an elective admission and underwent elective laparoscopic cholecystectomy. No complications
during procedure, discharged home. Readmitted 3 days later with abdominal pain and vomiting. CT
showed haematomas in RUQ and pelvis also low HB. Returned to theatre for laparoscopy and washout
700-ml clot removal. Also treated with antibiotics and blood transfusion. Developed large blisters around
drain site – scarring occurred. In the first operation notes – comment ‘a little oozy tranexamic acid given’
but nothing documented on anaesthetic record or treatment sheet to indicate administration. Developed
an ileus and chest infection post second operation. Discharged with OPA follow-up
ITU/HDU Lady admitted to ITU following collision with a golf buggy. Reason for admission listed as poly-trauma.
Injuries included left 3–12 posterior rib fractures, left 3–7 anterior rib fractures, bilateral pelvic rami fractures
and right sacral fracture, 3 × lumbar fracture right-sided spinal femoral fracture, haemodynamically unstable
due to bleeding, required massive transfusion. Extubated but deteriorated despite NIV. CXR showed bilateral
basal changes. Haemophilus in NBL. i.v. Tazocin given re-intubated and commenced on meropenem for
Pseudomonas HAP. E. coli isolated sensitive to Tazocin. Tracheotomy and progress impaired by severe pain
through admission
Obese patient. Attended for elective gall bladder removal. Surgery uneventful, post op patient
complaining of pain. PCA set up, anaesthetist attended × 2 as patient still in pain. On return to the ward
patient difficult to rouse, naloxone given – diagnosis documented as ?too much opioid. Abdomen
tender. Patient noted to not have passed urine for > 15 hours. Catheter passed, following day patient
developed distended abdomen and cardiac SVT. Treated with cardiac drugs, USS showed paralytic ileus.
Commenced treatment. Improvement noted from this point. Discharged home 4 days later
continued
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TABLE 60 Examples of AEs identified through the Harm2 tool at different points in the process of care (continued )
Origin of A&E Summative overview of episode of care
General ward Patient admitted with acute abdominal pain. Had been discharged the day previously for the same
condition. On first admission had a urine dipstick positive to infection and constipation was only treated
for constipation. On second admission was then treated for urosepsis. The urine sample on first visit
was not followed up. There was no bladder scan to check for residual urine present
Admitted with confusion and recent falls ?UTI – treated with oral antibiotics. Fell in hospital fractured
right inferior pubic rami – managed conservatively. CT head > NAD. Reviewed by old age team –
diagnosed probable dementia. Patient fell again – no injury sustained – risk assessments completed.
SW, physiotherapy and OT input – patient discharged home with private carers following best interests
meeting with family input
Female admitted with abdominal pain constant pain associated with hot/chills and rigors and nausea.
Likely appendicitis for exploratory lap following unremarkable USS. Planned surgery cancelled as too
late to go to theatre. Pyrexial CRP high 340, WCC 23, neutrophils 20.2 for i.v. antibiotics pre surgery
and laparoscopic appendectomy; finding acute appendicitis – gangrenous appendix removed. For i.v.
antibiotics post operation. Nursing notes show that gentamycin delayed because of prescribing problem
with SHO. Venflon tissued 13:30 and SHO not available to recanulate until 16:15, so antibiotics
delayed. Venflon tissued again the following day 02:00, no antibiotics overnight as venflon not
replaced. Continued temperature spikes and abdominal pain. US pelvis shared collection of fluid in
pelvis post operation. Patient encouraged to mobilise and increased analgesia. Patient mobile and well.
Apyrexial on discharge with antibiotics
Discharge Admitted to acute elderly unit from nursing home care with increased confusion, agitation and
dehydration. Attributed to high opiate dose. Patient also in acute renal failure therefore opiates
withdrawn, fluids and U+Es monitored and patient discharged back to nursing home once normalising.
Patient readmitted on the same day with some problems but extreme pain also because of withdrawal
of her long-term opiate analgesia. Remained an inpatient for 46 more days prior to her death in
November
Lady admitted for a laparoscopic cholecystectomy. Discharged home following day. There is
documentation in the clinical notes stating that wound felt hot on day of discharge. Unable to locate
any documentation relating to wound prior to discharge home. Patient readmitted with wound
infection which burst and patient taken to theatre for exploration of infected wound. Required i.v.
antibiotics and packing of wound. Antibiotics changed to oral once patient was systemically well and
discharged home
Admitted for refashioning of a stoma to reduce prolapse. Discharged home after 2 days but then
readmitted the following day for a further refashioning. Stoma was not functioning prior to first
discharge. Patient discharged back to nursing home once the stoma became patient. Note: ‘blackened
areas’ to stoma upon readmission
Patient was admitted with a rugby injury – a fracture to left ankle. Patient underwent surgery – no
complications (ORIF) – radiograph reviewed by team – satisfactory – patient discharged home with
follow-up appointment and equipment. Radiograph re-reviewed by senior member who felt the
postoperative result was unsatisfactory, the patient was recalled for a redo fixation. Second operation
was successful
A&E, accident and emergency department; CRP, C-reactive protein; CT, computerised tomography; CXR, chest radiograph;
DN, district (community) nurse; E. coli, Escherichia coli; HB, haemoglobin; HDU, high-dependency unit; NAD, nothing abnormal
detected; NBM, nil by mouth; NBL, non-bronchoscopic bronchoalveolar lavage; NIV, non-invasive ventilation; NOF, neck of
femur; O/A, on assessment; O/E, on examination; obs and gynae, obstetrics and gynaecology; OPA, outpatient appointment;
ORIF, open reduction internal fixation; OT, occupational therapy; PCA, patient-controlled analgesia; RIF, right inguinal fossa;
ROM, range of movement; RUQ, right upper quadrant; SHO, senior house officer; SVT, supraventricular tachycardia; SW, social
worker; U+E, urea and electrolytes; US, ultrasound; USS, ultrasound scan; UTI, urinary tract infection.
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Appendix 12 Example of organisational report
 
40% 53% 7% 0% 0% 
34% 49% 11% 3% 2% 
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